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BACKGROUND: Prescription medications are widely used, particularly among older 
adults, with 46% of adults overall and 85% of older adults (65 years old and older) using 
at least one medication (Martin et al., 2019). Three percent of adults overall and 39% of 
older adults use 5 or more medications, constituting polypharmacy (Kantor et al., 2015). 
While there are many medications, as well as polypharmacy, that are known to have 
cognitive effects, many other widely used medications have been inconsistently 
associated with changes in cognition. Additionally, the degree of change, independent of 
effects of a possible underlying neurodegenerative process, is unknown. This is 
problematic for physicians, specifically neuropsychologists, who are tasked with 
evaluating cognition and providing differential diagnoses for potential cognitive change. 
OBJECTIVES: The current study sought to evaluate the effects of medication and 
polypharmacy on global and domain specific cognitive functioning in a broad clinical 
sample of adults using a comprehensive battery of neuropsychological tests. METHODS: 
Seven hundred and fifty archival neuropsychological data files were reviewed for 
inclusion. Four hundred and ninety-seven cases were ultimately retained for analyses 
(mean age = 40.75, SD = 14.61, range = 18-80 years). Most of the sample identified as 
 
 xviii 
female (52%) and Caucasian (94%). The number of medications used by study 
participants ranged from 0 to 14 (M = 2.64, SD = 2.50) and 11.3% reported taking 6 or 
more medications. All participants completed a large flexible battery of common 
neuropsychological tests, which allowed for calculation of overall test battery 
performance and cognitive domain specific performances. RESULTS: Two-way 
Analyses of Covariance analyzed the interaction and main effects of specific medication 
groups and polypharmacy on global cognitive performance, as measured by the overall 
test battery mean and intra-individual variability. Significant main effects of analgesics, 
triptan, polypharmacy on IIV were identified. No significant interaction or main effects 
were identified for two-way Multivariate Analyses of Covariance evaluating the effects 
of medication and polypharmacy across nine cognitive domains. CONCLUSIONS: 
Subjects taking analgesic medications, and medications from the triptans drug class, 
showed more cognitive variability over the course of a neuropsychological evaluation, 
compared to those not taking these medications. Additionally, subjects without 
polypharmacy showed more cognitive variability than those taking more than 5 
medications and those who were not taking any medications. Study limitations and 









The percent of adults and older adults in the population is steadily increasing. By 
2030, The United Nations Department of Economic and Social Affairs, Population 
Division (UN; 2019) estimates that in the United States (US), 77% of the population will 
be over the age of 20 and 37% of the population will be over the age of 50. These are 5% 
and 11% increases in the size of these age groups since 1990. The UN estimates that 
these US age cohorts will continue to increase in size over the next 20 years to include 
78% and 41% of the total US population, respectively, in the year 2050.  
One explanation for the increased population of adult and older adult cohorts in 
the US is the overall increase in life expectancy, following a reduction in death rates in 
late life (Zhaurova, 2008). For example, declines in smoking rates have led to fewer 
deaths due to cardiovascular disease (Silverstein et al., 2001; Stewart et al., 2009). 
Availability of Medicare coverage for individuals over the age of 65 has improved access 
to health interventions for older adults in the US, including access to prescription 
medication (Crimmins, & Beltrán-Sánchez, 2010). Additionally, a greater focus on 
prevention of disease and evolution of medical treatments have lowered the instances of 
fatalities due to heart attack, stroke, and cancer (Baigent et al., 2005; Law et al., 2009). 
However, longer life expectancies do not necessarily equate to a healthier population of 
adults and older adults. 
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For example, rates of obesity have increased drastically since the 1980s across all 
age groups (Flegal et al., 2016; Ogden et al., 2006). Similarly, prevalence rates for 
arthritis and musculoskeletal problems have been on the rise (Reynolds et al., 1998). 
Biomarker trends indicate that individuals between the ages of 40 and 64 are being 
diagnosed and treated for hypertension and high cholesterol more than in previous years 
(Martin et al., 2010). Additionally, trends of higher C-reactive protein (CRP) levels, an 
indicator of body inflammation, in men and glycated hemoglobin levels, an indicator of 
excess sugar and possible uncontrolled diabetes, in women between the ages of 40 and 64 
are evident (Martin et al., 2010).  
These changes are consistent with data from the Center for Disease Control and 
Prevention (CDC) showing significant increases in adult obesity since 1999 (Hales et al., 
2017). Moreover, evidence from the National Health Interview Survey generally shows 
increases in heart disease, heart attacks, stroke, cancer, and diabetes in men over 30 and 
women over 40 (Crimmins & Beltrán-Sánchez, 2010). Further, the rates of comorbidity 
as well as the number of comorbid diseases prevalent in older adults are significantly 
higher than in previous decades (Crimmins & Saito, 2000). Recent estimates suggest that 
most community dwelling older adults are diagnosed with two or more chronic 
conditions (Barnett et al., 2012). However, for individuals residing in care facilities, the 
number of comorbid conditions is significantly higher. One study conducted in Germany 
reported that individuals in residential care facilities averaged 17 chronic conditions 
(Akner, 2009).
However, not all prevalence rates are rising. Specifically, over the past decade, 
incidents of high cholesterol and hypertension appear to be declining (Crimmins et al., 
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2005; Crimmins et al., 2010). Given the relations between high cholesterol and 
hypertension with heart disease and stroke (Johnson et al., 2014), the leading and fifth 
leading causes of death in the US (Murphy et al., 2018), respectively, these findings 
support a decrease in late life mortality. Yet, in the context of the biomarker trends 
described above, it is most likely that these declines are attributable to the use of 
prescription drugs to treat or manage these diseases rather than a reduction in diagnoses 
of these conditions altogether (Crimmins & Beltrán-Sánchez, 2010).
Thus, while more people are living into older adulthood, disease morbidity 
appears to be expanding. This fact is supported by the widespread use of prescription 
medications to both prevent and treat conditions plaguing adults and older adults. A 
national US survey conducted in 2011 and 2012 indicated that 59% of adults over the age 
of 20 reported using one or more prescription medications (Kantor et al., 2015). Fifteen 
percent of these adults reported using 5 or more medications (Kantor et al., 2015). For 
Americans over the age of 65, 90% reported using one or more prescription medications 
and 39% reported using five or more prescription medications (Kantor et al., 2015).
These numbers are generally consistent with international trends of medication 
use. Across all age groups, in the United Kingdom (UK), 43% of patients were prescribed 
at least one regular prescription medication by their primary care physician and generally 
averaged four regular prescription medications (Petty et al., 2014). However, when 
focusing specifically on community-dwelling older adults, data from the UK (Clague et 
al., 2016; McLean et al., 2017; Petty et al., 2014), Norway (Andersen et al., 2011), and 
Spain (del Ser et al., 2019) suggest that 70% to 95% of patients used at least one 
prescription medication and on average took between three and four different drugs or 
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medications, concurrently. Therefore, most adults and older adults in the US and 
internationally regularly use medications. 
While the use of these medications in pharmacotherapy are ideally effective, safe, 
and selective in their effects, there is no guarantee that any drug will be without 
unintended side effects, such as a decline in cognitive functioning (Burchum & 
Rosenthal, 2016; Jyrkkä et al., 2011; Maher et al., 2014; Martin et al., 2000). For 
example, opioids (Allegri et al., 2019), anticholinergic medications (Risacher et al., 
2016), certain bladder relaxants (Obermann et al., 2013), and various antiepileptic 
medications (Nevado-Holgado et al., 2016; Park & Kwon, 2008; Stein & Strickland, 
1998), have been associated with cognitive decline. Additionally, polypharmacy (use of 
five or more drugs) and excessive polypharmacy (use of 10 or more drugs) have been 
associated with changes in cognitive functioning (Jyrkkä et al., 2011; Sordahl et al., 
2019).
In the US, a subset of these side effects is identified in clinical trials, prior to 
general use of the drug, as approved by the Food and Drug Administration (FDA). 
However, while clinical trials are typically conducted in samples composed of 500 to 
5000 patients, patient samples rarely include older adults, patients on multiple regular 
medications due to comorbidities, or other cognitively vulnerable populations (Boyd et 
al., 2012; Burchum & Rosenthal, 2016; Cho et al., 2011; McMurdo, 2005). Additionally, 
only a few hundred patients participating in clinical trials test the prescribed medication 
for more than 3 to 6 months (Burchum & Rosenthal, 2016).  
Therefore, some variations in pharmacokinetics and pharmacodynamics across 
patient populations and long-term effects of many prescription drugs may not be properly 
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vetted prior to their widespread use (Katzung, 2018). Further, neither clinical testing nor 
FDA approval is required for combination medications prior to their public release (FDA, 
2017). Instead, FDA investigations into the safety of a combination medication only 
occur after public health concerns are reported (FDA, 2017).
The combination of high use patterns of prescription medications (Andersen et al., 
2011; Clague et al., 2016; del Ser et al., 2019; Denison et al., 2012; Kantor et al., 2015; 
Kelly et al., 2005; McLean et al., 2017; Petty et al., 2014; Qato et al., 2008) and the 
limitations in evaluations of the effects of these drugs (Burchum & Rosenthal, 2016; Cho 
et al., 2011; FDA, 2017) suggests that there are more side effects of using currently 
available drugs than we are presently aware. Many of these possible side effects may 
directly or indirectly impact cognitive functioning. This creates a challenge for physicians 
across professional fields in determining the etiology of changes in a patient’s cognitive 
functioning. Neuropsychologists, in particular, who spend over three-fourths of their time 
evaluating the cognitive abilities of adults (Rabin et al., 2016), must be able to determine 
the effects of specific drugs or interactions between multiple drugs to accurately interpret 
results from neuropsychological assessments. Without accurate and thorough studies 
evaluating these potential effects on cognitive functioning, implications may include 
inappropriate diagnosis, delayed treatment of appropriate diagnosis, use of potentially 
inappropriate medications (PIMs), increased or subsequent adverse drug reactions (e.g., 
falls or delirium), financial cost of increased medical care, motor vehicle accidents, 




Therefore, to further the understanding of medication effects in the context of 
neuropsychological assessment, this study will examine the effects of medication on 
cognition in a clinical sample using a semi-flexible battery of common 
neuropsychological tests. The following literature review summarizes relevant concepts 
of clinical pharmacology and information on patterns of medication use. Additionally, 
this review will explore research regarding the effects of various clinical pharmacology 









 The field of clinical pharmacology is concerned with all aspects of how drugs 
function in humans, where a drug is defined as any chemical that impacts life (Burchum 
& Rosenthal, 2016). This includes the study of drugs and drug interactions across clinical 
and non-clinical (i.e., healthy) populations. Therefore, the basic principles of clinical 
pharmacology apply to the development and testing of new drugs, as well as to the use of 
established drugs to prevent or treat disease (Katzung, 2018). Theoretically, these basic 
principles are grounded in a shared goal: to develop and use a drug/drugs to safely and 
reliably create desired responses, without side effects or unintended interactions. 
However, the innumerable complexities of the interactions between biophysiology, 
biochemistry, genetics, psychology, and other processes that contribute to human 
functioning all but preclude the possibility of ever developing a “perfect drug.”  
Consequently, the primary objective in the medical use of drugs is to maximize the 
benefits of therapeutics while minimizing harm (Burchum & Rosenthal, 2016; Katzung, 
2018). 
Ultimately, therapeutic outcomes depend on many different factors that can be 
related to the patient, the drug, the treating physician, or the surrounding environment. 
Although, the drug response within the human body is arguably the factor of greatest 
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consequence, given the primary objective of pharmacotherapy. Specifically, if the 
response is too high, the drug will accumulate throughout the body, leading to toxicity 
(Burchum & Rosenthal, 2016). Conversely, if the response is too low, concentrations of 
the drug in the bloodstream will decrease, leading to possible treatment failure. 
In each of these cases, the harm created by the inappropriate intensity of the drug 
reaction outweighs the benefits. When the strength of the drug is too low, there is no 
benefit of pharmacotherapeutics. Additionally, given the possibility that drug exposure, 
and subsequent treatment failure, increases drug-resistance of the disease or diagnosis, a 
low intensity drug reaction may cause more than minimal harm (Martinez et al., 2012). 
On the other hand, severe adverse effects have been associated with drug toxicity, such as 
the development of delirium, dementia, and even death (Moore & O’Keeffe, 1999). 
Therefore, when a drug is administered, ensuring that the intensity of response will be 
appropriate is essential to achieving the primary therapeutic objective in clinical 
pharmacology. Several factors that contribute to variations in the intensity of a drug 
response, which may lead to overall harmful or negative drug effects, are explored below. 
 
Factors Related to Drug Intensity 
Drug Administration. 
First, variables related to drug administration can significantly affect the strength 
of a drug. Specifically, dosage, route of administration, and frequency or timing of an 
administered medication could lead to very high or very low concentrations of a drug in 
the bloodstream (Burchum & Rosenthal, 2016; Katzung, 2018). Therefore, specific drug 
dose regimens that dictate these factors (e.g., 30 mg, once daily, at bedtime, taken orally) 
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are designed to achieve steady-state drug concentrations that provide the most benefit 
from therapeutic drug intervention while minimizing drug toxicity (Brandt, 2013; 
Martinez et al., 2012). However, medication errors contribute to variability in drug 
dosage, route of administration, and timing that affect the intensity of the drug reaction.
Pharmacokinetics. 
Pharmacokinetics, which determine how drugs move into, through, and out of the 
body in four basic processes (i.e., absorption, distribution, metabolism, and excretion), 
also plays a role in determining drug reaction intensity (Stahl, 2013). Absorption is the 
process by which a drug moves from the administration site into the blood (Burchum & 
Rosenthal, 2016). Distribution is the process by which a drug moves throughout the body, 
from the blood and into cells. Metabolism is the process by which drugs are altered or 
transformed by enzymes (i.e., enzymatic alterations) to promote excretion. Excretion is 
the process by which drugs are removed from the body. Ultimately, these processes work 
collaboratively to determine the how much of a drug arrives to the sites of action and how 
long the drug remains at its sites of action (Katzung, 2018). However, factors related to 
absorption and elimination (i.e., metabolism and excretion) have unique roles throughout 
this process that impact the intensity of a drug response. 
Specifically, the amount of drug that is absorbed following drug administration 
and how quickly the drug is absorbed are the first factors that contribute to the strength of 
a drug response. Essentially, higher and more quick absorption leads to greater 
accumulation of the drug in the body, whereas lower and slower absorption leads to a 
smaller accumulation of the drug in the body (Burchum & Rosenthal, 2016; Katzung, 
2018). The concentration of the drug in the body can be altered again based on the 
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outcomes of the metabolism. In addition to altering drug compounds to improve 
excretion, the results of enzymatic alterations can include activation or deactivation of 
compounds or enhanced effects of an administered drug (Burchum & Rosenthal, 2016). 
Enzymatic alterations that activate previously inactive compounds (i.e., prodrug) or 
enhance the effect of the drug may increase the concentration of the drug in the body, 
potentially to toxic levels (Katzung, 2018). Enzymatic alterations that deactivate drugs, 
on the other hand, reduce the concentration of the active drug in the bloodstream 
(Burchum & Rosenthal, 2016).
The pharmacokinetic variables that impact the intensity of a drug response 
described up to this point are generally inherent to pharmacokinetic processes. However, 
additional variables that depend on the individual, the drug, and circumstance of 
pharmacotherapeutics may also impact pharmacokinetic processes and thus, the intensity 
of a drug response. For instance, age, genetics, frailty, and malnutrition have all been 
associated with reductions in drug metabolism (Katzung, 2018; Kinirons & O'Mahony, 
2004). Therefore, rather than maintaining the concentration of the drug through 
converting the drug to an inactive form and excreting it at a regular rate, the active drug 
accumulates. This leads to an increase in the concentration of the drug in the system. 
Similarly, the process of excretion slows dramatically for individuals with chronic kidney 
disease and those diagnosed with renal failure, conditions that are most common among 
individuals over the age of 65 (CDC, 2019). Since excretion primarily occurs in the 
kidneys, slowed excretion of the drug increases the intensity of the drug response 
(Burchum & Rosenthal, 2016). 
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Additionally, specific properties of a drug may allow it to induce or inhibit drug-
metabolizing enzymes during the process of metabolism, which in turn impact the drug 
reaction. If drug-metabolizing enzymes are induced, the concentration of the drug will 
decline and reduce the intensity of the drug reaction (Burchum & Rosenthal, 2016). 
Conversely, if drug-metabolizing enzymes are inhibited, then the concentration of the 
drug will rise and increase the intensity of the drug reaction. Finally, competition for 
metabolism may occur if two or more drugs utilize the same metabolic pathway 
(Katzung, 2018). This competition could result in reduced metabolism for one or both/all 
of the drugs involved, thereby allowing for the drug(s) to accumulate in the system.  
Pharmacodynamics.
 While pharmacokinetics determine how much of an administered dose gets to its 
sites of action and how long the drug remains active there, pharmacodynamics dictate the 
intensity and type of reaction a drug has when it is at its sites of action (Burchum & 
Rosenthal, 2016). To initiate this process, a drug interacts with either a drug binding 
receptor or other small molecules. This interaction produces a series of events that lead to 
the drug response. At this stage, much of the intensity of a drug response is due to the 
dose-response relationship, which is a drug-specific relationship between the size of the 
administered dose and the intensity of the drug’s response (Katzung, 2018). However, 
this relationship is moderated by factors such as the functional state of the patient, drug 
tolerance or sensitivity, and placebo effects (Burchum & Rosenthal, 2016). 
Individual Differences.
 Patient-specific factors involved in determining the intensity of a drug response 
explain differences in drug responses between individual patients (Burchum & Rosenthal, 
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2016). Although some of these factors were discussed above in terms of their 
relationships with pharmacokinetic processes, individual differences can impact 
pharmacokinetics and pharmacodynamics more broadly to alter the intensity of a drug 
response. Generally, these factors are categorized in three domains: physiological 
variables, pathological variables, and genetic variables. 
Physiological variables that moderate the intensity of drug responses include age, 
gender, weight, hormonal status, diet, and oxidative stress (Bailey, 1983; Burchum & 
Rosenthal, 2016; Deavall et al., 2012; Katzung, 2018). Pathological variables that 
moderate the intensity of drug responses include impairment of the liver, impairment of 
the kidneys, frailty, and chronic brain pathology (Katzung, 2018; Kinirons & O'Mahony, 
2004; Moore & O’Keeffe, 1999). Genetic predispositions to drug reactions also moderate 
the intensity of drug responses (Katzung, 2018). While these individual difference 
variables do not constitute a comprehensive list of patient characteristics, individual 
variation must be considered both in terms of individual contributions to drug intensity, 
as well as with regard to interactions between these differences and pharmacokinetic and 
pharmacodynamic processes in order to maximize the benefits while minimizing harm in 
pharmacotherapeutics.  
Drug Interactions
 A further consideration in pharmacotherapeutics involves drug interactions. This 
can include interactions among two prescribed drugs. Although an administered drug 
may also interact with food, tobacco, caffeine, or other substances in the body. When 
drugs interact, there are three possible outcomes: the effects of one drug intensifies 
(potentiative), the effect of one drug reduces (inhibitory), or the interactive/combined 
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effect is a new reaction that is not seen when either drug is used individually (Burchum & 
Rosenthal, 2016). This is similar to the concept of agonists and antagonists for specific 
substances but refers specifically to drug interactions. Potentiative and inhibitory 
outcomes may influence therapeutic effects positively by both increasing therapeutic 
effects and decreasing adverse effects, respectively (Burchum & Rosenthal, 2016). 
However, potentiative and inhibitory outcomes could also negatively impact therapeutic 
effects. Specifically, potentiative interactions may increase adverse effects and inhibitory 
interactions may reduce therapeutic effects (Burchum & Rosenthal, 2016). Not much is 
known about the implications of interactions in which a new response, not produced 
when either drug is used independently, occurs as this outcome is rare (Burchum & 
Rosenthal, 2016).
Mechanisms of Interaction. 
 There are four mechanisms in which drugs interact: direct interactions, combined 
toxicity, pharmacokinetic interactions, and pharmacodynamic interactions (Burchum & 
Rosenthal, 2016). Direct interactions occur due to the physical or chemical properties of 
the drugs involved and generally result in both drugs becoming inactive (Burchum & 
Rosenthal, 2016). Although direct reactions can occur inside the body, water inside the 
body dilutes a drug following administration, so this is less likely to occur (Burchum & 
Rosenthal, 2016). Combined toxicity occurs when two drugs that are toxic to the same 
organ are administered (Burchum & Rosenthal, 2016). This results in greater toxic effects 




Pharmacokinetic interactions, on the other hand, can affect any of the four basic 
pharmacokinetic processes (Burchum & Rosenthal, 2016), although only alterations in 
metabolism will be specified here given its complexity. All pharmacokinetic interactions 
either enhance or reduce the primary process for the other drug (see pharmacokinetics 
section above) and oftentimes have implications for drug treatment. Specifically, in terms 
of metabolism, some drugs induce or increase the metabolism of other drugs by 
increasing enzymes that process the other drug (i.e., synthesizing; Katzung, 2018). 
Ultimately, this can increase the rate of metabolism of the other drug by a factor or two or 
three in a week-long period (Burchum & Rosenthal, 2016). After an increase in 
metabolism, the rate of metabolism will not return to normal until after the inducing 
agent is removed. Conversely, some drugs may decrease metabolism of another drug by 
inhibiting enzymes that would metabolize the other drug (Katzung, 2018). In some cases, 
inhibition of drug metabolism can be beneficial, however, generally there are many 
adverse effects (Burchum & Rosenthal, 2016). 
 Pharmacodynamic interactions can either occur at the same receptor or at separate 
receptors and can be potentiative or inhibitory (Burchum & Rosenthal, 2016). Although 
Burchum and Rosenthal (2016) note that interactions occurring at the same receptor are 
almost always inhibitory. These types of interactions can have significant implications for 
drug treatment. For example, interactions occurring at the same receptor may serve to 
reduce beneficial therapeutic effects or reduce toxicity. Interactions occurring from drugs 
acting at separate sites can also be potentiative or inhibitory, but only if both drugs 





Overall, drug interaction is another factor in which drug intensity may be altered. 
However, the specific responses that may occur for any particular interaction are 
dependent on the therapeutic response and mechanisms of action for each drug involved. 
Nevertheless, any drug interaction has the potential to impact therapeutic effects. In some 
circumstances, this can be beneficial, such as when an interaction increases the 
therapeutic effect of a drug or reduces toxicity. Although, in other circumstances, 
interactions can be detrimental due to reduced therapeutic effects or increased toxicity. 
Awareness of these potential outcomes are particularly important for drugs with a 
narrow therapeutic range. These drugs are particularly sensitive to interactions, with 
slight increases in the concentration of the drug leading to drug toxicity and slight 
reductions in the drug concentration leading to treatment failure (Burchum & Rosenthal, 
2016). Additionally, the risk of harmful interactions increases as the number of drugs 
administered increases. While a large number of important interactions have been 
identified, allowing for some detrimental effects to be reduced, many more have not been 
identified (Burchum & Rosenthal, 2016). Therefore, significant risk of harmful effects 
remains when large numbers of drugs are prescribed and interact. 
Regulation of Drugs
Some of the risk of a potential harmful effect is evaluated through assessments of 
a drug’s basic properties, such as pharmacokinetics (i.e., absorption, distribution, 
metabolism, excretion), drug functioning in healthy participants, and drug functioning in 
clinical samples, per FDA guidelines (Burchum & Rosenthal, 2016). However, even after 
a drug is considered “safe” and “effective” by FDA standards (see FDA, 2017) and 
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approved for general use, questions remain regarding the potential for various side effects 
(Katzung, 2018). This is particularly true for adults with co-morbidities and older adults, 
who may be more sensitive to cognitive effects and who are often excluded from 
participation in clinical trials (Boyd et al., 2012; Cho et al., 2011; McMurdo, 2005). 
Additionally, the subtlety with which many cognitive effects may occur suggests that it is 
unlikely for most cognitive changes to be identified during the clinical trial phase of drug 
testing. 
Given these limitations in the regulation of drugs and the sizeable potential for 
previously undetected cognitive effects accompanying their use, it would follow that 
many patients and physicians alike would be wary of the widespread use of medications. 
However, current estimates suggest that this may not be the case (Kantor et al., 2015; 
Martin et al., 2019). In an effort to elucidate the magnitude of potential risk for cognitive 
effects of prescription medication, the following section will review patterns of 
medication use and characteristics of persons who use prescription medications. 
 
Patterns of Medication Use 
 
Prescription Medications Over Time 
Despite the need for further testing after FDA approval to fully understand the 
effects of many commonly used medications, specifically with regard to cognitive side-
effects, the use of prescription medications has steadily risen until recent years. In an 
analysis of data from National Health and Nutrition Examination Survey (NHANES), 
Kantor and colleagues (2015) found that 51% of adults in the US population were 
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prescribed one or more medications between 1999 and 2000. Two years later, the 
proportion of individuals over the age of 20 prescribed at least one medication rose to 
54% (Kantor et al., 2015). By 2005 and 2006, Kantor and colleagues found that the 
prevalence of using any prescription medication for adults in the US was 55%. These 
estimates are generally consistent with data from Che and colleagues’ (2014) survey of 
prescription medication use in Wisconsinites from 2008 to 2010, in which 54% of 
Americans between the ages of 21 and 74 reported using at least one prescription 
medication. The most recent data analyzed from Kantor et al. (2015) was from 2011 and 
2012. At that time, 59% of Americans over the age of 20 were prescribed at least one 
medication (Kantor et al., 2015).
However, there is significant variability in reported rates of medication use across 
studies. For example, data collected from 2009 to 2011 examining the rates of medication 
use in community-dwelling adults over the age of 50 found that 69% of participants used 
one or more prescription medications (Peklar et al., 2014). Contrarily, in a 2010 to 2011 
study of medication use in community-dwelling adults between the ages of 62 and 85, 
approximately 88% used prescription medications (Qato et al., 2016). A third study 
analyzing data from 2011 found that 75% of adults over the age of 60 were prescribed at 
least one long-term medication (Petty et al., 2014). While these differences are likely due 
to a combination of methodological differences and sample specific factors, described in 
more detail below, the extent of variability in these estimates demonstrates the challenges 
in comparing rates of medication use across studies.
To date, no known studies examine the rates of prescription medication use 
combining adult and older adult age groups in the most recent decade to directly compare 
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with Kantor and colleagues’ (2015) previous work. However, a US National Center for 
Health Statistics (NCHS) brief noted that between 2015 and 2016, 47% of adults between 
the ages of 20 and 59 reported using one or more prescription drugs (Martin et al., 2019). 
Alternatively, 85% of adults over the age of 60 reported using one or more prescription 
drugs (Martin et al., 2019). Overall, the rates of prescription drug use across all ages were 
lower than rates from nearly a decade prior in 2007-2008 (rates of 46% and 48%, 
respectively; Martin et al., 2019). When examining adult (20-59) and older adult (60+) 
age groups separately, slight declines were observed for both adults and older adults 
(Martin et al., 2019). Although neither of these reductions in prescription drug use from 
2007-2008 to 2015-2016 were statistically significant. Therefore, it is possible that rates 
of prescription medication use are leveling or even declining for adults. Nevertheless, use 
of prescription medications continues to be very high. 
Differences in Use of Medications by Age.
Literature has consistently shown that use of prescription medication increases 
with age (Che et al., 2014; Kantor et al., 2015; Martin et al., 2019; Petty et al., 2014; Qato 
et al., 2008). In the US, Qato and colleagues (2008) found that 90% of older adults 
between the ages of 75 and 85 reported using one or more prescription medications 
compared to 74% of the youngest group, aged 57 to 64. This is consistent with Gurwitz 
and colleagues’ (2003) findings that older adults are the largest group of purchasers of 
prescriptions, OTC medications, and dietary supplements. 
In a broader sample of adults, Che et al. (2014) found a similar pattern. Only a 
third of adults aged 21 to 39 reported using at least one prescription medication regularly 
between 2008 and 2010 compared to almost three-fourths of adults aged 60 to 74. A 
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subsequent study of data collected in 2011 and 2012 found that 35% of adults between 
the ages of 20 and 39 used one or more prescription medications, compared to 65% of 
those between the ages of 40 and 64 and 90% of those over the age of 65 (Kantor et al., 
2015). Different rates of prescription drug use were identified in a 2015 to 2016 US 
NCHS brief, although the pattern remained the same. Specifically, 47% of people 
between the ages of 20 and 59 reported prescription drug use compared to 80% of people 
over the age of 60 (Martin et al., 2019). This relationship between age and prescription 
medication use was also evident in comparisons of medication use by sex and race 
(Martin et al., 2019).  
Differences in Use of Medications by Gender.
For younger adults, between the ages of 20 and 59, prescription medication use 
was higher among women than men, 56% compared to 37%, according to a NCHS study 
conducted in 2015 and 2016 (Martin et al., 2019). Women (86%) also showed a higher 
use of prescription medications than men (77%) in a study conducted in 2005 and 2006 
of older adults ranging from 57 to 85 years old (Qato et al., 2008). However, a more 
recent study found that for adults over the age of 60, there was no difference between 
men and women in their use of prescription drugs (Martin et al., 2019). When examined 
across all age groups, this NCHS study found prescription medication use to be higher in 
women (50%) than men (42%; Martin et al., 2019). 
Differences in Use of Medications by Race. 
 In addition to differences in prescription medication use across age and gender, 
prescription medication use also varies across race. Overall, use of prescription 
medication is highest among persons who identified as White (50%), followed by persons 
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who identified as Black (45%), according to the most recent data from NCHS (Martin et 
al., 2019). Use of prescription medications is lowest among those who identified as 
Hispanic (37%) or Asian (33%; Martin et al., 2019). When examining older and younger 
adults separately, adults between the ages of 20 and 59 showed the same pattern of 
prescription drug use as the overall sample: 52.4% White, 45.3% Black, 33.6% Hispanic, 
and 30.2% Asian (Martin et al., 2019). However, no difference in use of prescription 
medication was observed across racial or ethnic groups for older adults (e.g., people over 
the age of 60; Martin et al., 2019).
Other Factors Contributing to Differences in Use of Medications. 
 In addition to age, gender, and race, several other factors have also been 
associated with differential uses of medications. For example, rates of prescription 
medication use differed across various levels of education, income, insurance coverage, 
and Body Mass Index (BMI) in a broad sample of adults over the age of 20 (Kantor et al., 
2015). Specifically, of adults reporting “college” as their highest level of education, 61% 
reported using at least one prescription medication. In contrast, only 57% of adults who 
reported having less than 12 years of education and adults who reported completing only 
“some college” reported using one or more medication. Prevalence of medication use 
also increased with reported family income (Kantor et al., 2015). Of individuals with a 
family income below the federal poverty level, 49% reported using one or more 
prescription medications compared to 65% of adults who reported the highest level of 
family income (above 88,000). Regarding insurance coverage, not surprisingly, only 31% 
of adults who did not have insurance reported taking prescription medications compared 
to 57% of adults who had private insurance and 64% of adults who had insurance through 
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the government (Kantor et al., 2015). However, differences in medication use by 
insurance coverage was only calculated for individuals under the age of 65 since nearly 
all adults over the age of 65 participating in this study reported having some form of 
health insurance. 
Lastly, when evaluating medication use based on BMI, Kantor and colleagues 
(2015) found that 59% of adults with a BMI below 18.5, 52% of adults with a BMI 
between 18 and 25, and 57% of adults with a BMI between 25 and 30 reported using one 
or more prescription medications. Additionally, 62% of adults with a BMI between 30 
and 35, 68% of adults with a BMI between 35 and 40, and 73% of adults with a BMI 
over 40 used one or more prescription medications. Based on the CDC recommended 
classifications for BMI, which indicate normal BMI as BMI between 18.5 and 24.9 
(CDC, 2017), findings from Kantor et al. (2015) indicate that adults with a BMI in the 
obese category were significantly more likely to use medications than individuals with 
BMIs in the normal range.
Similar results were identified by Qato and colleagues (2008) in their study of 
medication and dietary supplement use in older adults. Specifically, older adults with 
more co-morbid conditions, who classified themselves as “nonpoor”, and who reported 
higher levels of education were more likely to use one or more medications. Although, 
this included use of any combination of prescription, OTC medications, and dietary 
supplements. 
Common Medications 
Despite differences in use of medications across demographic variables, Kantor et 
al. (2015) identified several of the most common prescription medications used by adults 
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in 2011 and 2012. Overall, antihypertensives (27%), antihyperlipidemic agents (18%), 
antidepressants (13%), prescription analgesics (11%), antidiabetic agents (8.2%), proton 
pump inhibitors (7.8%), and thyroid hormones (6.4%) were the most common therapeutic 
groups of medications prescribed for individuals over the age of 20. Specifically, 
simvastatin, a lipid modifying agent used to treat high cholesterol (WHO Collaborating 
Centre for Drug Statistics Methodology [WHO], 2021), was the most commonly reported 
prescription medication, taken by 7.9% of the sample (Kantor et al., 2015). Lisinopril, 
levothyroxine, metoprolol, metformin, hydrochlorothiazide, omeprazole, amlodipine, 
atorvastatin, and albuterol were also among the top 10 medications reported by Kantor et 
al. study participants.
Qato and colleagues (2016) found that the most common medications for older 
adults between the ages of 62 and 85 in 2010 and 2011, were nearly identical to those 
reported by Kantor et al. (2015) for their broader sample of adults. Antihypertensives was 
the most common therapeutic group of prescription medications, reported by 65.1% of 
older adults (Qato et al., 2016). Analgesics (54.3%), antihyperlipidemics (50.1%), 
coagulation modifiers (47.6%), respiratory agents (19.6%), proton pump inhibitors 
(18.5%), antidiabetic agents (17.8), and thyroid hormones (15.8%) were also among the 
most common therapeutic groups of medications prescribed to older adults. In terms of 
specific medications, simvastatin (22.5%), lisinopril (19.9%), hydrochlorothiazide 
(19.3%), levothyroxine sodium (15.4%), metoprolol (14.9%), amlodipine (13.4%), 
metformin (12.6%), atorvastatin calcium (9.7%), atenolol (8.5%), and furosemide (8.2%) 
were most commonly reported (Qato et al., 2016). 
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 However, when Martin et al. (2019) directly compared older and younger adults 
in the most recent MCHS data from 2015 and 2016, the most common therapeutic group 
of prescription medication differed. For younger adults, aged 20 to 59, antidepressants 
were the most commonly reported therapeutic group of prescription medications (Martin 
et al., 2019). In contrast, the most common therapeutic group of prescription medications 
for adults over the age of 60 was lipid-lowering drugs (Martin et al., 2019). These 
differences are not unusual given that different health conditions are more prominent at 
different stages of life. 
 Overall, the use of prescription medications is extensive and more prevalent than 
in previous decades (Kantor et al., 2015; Martin et al., 2019; Qato et al., 2016). While 
various demographic variables have been associated with medication use, age appears to 
be the most significant, with older adults reporting higher consumption of prescription 
medications than younger adults (Che et al., 2014; Kantor et al., 2015; Martin et al., 
2019; Petty et al., 2014; Qato et al., 2008). However, many adults use more than one 
medication (Che et al., 2014; Denison et al., 2012; Freund et al., 2013; Gahche et al., 
2017; Kantor et al., 2015; Qato et al., 2016), which as described above, can impact the 
pharmacokinetics and pharmacodynamics of the prescriptions and potentially lead to 
detrimental side effects. Therefore, the literature below describes polypharmacy and its 
prevalence in prescription medication use.
Polypharmacy 
 Polypharmacy has featured prominently in studies of pharmacology, nursing 
practice, and treatment of diagnoses and diseases across fields (e.g., neurology, 
psychiatry, gerontology, endocrinology, and cardiology) given its relationship with drug 
 
 24 
related problems (DRPs) that can interfere with treatment or recovery (Viktil et al., 
2007). However, no formal definition of polypharmacy has been identified. Some studies 
define polypharmacy as the use of two or more medications (Frazier, 2005; Fulton & 
Allen, 2005). Others define polypharmacy as the use of more drugs than appropriate 
given a patient presentation (Fulton & Allen, 2005; Tjia et al., 2013). Additionally, 
polypharmacy has been termed the concurrent use of two or more medications that treat 
the same symptom, illness, or disease, or treatment with two drugs from the same drug 
class (Brager & Sloand, 2005). The benchmark of five or more medications has also been 
used in an effort to standardize definitions of polypharmacy with a customary cutoff 
value (Viktil et al., 2007).
Through an investigation of the cutoff of five or more medications and DRPs in 
patients admitted to the hospital, Viktil et al. (2007) revealed a linear relationship 
between number of medications used prior to admittance and number of DRPs. With 
every increase in number of medications, there was a nearly 9% increase in DRPs. 
Further, individuals admitted to the hospital with five or more regular medications 
experienced significantly more DRPs than patients admitted to the hospital with less than 
five regular medications (Viktil et al., 2007). However, there is no evidence to suggest 
that this relationship is due to the cutoff of 5 or more medications to identify 
polypharmacy rather than a function of the linear relationship between number of 
medications and DRP. This suggests that indicating polypharmacy with a cut off of 5 or 
more medications may be entirely arbitrary and not serve as an adequate value to 
differentiate risk for DRPs in research or clinical practice as it was intended. Despite this 
explanation, many researchers continue to use the cutoff of 5 or more medications to 
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indicate polypharmacy when discerning high risk patients and in describing various 
qualities of the samples that fall in this category (e.g., Che et al., 2014; Jyrkkä et al., 
2011; Kantor et al., 2015; Qato et al., 2008, Qato et al., 2016). 
For example, an investigation into medication use in older adults, Qato et al. 
(2008) found that over 50% of adults between the ages of 57 and 85 took 5 or more 
prescription medications, OTC medications, or dietary supplements. Additionally, of 
those older adults using prescription medications, nearly 70% reported also using OTC 
medications, dietary supplements, or both (Qato et al., 2008). A follow-up study 
conducted five years later from 2010 to 2011 examined the use of medication in older 
Americans between the ages of 62 and 85 (Qato et al., 2016). Rates of polypharmacy for 
any combination of medications increased from 50% to 67% of older adults who used 5 
or more prescription or OTC medications or dietary supplements (Qato et al., 2016). 
Prescription Medications
When specifically considering the relationship between prescription medication 
and polypharmacy, Qato et al. (2008) found that 29% of older Americans between 57 and 
85 years old reported using five or more medications. In a follow-up study examining the 
use of medication in adults between the ages of 62 and 85, Qato et al., (2016) found the 
rate of polypharmacy for prescription medications increased to approximately 36%. 
Conversely, in an investigation of prescription medication use in a broader sample of 
adults over the age of 20, Kantor and colleagues (2015) found that only 15% of adults 
reported using five or more medications. The variation in these prevalence rates, like that 
observed for use of at least one prescription medication, is likely due to the differences in 
the age of the participants across studies. 
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When stratified by age, prevalence rates for polypharmacy become more 
consistent across studies. In fact, when Kantor and colleagues’ (2015) sample is stratified 
by age cohorts, older adults over the age of 65 reported the most instances of 
polypharmacy, with 39% of this group reporting use of five or more prescription 
medications. Conversely, only 3% of individuals aged 20 to 39 reported using five or 
more prescription medications (Kantor et al., 2015).
This concept is further exemplified in a study that reviewed instances of 
prescription drugs recorded in an electronic medical record of adult patients seen in 
primary care settings (Freund et al., 2013). Patients aged 18-23, 25-34, 35-44, and 45-54 
years old were found to have the following rates of polypharmacy: 20%, 29%, 40%, and 
55%, respectively. While these rates are slightly higher than those obtained by Kantor et 
al. (2015), Qato et al. (2008), and Qato et al. (2016), likely due to the number of 
prescriptions being determined by a medical record system rather than through in-person 
interviews, the rates of polypharmacy still appear to increase with age much like that of 
individual medication use. 
Like age, gender was also associated rates of polypharmacy. Overall, women 
between the ages of 21 and 74 were more likely to experience polypharmacy than men, 
according to data collected between 2008 and 2010 (Che et al., 2014). Specifically, 16% 
of women reported using five or more prescription medications compared to almost 11% 
of men (Che et al., 2014). These results are nearly identical to Kantor and colleagues’ 
(2015) report that 16% of women and 13% of men used five or more prescription 
medications in 2011 and 2012. Similar patterns are observed in older adults in the 57 to 
64 and 65 to 74 age groups (Qato et al., 2008). However, individuals from the oldest age 
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group, composed of individuals between 75 and 85 years old, did not show any 
differences in polypharmacy across gender (Qato et al., 2008). 
Associations between race, BMI, smoking history and rates of polypharmacy have 
also been identified (Che et al., 2014; Kantor et al., 2015). In a broad study of adults over 
the age of 20, 17% of adults who identified as white reported taking five or more 
medications compared to 14% of adults who identified as black (Kantor et al., 2015). 
When evaluating use of five or more medications based on BMI, Kantor and colleagues 
found that 18% of adults with a BMI below 18.5, 8.4% of adults with a BMI between 18 
and 25, and 12% of adults with a BMI between 25 and 30 reported using five or more 
prescription medications. Additionally, 17% of adults with a BMI between 30 and 35, 
24% of adults with a BMI between 35 and 40, and 29% of adults with a BMI over 40 
used five or more prescription medications. Based on the CDC (2017) recommended 
classifications for BMI, which indicate normal BMI as between 18.5 and 24.9, adults 
classified as obese were significantly more likely to use medications than individuals 
with BMIs in the normal range (Kantor et al., 2015). Further, adults who reported a 
history of smoking were nearly twice as likely to use five or more prescription 
medications than adults without a history of smoking (Che et al., 2014).
Not surprisingly, family income, health insurance coverage, and being able to 
identify a regular source of care were also linked with greater use of polypharmacy in 
prescription medications (Che et al., 2014; Kantor et al., 2015). Family income was 
negatively related to polypharmacy; meaning that adults reporting lower family incomes 
were more likely to report taking five or more medications than adults who reported 
higher incomes (Che et al., 2014; Kantor et al., 2015). Additionally, adults who reported 
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having insurance through the government (Medicaid or Medicare), having prescription 
drug coverage, and who identified a location where they typically receive healthcare were 
more likely to use five or more medications (Che et al., 2014; Kantor et al., 2015). 
 Overall, use of prescription medication is extensive, and frequently occurs 
alongside four or more other medications, as is the case in polypharmacy. While these 
medications are evaluated by the FDA prior to widespread use, that does not mean they 
are without side effects, particularly with regard to cognition. Additionally, given the 
limits in assessment of medication side effects prior to FDA approval and release, it is 
likely that additional side effects are present, including those that affect cognition. The 
following section details the cognitive effects that have been observed following the use 
of various medications.  
 
Cognitive Effects of Medications 
Ultimately, any medication may cause cognitive effects, such as confusion 
associated with delirium, if the drug concentration reaches a toxic level (Moore & 
O’Keeffe, 1999). Although, delirium-like events are not necessary in order for 
medications to impact cognitive functioning. Many medications have been associated 
with more subtle changes in cognition, even in studies of relatively young and healthy 
samples (see Allegri et al., 2019; Nevado-Holgado et al., 2016; Prado & Crowe, 2019; 
and Prado et al., 2018). However, for individuals who are cognitively vulnerable due to 
stroke, traumatic brain injury, or advanced age, these effects may cause more significant 
changes or chronic cognitive impairment (Moore & O’Keeffe, 1999). Further, for 
individuals who have already been diagnosed with cognitive impairment, this could mean 
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worsening impairment or a significant enough decline to warrant a diagnosis of dementia 
(Campbell et al., 2009). 
The American Geriatrics Society (AGS) Beers Criteria for Potentially 
Inappropriate Medication Use in Older Adults (AGS Beers Criteria) provides a specific 
list of medications that are typically best to avoid in older adults with the goal of reducing 
their exposure to PIMs that may increase risk of negative effects (Fick et al., 2019). 
However, decisions regarding pharmacological treatment are not always clear cut, and 
depending on various situational factors, may still lead to the use of PIMs that increase 
the risk of drug toxicity or negative drug interactions in older individuals. This, in turn, 
may produce cognitive impairment. This is of particular concern in cognitively 
vulnerable populations who may be at a higher risk of using PIMs (Gnjidic et al., 2018; 
Miller et al., 2017). 
Medications of primary concern for both researchers and clinicians are those 
known to have sedative or anticholinergic effects due to their effect on the central 
nervous system (CNS). Specifically, anticholinergic effects have consistently been 
related to the development of cognitive impairment, delirium, and dementia (Campbell et 
al., 2009; Marvanova, 2016; Moore & O’Keeffe, 1999). The 2019 AGS Beers Criteria 
provides a strong recommendation to avoid prescribing drugs with strong anticholinergic 
properties, such as first-generation antihistamines, antispasmodics, and certain 
antiparkinsonian agents. 
Anticholinergics 
 Cholinergic pathways have long been associated with cognitive functioning, and 
memory in particular (Campbell et al., 2009; Stein & Strickland, 1998). Therefore, when 
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this pathway is interrupted, as is the case in the use of anticholinergic drugs, impairments 
in cognitive functioning may occur. Many explanations have been provided for this 
relationship, such as increased brain cell death (Del Pino et al., 2016) or synaptic pruning 
and degeneration (Geula, 1998) at the sites of action for anticholinergic drugs. Although, 
an anticholinergic drug, or a drug with a strong anticholinergic effect, functions in much 
the same way as Alzheimer disease pathology. Specifically, these drugs act as antagonists 
and block muscarinic receptors (Katzung, 2018; Lam, 2017; Lepkowsky, 2016). As a 
result of this antagonist effect, reactions that are essential to the communication between 
neurons for adequate attention, memory, and learning are significantly reduced, leading 
to functional impairments in these cognitive domains (Lam, 2017; Lepkowsky, 2016; 
Tannenbaum et al., 2012).
Risacher and colleagues’ (2016) demonstrated this in a study of anticholinergic 
medication use, cognitive functioning, and brain atrophy in cognitively normal older 
adults. Overall cognitive functioning and performance on tasks of immediate memory 
and executive functioning were significantly lower for patients taking anticholinergic 
medications compared to patients who were not taking anticholinergic medications 
(Risacher et al., 2016). Additionally, structural magnetic resonance imaging (MRI) 
reviled greater brain atrophy in patients taking anticholinergic medications than patients 
not taking anticholinergic medications, as evidenced by reduced overall cortical volume 
and enlargement of the lateral ventricles. Further, patients in this study using 
anticholinergic medications showed reduced cortical thickness in the medial temporal 
lobe (Risacher et al., 2016), an area known for its involvement in episodic memory and 
learning (Squire, 2004). 
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Anticholinergic effects have been documented for amitriptyline, clomipramine, 
amoxapine, hydroxyzine, digoxin, furosemide, codeine, and chlorpheniramine among 
others (Marvanova, 2016; Sordahl et al., 2019; see Table 1 for a list of the drug families 
and therapeutic uses of a subset of common medications that act on anticholinergic 
pathways). However, use of one anticholinergic drug will not necessarily lead to negative 
cognitive effects. Rather, it is the collective potency of the anticholinergic effect of the 
drug/drugs used, or anticholinergic burden, that leads to impairment (Lam, 2017). For 
example, in Risacher and colleagues’ (2016) study, anticholinergic burden was negatively 
related to overall cognitive function, as well as immediate recall and executive 
functioning performance. This effect is often more pronounced in older adults, given the 
reduced number of cholinergic neurons or receptors, in conjunction with various other 
pharmacokinetic and pharmacodynamic factors compared to younger adults (Campbell et 
al., 2009).
While medications with strong anticholinergic effects contribute to a large portion 
of negative cognitive side effects, there are many other ways that medications may 
impact cognitive functioning. For example, reduced cerebral blood flow (Marvanova, 
2016), the creation of neurotoxic metabolites (Kornitzer et al., 2006; Marvanova, 2016), 
and imbalances in fluids or electrolytes (Marvanova, 2016) have been suggested as 
possible mechanisms of cognitive dysfunction following the use of certain medications. 
Although, the potential for cognitive effects of medication depends on the specific 
pharmacodynamic effect of the drug itself, which can vary as a function of therapeutic 
use and drug families. Therefore, the cognitive effects of medications from a selection of 






Common Medications with Anticholinergic Properties 
Therapeutic Use Drug Family Drug Name (generic) 
Anxiolytic Benzodiazepine Alprazolam 
Antihistamine First-Generation H1 Antagonist Diphenhydramine  
Movement Disorder Central Muscarinic Antagonist Benztropine 
Antidepressant MRI Amitriptyline 
Antidepressant SSRI Paroxetine 
Antipsychotic Atypical Antipsychotics Quetiapine 
Antidepressant MRI Clomipramine 
Cardiovascular Antiarrhythmic Disopyramide 
Cardiovascular Diuretic Furosemide 
Urological Antispasmodic Oxybutynin 
Note. Adapted from Sordahl et al. (2019) and Marvanova, (2016). MRI = Monoamine 
Reuptake Inhibitors, SSRI = Selective Serotonin Reuptake Inhibitor. Medication 
classifications based on the ACT Classification Index from the (WHO Collaborating 




 The cognitive effects of antidepressants are varied across drug classes or families. 
Tricyclic antidepressants (TCAs) are widely known for their negative cognitive effects, 
likely due to the combination of sedative and anticholinergic effects of drugs in this 
family (Sordahl et al., 2019; Stein & Strickland, 1998). In terms of cognitive effects, 
TCAs have been associated with impairments in sustained attention, speed of information 
processing, memory, and psychomotor functioning (Horst & Preskorn 1998; Stein & 
Strickland, 1998; Tannenbaum et al., 2012). However, in a recent meta-analysis 
analyzing cognitive effects of antidepressants in depressed and non-depressed samples, 
TCAs did not significantly impact performance in any cognitive domain for which it was 
assessed (i.e., sustained and divided attention, immediate and delayed memory, 
processing speed, and psychomotor functioning; Prado et al., 2018). Given that TCAs 
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were only assessed in depressed patients, this finding is complicated by the cognitive 
benefits resulting from the remittance of symptoms of depression.
In the same meta-analysis, selective serotonin reuptake inhibitors (SSRIs), 
serotonin and norepinephrine reuptake inhibitors (SNRIs), and serotonin modulator and 
stimulators (SMSs), all showed significant positive effects in several cognitive domains 
(Prado et al., 2018). Although, the magnitudes of the identified effects were small and 
only significant in the depressed sample. Therefore, it is possible that these effects are 
due to the resolution of symptoms of depression and thus, only speak to the cognitive 
effects of depression. Additionally, in many of Prado and colleagues’ analyses, only two 
or three studies were included, significantly reducing the likelihood of identifying an 
effect if one is present. 
Nonetheless, results from Prado et al. (2018) were significant for small, positive 
effects of SSRI use on tasks of divided attention, executive functioning, immediate and 
delayed memory, and processing speed. SNRI use also showed small, positive effects on 
tasks of divided attention, executive functioning, and delayed memory. SMS use showed 
small, positive effects for divided attention, processing speed, and delayed memory. No 
significant effects were observed for selective serotonin reuptake enhancers (SSREs) in 
the depressed samples. In non-depressed patients, only SSRIs and SNRIs were analyzed, 
and no significant effects were observed in any cognitive domain (i.e., sustained and 
divided attention, immediate and delayed memory, expressive language, visual 
spatial/construction skills, working memory, processing speed, and psychomotor 
functioning; Prado et al., 2018).  
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The cognitive effects of trazodone, a serotonin receptor antagonists and reuptake 
inhibitor (SARI) often used for sleep initiation, have also been evaluated in recent 
studies. However, the literature is mixed. Following seven days of use, Roth and 
colleagues (2011) found small but significant declines in performance on tests of short-
term memory, verbal learning, and motor functioning in a sample of young adults 
diagnosed with insomnia. Conversely, Rush et al. (1997) found acute performance on 
measures of learning and recall for 50 mg, 100 mg, and 200 mg of trazodone did not 
differ from participants who were administered a placebo, when assessed six-hours 
following drug administration. In a third study, Camargos et al. (2015) found no changes 
in overall cognitive functioning, attention, working memory, and processing speed after 
two-weeks of trazodone use in older adults diagnosed with Alzheimer’s disease. 
However, the participants were significantly cognitively impaired prior to inclusion in the 
study (mean Mini-Mental State Exam [MMSE] = 11.2/30, where 25 or more indicates 
cognitive functioning is within normal limits). Due to this impairment, the participants 
were unable to complete assessments of verbal learning and memory, which significantly 
limited the possibility of detecting further decline (Camargos et al., 2015).
Overall, most evidence suggests that use of TCAs leads to poorer cognitive 
functioning (Horst & Preskorn 1998; Stein & Strickland, 1998). Trazadone may 
negatively impact various aspects of cognitive functioning. However, more literature is 
needed on the various acute and long-term effects of trazodone use and the potential for 
cognitive effects in both clinical and non-clinical samples. While there is no clear 
evidence of a negative effect of other antidepressant medications (i.e., SSRIs, SNRIs, 
SMSs, SSREs), and some literature suggests SSRIs and SNRIs may have a positive effect 
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on cognition in depressed samples, more evidence is required to unequivocally make 
claims regarding the cognitive effects of these drug classes given the limitations of the 
presently available literature. 
Anxiolytics
 In terms of anxiolytics, the use of benzodiazepines has often been associated with 
changes in cognitive functioning across domains, consistent with known sedative and 
anticholinergic effects (del Ser et al., 2019; Koelega, 1989; Picton et al., 2018; Stein & 
Strickland, 1998; Tannenbaum et al., 2012). Specifically, reductions in sustained 
attention, psychomotor speed, speed of information processing, and memory 
performances have been observed (del Ser et al., 2019; Stein & Strickland, 1998; 
Tannenbaum et al., 2012). While impairments in memory and attention domains appear 
to be dose-dependent, they appear to persist over time (Moore & O’Keeffe, 1999; Stein & 
Strickland, 1998). However, psychomotor slowing appears to return to normal following 
sustained use due to increased tolerance of sedation effects (Koelega, 1989). 
Additionally, a recent longitudinal study of cognitively normal older adults found 
statistically significant reductions in processing speed at a two-year follow-up (del Ser et 
al., 2019). Although, the effect of this finding was small.  
Despite frequent findings of cognitive impairment across a variety of cognitive 
domains following benzodiazepine use, there continues to be variability in findings of 
impairment, and discrepancies regarding which domains are affected. Nader and Gowing 
(2020) demonstrated this in their recent review of literature examining the association 
between long-term exposure to benzodiazepines and risk of cognitive decline in adults. 
Of the 14 studies reviewed, only three supported an association between long-term 
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benzodiazepine use and cognitive impairment with small to medium effect sizes. 
However, there was no consistency with regard to affected domains across all three 
studies. Additionally, definitions of long-term use, cognitive domains assessed, cognitive 
tests within domains, scoring of cognitive tests, and statistical analyses differed across all 
included studies, likely contributing to the inconsistent results.
 In terms of global cognitive functioning, recent studies of the effects of 
benzodiazepines in elderly populations were also mixed (Nader & Gowing, 2020; Picton 
et al., 2018). For example, in reviews of studies examining benzodiazepine use in the 
elderly, only three of nine prospective clinical trials and five of seven case-control studies 
found significant differences in overall cognitive functioning between individuals 
prescribed benzodiazepines and controls (Picton et al., 2018). However, of the studies 
that did not find impairments in global cognitive functioning in individuals using 
benzodiazepines, many had smaller sample sizes and shorter follow-up periods. A more 
recent longitudinal study evaluating benzodiazepine use and the risk of cognitive 
impairment in older adults found that while benzodiazepine use did not increase the risk 
of the development of dementia, it did increase the risk of milder cognitive impairment 
(Nafti et al., 2020). Additionally, literature examining the effects of longer acting 
benzodiazepines indicates that they are more strongly related to cognitive decline in older 
adults, compared to shorter acting benzodiazepines (Picton et al., 2018). For example, del 
Ser et al. (2019) found that bromazepam, in particular, was associated with a higher rate 




The AGS Beers Criteria (2019) note that there is moderate evidence that 
benzodiazepines increase the risk of cognitive impairment and delirium in older adults 
and strongly recommend they are avoided. Despite this recommendation, benzodiazepine 
use remains common in older adults, particularly women, making them especially 
susceptible to negative cognitive effects of these prescriptions (Olfson et al., 2015; Maust 
et al., 2016). There is very little evidence regarding the effects of other anxiolytics on 
cognitive functioning. Although, in a comparison of buspirone, an atypical anxiolytic and 
a benzodiazepine, buspirone did not show a statistically significant effect on cognitive 
functioning (Stein & Strickland, 1998). Therefore, no strong conclusions can be drawn 
regarding the effect of anxiolytics on cognitive functioning. 
Analgesics
Overall, use of analgesics, and opioids in particular, have been associated with 
cognitive deficits across a range of cognitive domains. In some cases, these negative 
effects have been associated with anticholinergic or neurotoxic effects of drug 
metabolites, however, that is not always the case (Kornitzer et al., 2006). With the use of 
opioids, Ersek and colleagues (2004) noted that reductions in psychomotor speed, poor 
attention, and impairments in memory were commonly cited in the literature. However, a 
more recent meta-analytic review found impairments in the domains of verbal working 
memory, cognitive impulsivity, and cognitive flexibility for individuals using opioids 
compared to healthy controls (Baldacchino et al., 2012). Conversely, Allegri and 
colleagues’ (2019) meta-analytic review of the long-term effects of opioid use on 
cognition only identified differential performances in the attention domain, with 
individuals taking opioid medications having a significantly poorer performance than 
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those taking non-CNS acting medications. In both Baldacchino et al. (2012) and Allegri 
et al. (2019), the magnitudes of the effects were medium. Additionally, one longitudinal 
study of opioid use in older adults found that opioid use was associated with global 
cognitive decline, although this effect was only evident in participants over the age of 75 
and did not control for the effect of pain (Puustinen et al., 2011). 
Therefore, opioids appear to have a significant effect of cognition, although the 
specific domains affected may vary. One possible reason for this may be due to the 
heterogeneity in chemical structures, pharmacokinetics, and pharmacodynamics of the 
opioids used in these studies. For instance, morphine has been associated with reduced 
psychomotor speed, verbal processing, and attention, whereas oxycodone has been 
associated with reduced attention, verbal learning, working memory, and reaction time 
(Allegri et al., 2019).  
Apart from the cognitive effects associated with opioids, little is known about the 
cognitive effects of other types of analgesics. One study found that beginning naproxen 
was associated with improved processing speed from a baseline assessment (Obermann et 
al., 2013). However, given that pain was not controlled for in this study, this 
improvement may be due to the resolution of pain rather than an effect of the drug 
specifically. Overall, opioids appear to significantly affect cognitive functioning, 
particularly in working memory, psychomotor speed, and attention. However, more 
research into specific medications within this therapeutic group is necessary in order to 






 Impairments in a broad range of cognitive domains have been observed across a 
variety of antiepileptic medications (Stein & Strickland, 1998). Broadly, long-term use of 
antiepileptic drugs (AEDs) has been associated with poor performance on tests of 
attention and concentration, psychomotor functioning, and verbal fluency (Park & Kwon, 
2008; Stein & Strickland,1998). Although short term use of AEDs shows less consistent 
effects on cognitive functioning, likely due to various methodological problems in these 
studies (Park & Kwon, 2008).  
In general, older antiepileptic medications appear to show more diffuse and 
intense effects than newer medications (Park & Kwon, 2008; Stein & Strickland, 1998). 
For example, the negative neuropsychological effects of phenobarbital include sedative- 
and dose-dependent impairments in measured intelligence quotient (IQ; Calandre et al., 
1990; Farwell et al., 1992), attention and concentration (see Smith, 1991 for a review), as 
well as memory and psychomotor speed (MacLeod et al., 1978). Additionally, phenytoin 
and carbamazepine use are generally associated with impairment in psychomotor speed 
and slowed verbal responding, respectively (Stein & Strickland, 1998). Yet, there is 
evidence to suggest topiramate and levetiracetam, two newer AEDs, produce greater 
reductions in cognitive functioning than any other AEDs. Specifically, Nevado-Holgado 
and colleagues (2016) found that use of topiramate was associated with the worst 
reasoning and memory performances of individuals using active CNS medications. Use 
of levetiracetam, on the other hand, was associated with memory performances that were 
only slightly better than that of topiramate but poorer than other AEDs and worse 
reaction time compared to other AEDs (Nevado-Holgado et al., 2016). Therefore, long-
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term use of AEDs is consistently related to reduced cognitive functioning across many 
cognitive domains, although measures of attention and psychomotor speed may be most 
sensitive to these effects.
Cardiovascular 
 Overall, findings of cognitive effects of cardiovascular medications across studies 
are variable, likely suggesting differential effects of specific medications or drug families 
used in cardiovascular treatments. Specifically, one meta-analysis studying the effect of 
various antihypertensive medications on cognitive functioning in patients without a 
history of cerebrovascular disease (e.g., stroke, stenosis, and aneurysm) found a 
significant positive effect of antihypertensive medication use on overall cognitive 
functioning (Marpillat et al., 2013). Although the effect size for this finding was small in 
magnitude and only significant for the first 6 months of therapeutic treatment. In terms of 
specific cognitive domains, significant positive effects following use of antihypertensive 
medications were identified for executive functioning, processing speed, attention, and 
immediate and delayed memory, with effect sizes ranging from .20 to .40 (Marpillat et 
al., 2013). When analyzed by drug class/drug family, angiotensin II receptor blockers 
(ARBs) showed the largest benefit compared to a placebo on overall cognition, with a 
large, adjusted effect size of .6. Angiotensin-converting enzyme (ACE) inhibitor, beta-
blockers, and diuretics also showed significant positive effects on overall cognitive 
functioning, with effect sizes ranging from medium to large (Marpillat et al., 2013). 
 These results are consistent with results from Nevado-Holgado et al. (2016) that 
individuals prescribed ACE inhibitors, such as perindopril performed better on a test of 
reasoning compared to individuals prescribed other antihypertensive medications. 
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However, poorer reasoning and slowed reaction times were associated with the use of 
calcium channel blockers (CCBs) and diuretics, such as amlodipine and furosemide, 
respectively (Nevado-Holgado et al., 2016). Additionally, in a study of medication use in 
older adults, Obermann et al. (2013) found negative cognitive effects in processing speed 
and memory domains for starting furosemide between the baseline and one-year follow-
up. Despite these findings, del Ser and colleagues (2019) identified significant reductions 
in the conversion to MCI with the use of angiotensin II antagonists, and Losartan in 
particular, as well as with the use of hydrochlorothiazide, a diuretic.
One factor that may contribute to the variability in findings across cardiovascular 
drug families and specific medications is the anticholinergic properties of some of these 
medications. For instance, some diuretics, antiarrhythmics, vasodilators, CCBs, and beta-
blockers (e.g., furosemide, chlorthalidone, hydrochlorothiazide, disopyramide, quinidine, 
atenolol, captopril, hydralazine, metoprolol, nifedipine, and timolol maleate) have been 
rated as having possible anticholinergic activity that may contribute to overall 
anticholinergic cognitive burden (Marvanova, 2016). Further, many drugs (e.g., 
reserpine, methyldopa, clonidine, prazosin, and digoxin) within this therapeutic group 
have been associated with the development of delirium and worsening cognitive 
functions for individuals diagnosed with mild cognitive impairments or dementia 
secondary to neurotoxicity, imbalance of neurotransmitters in the CNS, fluid and 
electrolyte imbalances, and decreased cerebral blood flow (Marvanova, 2016). However, 
these effects are complicated by the improvement in cognitive symptoms or slowing of 
progressive cognitive dysfunction that results from hypertension and other cardiac-related 
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diseases. Therefore, further study of the cognitive effects of antihypertensive medications 
is warranted. 
Overall, many medications have been associated with changes in cognitive 
functioning. Although, these effects do not occur in a vacuum. Rather, these cognitive 
effects co-occur and interact with factors that contribute to drug intensity and therefore 
increase the risk of negative therapeutic effects. Older adults, in particular, are at a high 
risk of these negative cognitive effects. This is due in part to differences in 
pharmacokinetic processes and pharmacodynamics in older and younger adults (Fulton & 
Allen, 2005). Specifically, higher rates of liver and kidneys impairments, frailty, 
malnutrition, and chronic brain pathology in older adults compared to younger adults 
play a role in elevating this risk for older adults (Burchum & Rosenthal, 2016; Kinirons 
& O'Mahony, 2004; Moore & O’Keeffe, 1999). Furthermore, older adults have greater 
rates of comorbidities, and thus, polypharmacy, than younger adults (Barnett et al., 2012; 
Kantor et al., 2015), which may also contribute to findings of greater cognitive side 
effects from medication use.
 
Cognitive Effects of Polypharmacy 
Polypharmacy, defined as the concurrent use of two or more or the concurrent use 
of five or more medications, and excessive polypharmacy, defined as the concurrent use 
of 10 or more medications (Jyrkkä et al., 2011), have consistently been associated with 
greater impairment in cognitive functioning (Jyrkkä et al., 2011; Maher et al., 2014; 
Moore & O’Keefe, 1999; Sordahl et al., 2019). Although most analyses of these effects 
focus exclusively on the effects of opioids and polypharmacy in older adults. 
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Specifically, Wright et al. (2009) found that a combined daily dose of medications greater 
than three standard doses, across various CNS acting medications, was strongly related to 
overall cognitive decline in older adults. Similarly, the combined use of opioids and any 
other CNS acting medication (e.g., benzodiazepines and related drugs, antipsychotics, 
antidepressants, opioids, anticholinergics, and antiepileptics) in cognitively intact older 
adults was significantly related to global cognitive decline, even after controlling for 
other factors related to reduced cognitive functioning, such as age, sex, education, and 
various medical conditions (Puustinen et al., 2011). 
A recent meta-analysis evaluating the effects of opioid use found that the 
combined effects of opioid therapeutic treatment, antidepressants, and/or anticonvulsants 
was associated with worse performance on measures of attention compared to patients 
not taking CNS active medications (Allegri et al., 2019). Effect size estimates for this 
result were in the medium range (SMD: -.62; Allegri et al., 2019). With regard to 
anticholinergic medications, increased cognitive burden of anticholinergic medications, 
through the use of multiple anticholinergic medications, significantly increased the risk of 
negative cognitive effects, such as delirium and dementia (Agar et al., 2009; Boustani et 
al., 2008; Campbell et al., 2009; Marvanova, 2016; Moore & O’Keefe, 1999; Sordahl et 
al., 2019).  
While it is clear that there is an effect of polypharmacy on cognition, particularly 
in older adults who are taking multiple CNS active medications, more literature on this 
phenomenon in younger adults and for non-opioid medications is necessary. 
Additionally, in most of the studies described above, cognitive ability is evaluated based 
on a brief, screening measure of global cognition or single brief measures of specific 
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cognitive domains (e.g., digit-symbol substitution to assess psychomotor speed or digit 
span to assess working memory). This practice is problematic in that cognitive screening 
measures are narrow in scope, have relatively low sensitivity, and are generally designed 
to identify those who may need a more extensive evaluation (Roebuck-Spencer et al., 
2017). Given these limitations, the use of the brief screening measures significantly limits 
the ability to identify possible effects across the full breadth of cognitive domains, 
particularly if the effects are subtle. Unfortunately, this limitation in the assessment of 
cognitive functioning is not restricted to the evaluation of cognitive effects with respect 
to polypharmacy. Rather, this practice appears to be consistent across studies of 
medication and cognition. Most studies, even those evaluated within meta-analyses, 
utilize brief screening measures to evaluate overall cognitive functioning. Although, that 
is not the only measure of cognition available or used by researchers or physicians in the 
measurement of cognition. The following section will review some of the other measures 
of cognitive functioning used by researchers and physicians. 
 
Measuring Cognitive Dysfunction 
 
Global Cognition 
While most models of cognitive functioning recognize a general, latent factor of 
cognition, g, the most current framework, termed Cattell-Horn-Carroll (CHC; Flanagan 
& McGrew, 1997), primarily focuses on the assessment of many first order factors, 
narrow cognitive abilities, that are subsumed by second order factors, or broad cognitive 
abilities, which are then subsumed by the third order, overall factor. The CHC model has 
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been extensively evaluated and is widely accepted in its modeling of cognitive abilities, 
likely due to its foundation in factor analysis (Ackerman & Heggestad, 1997; McGrew, 
2009; Schneider & McGrew, 2012; Stankov, 2000). Therefore, the CHC model supports 
the guiding principles of cognitive assessment. 
The structure of the CHC model is hierarchical in nature and assumes that each 
factor is somewhat independent, suggesting that there is unique variance attributed to 
each factor, not accounted for by the remaining factors in that order (Flanagan & 
McGrew, 1997; Strauss et al., 2006). Therefore, given the multifaceted nature of 
cognition, the most accurate assessment of cognitive functioning should include 
multifaceted measures and techniques. However, given limitations in available tests, the 
ability of patients, the time allotted for the assessment constrain evaluations of cognitive 
functioning, this is not always possible, and therefore brief screening measures are 
heavily relied upon in research regarding cognition. 
One specific measure that has often been used in the assessment of overall 
cognitive functioning, is the Mini-Mental State Exam (MMSE; Folstein et al., 1975), 
particularly in relation to medication effects (e.g., Camargos et al., 2015; del Ser et al., 
2019; Jyrkkä et al., 2011; Marpillat et al., 2013; Ng et al., 2014; Puustinen et al., 2011; 
Sordahl et al., 2019; Wright et al., 2009). While various factor structures for this brief, 
screening measure of cognitive impairment have been identified, including both 
unidimensional and multidimensional structures, orientation, attention, and memory 
factors appear to be the most stable (Banos & Franklin, 2002; Jones & Gallo, 2000). 
However, factors containing items attributed to language functioning, and construction 
are less stable, and may be sample specific (Strauss et al., 2006). 
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Therefore, in terms of measurement of second order factors, or broad cognitive 
domains consistent with models of cognitive functioning, this measure is very limited. 
Additionally, given the development of this scale to assess cognitive impairment, there is 
a large ceiling effect for cognitively normal and mildly impaired patients (de Jager et al., 
2009; Hoops et al., 2009). Consequently, it may be nearly impossible to accurately detect 
small to moderate effects of various prescription medications on global cognitive 
functioning based on the use of this measure. Given the limitation of the MMSE, two 
additional measures of global cognitive functioning will be reviewed below, which may 
more accurately capture changes in cognitive functioning due to medication effects.
Overall Test Battery Mean 
 An Overall Test Battery Mean (OTBM) serves as a demographically corrected 
overall index of an individual’s performance across a battery of neuropsychological tests 
(Heaton et al., 2001; Miller & Rohling, 2001; Rohling et al., 2003). This is calculated by 
first converting all raw test scores to standardized scores either through the use of co-
normative data or through the use of independently normed data. Scores must then be 
converted to a common metric (e.g., T-scores, Z-scores, or standardized scores) and 
subsequently averaged. 
 Analysis of this index suggests that it is analogous to the Halstead Impairment 
Index (HII) derived from the standardized Halstead-Reitan Battery (HRB; Reitan & 
Wolfson, 1993; Rohling et al., 2003). Reliability estimates of this global index in samples 
with schizophrenia and normal controls suggest that the OTBM is stable over time and 
generally consistent with Full-Scale IQ (FSIQ) from the Wechsler Adult Intelligence 
Scale, third edition (WAIS-III; Heaton et al., 2001). Additionally, the OTBM is sensitive 
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to differential overall cognitive performances by individuals with various classifications 
of brain injury, groups diagnosed with general medical conditions, groups diagnosed with 
depression, and poor effort groups (Green et al., 2001). Therefore, the OTBM appears to 
be a sufficiently valid and reliable measure of global cognitive dysfunction. Given that 
the calculation of this measure is based on performance across cognitive domains 
assessed and is not limited to the domains provided within a single test, this index would 
likely reflect the general ability (g) described in the CHC model given adequate 
measurement of cognitive domains by individual test selection.
 However, there are some limitations to this measurement. Specifically, with 
regard to individuals who may demonstrate impairments in only select cognitive 
domains. Since the OTBM only provides an index of central tendency for an individual’s 
overall performance, individuals who are highly consistent in their performance across 
domains would receive the same index score as those who are highly variable, and likely 
show deficits in select domains. Therefore, cognitive intra-individual variability (e.g. 
Hilborn et al., 2009) may serve as another measure of global cognitive functioning that is 
particularly sensitive to subtle cognitive impairments.
Intra-Individual Variability 
 Cognitive intra-individual variability (IIV) serves as a measure of spread or 
dispersion for an individual’s performance either within a single measure across time 
(i.e., consistency) or across multiple measures that are in the same metric unit from a 
single assessment (i.e., dispersion; Hill et al., 2013; MacDonald et al., 2009). Therefore, 
it can be calculated in many different ways. The method most relevant to the present 
study is that of dispersion. IIV is calculated by taking the standard deviation (SD) around 
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an individual’s OTBM. Thus, greater IIV indicates greater differences in performance 
across tasks and domains of a neuropsychological assessment, whereas smaller IIV 
indicates more similar performances across tasks and domains of a neuropsychological 
assessment. 
 Several studies of cognitive IIV suggest that this measure is one of CNS 
dysfunction (Hill et al., 2013; Hultsch & MacDonald, 2004). Specifically, greater IIV has 
been associated with frontal lobe impairment (Stuss et al., 2003), various dementing 
illnesses (Ballard et al., 2001; Hultsch et al., 2000; Murtha et al., 2002; Walker et al., 
2000), and HIV status (Morgan et al., 2011). Additionally, cognitive IIV has been found 
to be positively associated with TBI severity (Hill et al., 2013) and experiences of 
cognitive decline in cognitively normal older adults (Hilborn et al., 2009). Thus, IIV may 
serve as a sensitive indicator of cognitive integrity when evaluating the potential effects 









STATEMENT OF THE PROBLEM 
 
The use of prescription medications in treating disease, relieving symptoms, and 
preventing future physical or mental health events is extensive. Particularly, in adults and 
older adults, who make up a considerable proportion of the population and are at the 
highest risk of health-related problems. Despite evaluations of most prescription 
medications prior to FDA approval and general use, risk of additional side effects 
remains. This is particularly relevant in the case of relatively subtle and long-term effects 
of prescription drug use in cognitively vulnerable populations, who are often excluded 
from clinical trials (Boyd et al., 2012; Cho et al., 2011; McMurdo, 2005). Therefore, the 
potential for patients to experience meaningful changes in cognitive functioning 
following prescription medication use is very high, particularly for patients who use 
multiple drugs. 
This issue is highly relevant for physicians, specifically neurologists and 
neuropsychologists. Without a clear understanding of the effects of medication groups 
and specific medications, these physicians are unable to adequately clarify diagnoses, 
make treatment recommendations, and inform prognoses of patients reporting cognitive 
changes due to their reliance on patterns of performance on cognitive testing (Schoenberg 
& Scott, 2011). Moreover, while the cognitive effects of some of these commonly 
prescribed medications have been elucidated in recent years in both cross sectional and 
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longitudinal studies, several limitations to the existing body of literature remain. 
First, few studies examine cognitive effects of medication or polypharmacy in 
broad clinical samples, limiting the generalizability of results. Second, across studies of 
the effects of medication on cognitive functioning, many psychiatric, neurological, and 
general medical diagnoses were inconsistently controlled for (e.g., del Ser et al., 2019 and 
Obermann et al., 2013). By not adequately controlling for these potential confounding 
variables, it is impossible to tease out the effects of pharmacotherapeutics from 
disease/diagnosis effects in these studies. Third, the existing literature on the effects of 
medication on cognition has generally avoided evaluations of a potential interaction 
effect with polypharmacy by statistically controlling for possible effects by entering the 
number of medications prescribed as a covariate in analyses (e.g., del Ser et al., 2019; 
Nevado-Holgado et al., 2016; Wright et al., 2009). While these types of analyses provide 
valuable information regarding the individual effects of medication and polypharmacy to 
cognitive performance, the results are not necessarily generalizable to a significant 
proportion of the population who use multiple medications concurrently.
Lastly, studies of medication effects on cognition generally restrict investigations 
to a few screening tests of overall functioning or evaluation of limited domains of 
cognitive functioning (e.g., del Ser et al., 2019; Jyrkka et al, 2011; Nevado-Holgado et 
al., 2016; Obermann et al., 2013; Wright et al., 2009). Though these narrow 
investigations have identified effects for some variables, a more thorough measurement 
of cognition may detect more subtle effects of altered cognitive functioning. 
Additionally, questions remain regarding the effects of medications and polypharmacy on 
common neuropsychological measures of global and domain-specific functioning across 
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a variety of cognitive domains. 
 
The Present Study 
The present study sought to add to and extend the literature regarding effects of 
medications and polypharmacy on cognition in a broad clinical sample (e.g., TBI, 
vascular/cerebrovascular accident [CVA], encephalitis, mental health diagnoses, etc.). 
Specifically, the present study consisted of a thorough evaluation of the independent and 
collaborative effects of medications and polypharmacy on cognitive functioning in both 
global and specific domains, as measured by a standardized battery of common 
neuropsychological tests. Given this objective, three primary aims were explored: (1) the 
effects of medications and polypharmacy on global cognitive functioning, as assessed by 
the OTBM; (2) the effects of medications and polypharmacy on global cognitive 
functioning, as assessed by variability in performance across cognitive domains (IIV); 
and (3) the effects of medications and polypharmacy on performance in specific cognitive 
domains.  
Hypotheses
The purpose of this dissertation is to address the following aims/hypotheses: 
Aim One.  
To examine the effects of medication use and polypharmacy on global cognitive 
functioning, as assessed by OTBM, two-way Analyses of Covariance (ANCOVAs) were 
used to evaluate the interaction and main effects of medication use and polypharmacy on 
the OTBM. Specifically, these analyses were used to determine if there was an 
interaction between medication use and polypharmacy level on OTBM, if there were 
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differential effects of medication use on the OTBM, and if there were differential effects 
of levels of polypharmacy on OTBM. To isolate the effects of medication use, levels of 
polypharmacy, and their potential interaction, psychiatric, neurological, and general 
medical diagnoses, as well as estimated premorbid functioning were each entered as 
covariates. Given this objective the following hypotheses were tested: 
1.1 There is a significant interaction between medication use and level of 
polypharmacy on OTBM. 
1.2 The OTBM of individuals using a medication is significantly different from 
the OTBM of those not using the medication. 
1.3 The OTBM of at least one polypharmacy level is significantly different from 
the other polypharmacy levels. 
Aim Two. 
To examine the effects of medication use and polypharmacy on global cognitive 
functioning, as assessed by IIV (see the Calculation of IIV section below), two-way 
ANCOVAs were used to evaluate the interaction and main effects of medication use and 
polypharmacy on IIV. Specifically, these analyses were used to determine if there was an 
interaction between therapeutic group and polypharmacy on IIV, if there were differential 
effects of medication use on IIV, and if there were differential effects of polypharmacy 
on IIV. To isolate the effects of medication use, levels of polypharmacy, and their 
potential interaction, psychiatric, neurological, and general medical diagnoses, as well as 
estimated premorbid functioning were each entered as covariates. Given this objective the 
following hypotheses were tested: 
2.1 There is a significant interaction between medication use and level of 
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polypharmacy on IIV. 
2.2 The IIV of individuals using a medication is significantly different from the 
IIV of those not using the medication. 
2.3 The IIV of at least one polypharmacy level is significantly different from the 
other polypharmacy levels. 
Aim Three. 
To examine the effects of medication use and polypharmacy on domain-specific 
cognitive functioning, two-way Multivariate Analyses of Covariance (MANCOVA) were 
used to evaluate the interaction and main effects of medication use and polypharmacy on 
the following cognitive domain means: Attention/Working Memory, Processing Speed, 
Verbal Reasoning, Visual Reasoning, Verbal Memory, Visual Memory, Executive 
Functioning, Dominant Motor and Sensory Functioning, and Non-Dominant Motor and 
Sensory Functioning. Specifically, these analyses were used to determine if there was an 
interaction between medications and polypharmacy on each cognitive domain mean, if 
there were differential effects of medication use on each cognitive domain, and if there 
were differential effects of polypharmacy on each cognitive domain mean. Given this 
objective the following hypotheses were tested: 
3.1 There is a significant interaction between medication use and polypharmacy 
on a domain-specific performance (e.g., domain mean). 
3.2 The domain mean of individuals using a medication is significantly different 
from the domain mean of those not using the medication. 
3.3 The domain mean of at least one polypharmacy level is significantly different 








Prior to data collection, this study was approved by the University of South 
Alabama Institutional Review Board (IRB; see Appendix A). Archival data from two 
practicing neuropsychologists, located in the Midwestern and Southeastern US, who 
utilized the Meyers Neuropsychological System (MNS; Meyers, 2013) were utilized in 
this study. Given that the study was retrospective nature and there was no foreseeable 
risk, informed consent was not necessary from study participants.  
All patients were evaluated between 1990 and 2020. At the time of their 
assessment, participants completed a clinical interview and a comprehensive flexible 
battery of neuropsychological tests, which included tests from the Meyers 
Neuropsychological Battery (MNB; Meyers & Rohling, 2004): subtests from the WAIS-
III (Wechsler, 1997) or Wechsler Adult Intelligence Scale IV (WAIS-IV; Wechsler, 
2008); Trail Making Test (TMT; Reitan & Wolfson, 1985); Judgement of Line 
Orientation (JLO; Benton et al., 1983a); Finger Tapping (FTT; Reitan & Wolfson, 1985); 
Finger Localization Test (FLT; Benton et al., 1983b); Token Test (TT; Spreen & Strauss, 
1998); North American Adult Reading Test (NAART; Spreen & Strauss, 1998); Sentence 
Repetition (SR; Spreen & Strauss, 1991); Controlled Oral Word Association Test (FAS; 
Spreen & Strauss, 1998); Animal Naming (Animals; Spreen & Strauss, 1998); Boston 
Naming (BNT; Spreen & Strauss, 1998); Dichotic Listening (DLT; Meyers et al., 2002; 
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Roberts et al., 1994); Auditory Verbal Learning Test (AVLT; Spreen & Strauss, 1998); 
Rey Complex Figure Test (RCFT; Meyers & Meyers, 1995); The Category Test - 
Victoria Revision (VCT; Spreen & Strauss, 1991); and Forced Choice (FC; Brandt et al., 
1985).  
 
Inclusion and Exclusion Criteria 
Cases were only included in the study if participants were over the age of 18, if 
medication information was included in the record, and the record contained sufficient 
(e.g., at least 20%) of the study variables. Given the likelihood that follow-up or re-
evaluation data could unintentionally overly influence statistical analyses, these cases 
were excluded from the study. Further, due to the distinct lower limit of standardized 
measurement on neuropsychological tests, subjects with premorbid estimations or an 
OTBM below the second percentile were not included in the study. Lastly, cases were 
excluded from the study on the basis of failed validity tests or if they had a diagnosis of 
malingering.  
With regard to validity testing, the generally accepted standard indicating invalid 
test performance is two or more failed validity measures over the course of a 
neuropsychological evaluation (Larrabee, 2008; Meyers & Volbrecht, 2003; Meyers et 
al., 2011). However, more recent literature indicates that many commonly used cut-offs 
for performance validity tests (PVTs) may not be appropriate for use in cognitively 
impaired samples due to high false-positive rates (McGuire et al., 2019; Martin et al., 
2020). Instead, a standard of three or more failed PVTs over the course of a 
neuropsychological evaluation has been suggested as a more appropriate indicator of 
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invalid performance in cognitively impaired samples (Martin et al., 2020). Therefore, if a 
subject was not diagnosed with cognitive impairment and failed two or more validity 
tests, they were excluded from the study. Contrarily, if the subject was diagnosed with 
cognitive impairment and the patient failed three or more PVTs, they were excluded from 
the study.  
 
Participants  
Seven hundred and fifty archived data files were reviewed for inclusion in this 
study. Of these cases, 110 subjects were under the age of 18 and were excluded. Of the 
remaining cases, two did not contain medication information, one did not include any 
cognitive test data, five cases were re-evaluations, and five cases were duplicate entries 
and therefore were excluded. An additional 35 cases were excluded due to containing 
insufficient cognitive data to calculate at least 20% of the study outcome variables. 
Of the remaining 592 cases, 22 cases were excluded due to having an OTBM 
below the second percentile (e.g., T < 30). Further, one case file listed a diagnosis of 
“malingering” and was excluded. Seventy-two additional cases were excluded due to 
concerns for performance validity as described above. The remaining 497 cases were 









Screening Process and Exclusion Criteria for Archival Case Review 
 
Note. OTBM = Overall Test Battery Mean. 
 
110 Under 18 750 Cases 
2 No Medication 
Information 640 Cases 
1 No Cognitive 
Test Data 
638 Cases 
5 Re-evaluation 637 Cases 
5 Duplicate 632 Cases 
35 Insufficient 
Cognitive Data 627 Cases 









Table 2 presents characteristics of the final sample. As can be seen, the final 
sample had a mean age of 40.75 (SD = 14.61, range = 18-80 years old). Average years of 
education was 12.93 (SD = 2.36). Fifty-two percent of the sample identified as female. A 
majority of the sample identified as Caucasian (n = 468, 94.0%). Number of medications 
used by each subject ranged from 0 to 14 medications (M = 2.64, SD = 2.50). 
Approximately 11% of cases had polypharmacy, as defined as using six or more 
medications. Table B.1 and Table B.2 detail the diagnoses and medications for sample 
participants, respectively. Additionally, given that medications with strong 
anticholinergic properties come from a variety of therapeutic use categories and 
medication families, medications with strong anticholinergic properties used by sample 
participants are also provided in table B.3. Table 3 details overall cognitive performance 
for the sample.
Of note, 47 subjects (9.5%) in this sample were considered “older adults,” as 
defined as age at or above 65 years, at the time of the evaluation. Given the generally 
small subsample of older adults, these groups were combined for all analyses. However, 
much like the literature on medication use, medication use significantly differed across 
these stages of life [c2(2, 497) = 17.75, p < .001). Specifically, 17.8 % of adults reported 
not taking any medications, 72.4% of adults reported taking 1-5 medications, and 9.8% of 
adults reported taking six or more medications (e.g., polypharmacy). For older adults on 
the other hand, all subjects were taking at least one medication. Approximately 75% of 
older adult subjects reported taking 1-5 medications. The remaining 25.5% of older adult 
subjects reported taking 6 or more medications (e.g., polypharmacy). Performance on 
cognitive measures did not differ between adults and older adults in the sample 
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[tOTBM(495)=0.30, p=.384; tattention(492)=0.97, p=.166; tprocessing speed (491)=-0.18, p=.430; 
tverbal reasoning(493)=1.03, p=.1.52; tvisual reasoning(494)=1.27, p=.102; tverbal memory(488)=-0.92, 
p=.179; tvisual memory(479)=0.12, p=.451; texecutive functions(495)=0.43, p=.333; tdominant 




Characteristics of the Final Sample 
 Total Sample Adult Older Adult 
Variable M (SD) M (SD) M (SD) 
Age 40.8 (14.6) 37.9 (12.1) 67.8 (6.5) 
Education 12.9 (2.4) 12.9 (2.3) 13.4 (3.1) 
Gender n (Valid %) n (Valid %) n (Valid %) 
       Male 237 (47.7%) 212 (47.1%) 25 (53.2%) 
       Female 259 (52.1%) 237 (52.7%) 22 (46.8%) 
Ethnicity    
       Asian/Asian American 3 (0.6%) 3 (0.7%) 0 (0.0%) 
       Black/African American 13 (2.6% 12 (2.7%) 1 (2.1%) 
       Caucasian 467 (94.0%) 421 (93.6%) 46 (97.9%) 
       Other 13 (2.6%) 13 (2.9%) 0 (0.0%) 
Medication Use    
       No Medications 80 (16.1%) 80 (17.6%) 0 (0.0%) 
       1-5 Medications 361 (72.6%) 326 (72.4%) 35 (74.5%) 
       Polypharmacy (6+) 56 (11.3) 44 (9.8%) 12 (25.5%) 
Forensic Evaluation 120 (24.1%) 114 (25.3%) 6 (12.8%) 
PVT Failures    
       0 263 (52.9%) 233 (51.8%) 30 (63.8%) 
       1 208 (41.9%) 194 (43.1%) 14 (29.8%) 
       2 26 (5.2%) 23 (5.1%) 3 (6.4%) 
Neuropsychology Practice    
       Midwestern 434 (87.3%) 393 (87.3%) 41 (87.2%) 
       Southeastern 63 (12.7%) 57 (12.7%) 3 (12.8%) 
Note. n = 497. M = mean. SD = Standard Deviation. n = frequency. Due to missing data 
across variables, frequencies of variables may not add up to the total sample size. PVT 








Summary of Cognitive Performance for Sample 
  n M SD 
Premorbid Estimate 485 46.5 4.3 
OTBM 497 44.5 5.5 
IIV 475 9.7 2.4 
Attention/Working Memory 494 44.3 6.9 
Processing Speed 493 45.1 7.7 
Verbal Reasoning 495 45.6 7.0 
Visual Reasoning 496 45.1 6.9 
Verbal Memory 490 42.1 10.7 
Visual Memory 481 43.8 10.5 
Executive Functioning 497 45.3 7.0 
Dominant Motor Function 463 46.8 8.3 
Non-Dominant Motor Function 462 46.3 7.7 
Note. N = 497. Sample sizes differ across variables due to missing values. n = 
sample size. M = mean. SD = Standard Deviation. OTBM = Overall Test Battery 
Mean. IIV = Intra-Individual Variability. OTBM and domain means are presented 






Meyers Neuropsychological Battery 
 All study participants completed the MNB (Meyers & Rohling, 2004) at the time 
of their assessment. The MNB, is a semi-flexible battery of common neuropsychological 
tests that are presented in a standard order. The tests that make up the core of this battery 
have been shown to be sensitive to brain injury (Meyers & Rohling, 2009; Meyers & 
Rohling, 2004; Volbrecht et al., 2000) and they rank among the most common tests used 
by clinical neuropsychologists overall (Rabin et al., 2016).  
The following tests are part of the MNB core measures: Block Design, 
Similarities, Digit Span, Arithmetic, Information, Coding, and Picture Completion from 
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the WAIS-III/IV (Meyers et al., 2013; Pilgrim et al., 1999), TMT (Reitan & Wolfson, 
1985), JLO (Benton et al., 1983a), FTT (Reitan & Wolfson, 1985), FLT (Benton et al., 
1983b), TT (Spreen & Strauss, 1998), NAART (Spreen & Strauss, 1998), SR (Spreen & 
Strauss, 1991), FAS (Spreen & Strauss, 1998), Animals (Spreen & Strauss, 1998), BNT 
(Spreen & Strauss, 1998), DLT (Meyers et al., 2002; Roberts et al., 1994), AVLT 
(Spreen & Strauss, 1998), RCFT (Meyers & Meyers, 1995), VCT (Spreen & Strauss, 
1991), and FC (Brandt et al., 1985). Scores derived from performance on these tests 
assess the following cognitive domains: Attention/Working Memory, Processing Speed, 
Verbal Reasoning, Visual Reasoning, Verbal Memory, Visual Memory, Executive 
Functioning, and Dominant and Non-Dominant Motor and Sensory Functioning (Lezak 
et al., 2012; Meyers & Rohling, 2009; Strauss et al., 2006). 
Given the semi-flexible nature of the MNB, other tests were added to the core 
MNB and/or were substituted for a core test at the discretion of the supervising 
neuropsychologist at the time of the assessment and, subsequently, factored into the 
calculation of study variables (e.g., OTBM, IIV, and cognitive domain means). Eleven 
additional neuropsychological tests were used across the sample. However, each of these 
tests was used for ≤ 5% of sample participants. Given this, for concision, only MNB core 
tests are described below. However, all tests (core and supplemental) used for sample 
participants and to which cognitive domain they assessed when administered are listed in 
Table B.4. 
Wechsler Adult Intelligence Scale.
The Wechsler Adult Intelligence Scale (WAIS) is a measure of intellectual 
functioning in older adolescents and adults. The two most recent versions, WAIS III and 
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WAIS IV, are composed of 10 core subtests that allow for the calculation of a FSIQ and 
four index scores: verbal ability (VCI), perceptual ability (POI or PRI), working memory 
(WMI), and processing speed (PSI; Wechsler, 1997; Wechsler, 2008). Internal 
consistency reliability is very high for the FSIQ, index scores, and core subtests. Further, 
subtest specificity is adequate across core subtests, an indication of the proportion of 
subtest variance that is reliable and unique to the subtest (Strauss et al., 2006). 
A short form of each version of the WAIS (III or IV) was used as part of the 
MNB, which includes the Block Design, Similarities, Digit Span, Arithmetic, 
Information, Coding, and Picture Completion subtests (Meyers et al., 2013). Each of the 
subtest comprising the short version is known to be sensitive to various forms of brain 
dysfunction (see Strauss et al., 2006). Additionally, index scores and FSIQ calculated 
from this abbreviated version correlate highly with the full-length scores, correlations 
range from .92 to .99 (Meyers et al., 2013; Pilgrim et al., 1999). Effect sizes calculated 
from comparisons of scores from the short form to the original are negligible (Meyers et 
al., 2013). Therefore, the short form of the WAIS III/IV appears to adequately assess IQ 
and index performances.
With regard to the specific subtests, block design is a measure of perceptual 
reasoning and visual spatial construction, in which patients are asked to arrange blocks to 
match a picture. Similarities is a measure of verbal abstraction, in which the participant is 
asked to describe how two words are alike. Digit Span and Arithmetic are measures of 
basic attention and working memory in which patients are asked to sequence 
progressively longer strings of digits and quickly solve mathematics-based word 
problems, respectively. Digit Symbol/Coding is a measure of visual attention, learning, 
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and processing speed, in which the patient decodes numbers based on a key. Information 
is a measure of crystallized knowledge, attention, and long-term verbal recall, in which 
patients are asked to answer questions of general knowledge. Picture completion is a 
measure of visual perception, in which the patient is asked to quickly identify what piece 
of various pictures was removed.
As can be seen from Table B.4, block design was part of the visual 
reasoning/perceptual organization MNB domain (Meyers & Rohling, 2009; Volbrecht et 
al., 2000; Wechsler, 1997; Wechsler, 2008). Similarities was part of the verbal 
reasoning/verbal comprehension MNB domain (Meyers & Rohling, 2009; Volbrecht et 
al., 2000; Wechsler, 1997; Wechsler, 2008). Digit Span and Arithmetic were part of the 
attention/working memory MNB domain (Meyers & Rohling, 2009; Volbrecht et al., 
2000; Wechsler, 1997; Wechsler, 2008). Digit Symbol/Coding was part of the processing 
speed MNB domain (Meyers & Rohling, 2009; Volbrecht et al., 2000; Wechsler, 1997; 
Wechsler, 2008). Information was part of the verbal reasoning/verbal comprehension 
MNB domain (Meyers & Rohling, 2009; Volbrecht et al., 2000; Wechsler, 1997; 
Wechsler, 2008). Picture completion was part of the visual reasoning/perceptual 
organization MNB domain (Meyers & Rohling, 2009; Volbrecht et al., 2000; Wechsler, 
1997; Wechsler, 2008).
Trail Making Test.
TMT is a two-part, timed task that first involves drawing a line to connect a 
sequence of numbers in ascending order (Part A), then drawing a line connecting both 
numbers and letters in ascending order by switching between connecting numbers and 
letters (i.e., 1-A-2-B; Part B; Reitan & Wolfson, 1985). TMT Part A serves as a measure 
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of attention and concentration, whereas Part B serves as a measure of sequencing and 
mental set shifting (Volbrecht et al., 2000). Each part of the TMT is highly sensitive to 
cognitive dysfunction across a range of populations, particularly those with deficits in 
attention and frontal lobe functions (Greenlief et al., 1985; Hervey et al., 2004; Mathias 
& Wheaton, 2007; Mitrushina et al., 2005; Reitan, 1958; Roca et al., 2013; Ruffolo et al., 
2000; Segalowitz et al., 1992). As indicated in Table B.4, TMT A was part of the 
processing speed MNB domain, whereas TMT B was part of the executive functioning 
MNB domain (Meyers & Rohling, 2009; Strauss et al., 2006). 
Judgement of Line Orientation.
JLO is a 30-item measure of visual perception in which patients compare and 
identify identically oriented lines from lines that have been shortened (Benton et al., 
1983a). Split-half reliability for the JLO is high, ranging from .84 to .91, and test-retest 
reliability is .90 (Strauss et al., 2006). JLO performance is highly related to performance 
on visual-spatial subtests of the WAIS (Strauss et al., 2006). Impairments on this test are 
associated with lesions in the right posterior parietal region (Benton et al., 1983a; Tranel 
et al., 2009). As indicated in Table B.4, JLO was part of the visual reasoning/perceptual 
organization MNB domain (Meyers et al., 2009). 
Finger Tapping.
FT, also known as the finger oscillation test, is a measure of psychomotor speed 
and persistence in which a patient rapidly taps their index finger on their dominant hand 
for 10 seconds (Reitan & Wolfson, 1985). The same procedure is subsequently used on 
the non-dominant hand. Reliability coefficients across studies is variable, with some 
coefficients as low as .58 (Strauss et al., 2006). Although, most reliability appears to 
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generally be between .77 and .94 (Lezak et al., 2012). FTT demonstrates strong 
convergent and discriminant validity, as evidenced by high correlations with performance 
on the Purdue Pegboard Test, another measure of psychomotor functioning requiring 
precise finger movements, and low correlations with grip strength and the processing 
speed index from the WAIS III (Strauss et al., 2006). As can be seen in Table B.4, FTT 
performance for the dominant hand was part of the dominant motor and sensory MNB 
domain, whereas FTT performance for the non-dominant hand was part of the non-
dominant motor and sensory MNB domain (Meyers, 2013). 
Finger Localization Test.
The FLT is a measure of tactile identification in which a patient identifies and 
names the finger indicated by the examiner (Benton et al., 1983b). This test is composed 
of three parts, in which the patient identifies the fingers touched by the examiner, then 
identifies the fingers touched by the examiner when their hand is hidden from view, then 
identifies pairs of fingers touched by the examiner simultaneously. Bilateral impairments 
on the FLT have been associated with lesions in the left posterior perisylvian region 
(Benton et al., 1983b). However, unilateral and contralateral impairments have been more 
associated with right hemisphere lesions (Gainotti & Tiacci, 1973). As indicated in Table 
B.4, FLT performance for the dominant hand were part of the dominant motor and 
sensory MNB domain, whereas FLT performance for the non-dominant hand were part of 
the non-dominant motor and sensory MNB domain (Meyers, 2013). 
Token Test.
The TT assesses receptive language and comprehension of instructions through 
the administration of 39 increasingly complex commands (Spreen & Strauss, 1998). 
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Internal reliability for the TT is high, coefficients ranging from .90 to .92 (Spellacy & 
Spreen, 1969). The TT correlates highly with other measures of receptive language, 
correlation of .71 with the Peabody Picture Vocabulary Test (Lass & Golden, 1975), 
suggesting high construct validity. The token test is sensitive to language disorders and 
focal left-hemisphere lesions (Strauss et al., 2006). As can be seen in Table B.4, TT was 
part of the verbal reasoning/verbal comprehension MNB domain (Meyers & Rohling, 
2009). 
North American Adult Reading Test.
The NAART is a 35-item measure of premorbid intellectual ability, in which a 
patient reads printed words (Spreen & Strauss, 1998). Reliability estimates are above .90 
(Raguet et al., 1996; Uttl, 2002) and predictive validity FSIQ and verbal comprehension 
is high, correlations range from .40 to .80 (Strauss et al., 2006). In the MNB the NAART 
was used in conjunction with demographic data to estimate pre-morbid IQ (Meyers, 
2013). Due to the role of this measure in determining estimated premorbid functioning, it 
was not included in the calculation of participant’s OTBM or IIV. 
Sentence Repetition.
SR is a 22-item test of verbal attention, expressive language, and receptive 
language in which patients repeat increasingly long sentences (Spreen & Strauss, 1991). 
Test-retest reliability after 1 year was .84, indicating that SR performance is generally 
stable over time (Klonoff et al., 1970). SR correlates highly with other tests of repetition, 
with correlation coefficients ranging from .75 to .88 (Lawriw, 1976; Shewan & Kertesz, 
1980). SR correlates moderately with the Wechsler Memory Scale overall memory 
quotient (.38; Vargo & Black, 1984). Further, SR appears to be sensitive to left 
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hemisphere impairment (Meyers et al., 2000). As indicated in Table B.4, SR was part of 
the attention/working memory MNB domain (Meyers & Rohling, 2009). 
Controlled Oral Word Association Test.
FAS is an assessment of word fluency and mental flexibility during which 
patients produce as many words as they can that begin with a specific letter in one minute 
(Spreen & Strauss, 1998). FAS consists of three trials with three different letters, 
typically F, A, and S. Internal consistency among F, A, and S and test-retest reliability is 
high, .83 and .74, respectively (Tombaugh et al., 1999). Correlations across different 
fluency tasks is high, with correlations ranging from .85 to .94 (Cohen & Stanczak, 2000; 
Lacy et al., 1996; Troyer, 2000). As indicated in Table B.4, FAS was part of the verbal 
reasoning/verbal comprehension MNB domain (Meyers & Rohling, 2009). 
Animal Naming.
Animals is an assessment of word fluency and mental flexibility in which patients 
produce as many words as they can in one minute that are within a specific semantic 
cluster (i.e., animals; Spreen & Strauss, 1998). Correlations between semantic fluency 
tests with various target categories are moderately high, with correlations ranging from 
.66 to .71 (Delis et al., 2001; Riva et al., 2000). FAS generally correlates moderately with 
animals, with correlation coefficients ranging from .31 to .47, suggesting that each test 
provides reliable and unique variance (Johnson-Selfridge et al., 1998; Riva et al., 2000; 
Strauss et al., 2006; Tombaugh et al., 1999). Semantic fluency also correlates moderately 
to tests of naming, with correlation coefficients ranging from .57 to .68 (Strauss et al., 
2006). As indicated in Table B.4, animals was part of the attention/working memory 




The BNT is a 60-item measure of confrontation naming in which a patient 
generates the common name of objects displayed (Spreen & Strauss, 1998). If the patient 
misperceives an object, a semantic cue is given. If the patient generates the correct name 
at that point, they are still awarded full points for the item. Measures of internal 
consistency reliability of the BNT range from .78 to .96 (Strauss et al., 2006). Flanagan 
and Jackson (1997) demonstrated adequate reliability over one to two-week periods in 
older adults, with performances correlated at .91. BNT correlates highly with other 
measures of confrontation naming, such as the Multilingual Aphasia Examination Visual 
Naming Test (Axelrod et al., 1994; Schefft et al., 2003). As indicated in Table B.4, BNT 
was part of the verbal reasoning/verbal comprehension MNB domain (Meyers & 
Rohling, 2009). 
Dichotic Listening.
DL is a 30-item test that involves listening to words produced in either the right or 
left ear or two words presented simultaneously in both ears and repeating the word(s) that 
were presented (Meyers et al., 2002; Roberts et al., 1994). This test measures both 
hemispheric speech dominance and central auditory processing via three index scores: 
left index, right index, and both ear index (Strauss et al., 2006). Test-retest reliability 
showed no significant differences in scores after six-weeks, suggesting adequate stability 
over time (Springer et al., 1991). DL scores are sensitive to both localized and diffuse 
brain injuries that affect the deep cerebral white matter pathways (Meyers et al., 2002; 
Roberts et al., 1994). As indicated in Table B.4, DL left and right index scores were part 
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of the verbal reasoning/verbal comprehension MNB domain, whereas the DL both ear 
index was part of the executive functioning MNB domain (Meyers & Rohling, 2009). 
Auditory Verbal Learning Test.
The AVLT, or the Rey Auditory Verbal Learning Test, is a measure of verbal 
learning and memory, which assesses immediate recall memory, learning over trials, 
susceptibility to interference, delayed recall memory, and recognition memory for 15 
target words (Spreen & Strauss, 1998). Internal reliability of the AVLT total score is .90 
(Van den Burg & Kingma, 1999), whereas test-retest reliability ranged from .60 to .70 
(Strauss et al., 2006). The AVLT delayed recall score correlates highly with the AVLT 
total score (Van den Burg & Kingma, 1999) suggesting strong construct validity. AVLT 
scores also correlate moderately well with other measures of learning and memory, 
suggesting that while the AVLT is similar to these other measures of learning and 
memory, it also provides reliable and unique variance compared to other measures 
(Crossen & Wiens, 1994; Johnstone et al., 2000; Stallings et al., 1995). This uniqueness 
may be derived from the non-contextualized nature of the word lists compared to other 
measures of list-learning memory and story memory. As indicated in Table B.4, AVLT 
trial 1 total was part of the attention/working memory MNB domain (Meyers & Rohling, 
2009). AVLT learning, immediate recall, delayed recall, and recognition were all part of 
the verbal memory/auditory memory and learning MNB domain (Meyers & Rohling, 
2009).
Rey Complex Figure Test. 
The RCFT is a measure of visual-spatial construction and visual memory, which 
assesses perceptual organization in the copy, as well as immediate and delayed recall and 
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recognition for a non-verbal stimulus (Meyers & Meyers, 1995). Split-half reliability, 
computed for the details of the figure, are above .60 for the figure copy and above .80 for 
both immediate and delayed recall conditions (Berry et al., 1991; Fasteneau et al., 1996). 
This suggests that the details from the figure are fairly consistent with regards to their 
saliency and the underlying processes involved in their perception and recreation of the 
stimulus. Further, test-retest reliability ranges from .76 to .89 for immediate recall, 
delayed recall, and recognition scores (Meyers & Meyers, 1995).
Correlational and factor analytic studies support the validity of the RCFT as a 
measure of visual-spatial construction and memory (Strauss et al., 2006). For example, 
RCFT copy scores are only moderately correlated with immediate and delayed recall 
scores, coefficients of .33 and .38, respectively (Meyers & Meyers, 1995). Additionally, 
immediate and delayed recall scores are correlated at .88, yet recognition scores are 
correlated with recall at .15 (Meyers & Meyers, 1995). This suggests that recall and 
recognition memory as assessed with the RCFT, are two distinct aspects of memory. In 
terms of convergent and discriminant validity, RCFT scores are significantly related to 
other tasks of memory and construction ability but are not related to measures of 
language (Meyers & Meyers, 1995). As indicated in Table B.4, RCFT copy was part of 
the visual reasoning/perceptual organization domain (Meyers & Rohling, 2009), and 
RCFT immediate recall, delayed recall, and recognition performance scores were all part 






The Category Test- Victoria Revision.
VCT is an 81-item test measure of reasoning and problem solving which consists 
of deducing a classification principle by using feedback from the administrator (Spreen & 
Strauss, 1991). The original Category Test shows strong psychometric properties, such as 
internal consistency above .95 and moderate correlations with FSIQ and performance 
subtests of the Wechsler tests (Strauss et al., 2006). The VCT appears to preform 
similarly, as evidenced by cross-validation studies (Kozel & Meyers, 1998; Sherrill, 
1985). As can be seen in Table B.4, VCT was part of the executive functioning MNB 
domain (Lezak et al., 2012; Strauss et al., 2006). 
Forced Choice.
FC is a measure of attention in which a patient recalls as many items as they can 
from a list of 20 words presented verbally (Brandt et al., 1985). Subsequently, the patient 
chooses which word was on the 20-item list from pairs of words. This test differentiates 
amnesia malingering simulators, normal controls, and clinical groups, with individuals 
malingering amnesia performing significantly worse than individuals with organic 
amnesia on the forced-choice portion of this measure (Brandt et al., 1985). Similar 
measures of forced-choice performance validity measures have shown satisfactory 
internal consistency scores with malingered head injury simulators (Inman et al., 1998). 
Additionally, Arnett and Franzen (1997) found that the free-recall portion of a similar 
memory test correlates moderately to the Wechsler Memory Scale delayed recall index. 
This suggests that the free recall portion may indeed serve as a measure of impairment. 
As indicated in Table B.4, FC is part of the attention/working memory domain (Meyers 




In addition to performance scores on the above tests, nine imbedded measures of 
performance validity are calculated within the MNB. These validity measures are derived 
from FC, RCFT, JLO, TT, DLT, SR, AVLT recognition, FTT, and Block Design, Digit 
Span, and Digit Symbol/Coding from the WAIS III/IV (Meyers & Rohling, 2004; Meyers 
& Volbrecht, 2003). Each of the nine measure relies on patterns of performance that are 
statistically improbable. For example, inconsistent patterns of functioning or impairments 
within and across tests, unusually poor performances on specific “easy” items, and 
significantly more errors across tests than would be expected for given observed patient 
characteristics each factor into a person’s performance on these validity scales. Failure on 
any one measure of performance validity is defined as follows: FC performance £ 10; 
attention, encoding, and storage memory error patterns (MEPs) in independently 
functioning individuals; Reliable Digit Span £ 6; JLO £ 12; TT Orientation £ 150; DLT £ 
9; SR £ 9; AVLT recognition £ 9; or FTT speed > 10 points above an estimated FTT 
speed calculated based on Block Design, Digit Symbol/Coding, and the RCFT copy 
(Meyers & Rohling, 2004; see Meyers & Volbercht, 2003 for detailed explanations of 
each performance validity measure).
Procedure 
Before the archival data was provided to the principal investigator, raw data were 
either normed using their respective manual (e.g., WAIS III/IV) and entered into the 
MNS, or they were entered into the MNS to be normed using a “smoothed” norming 
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system. Once standardized using the “smoothed” normative data, all standardized scores 
were converted to a common metric (T-scores) using the following formula:  
! = #$%% − 103 * ∗ 10, + 50 
where T is the normed ss minus the arbitrary mean used for ss, divided by the arbitrary 
SD of ss, multiplied by the arbitrary SD used for T-scores, and finally added to the 
arbitrary mean used for T-scores (Miller & Rohling, 2001). Data were then integrated 
into a modified Rohling Interpretive Method approach (RIM; Meyers, 2013). 
The Rohling Interpretive Method 
RMI (Miller & Rohling, 2001) provides a statistical method of evaluation and 
interpretation of standardized scores from flexible batteries that is similar to summaries 
provided through co-normed fixed batteries, such as the HII (Reitan & Wolfson, 1985). 
The basis of this methodology is derived from recommended practices for conducting 
meta-analytic reviews and allows for examination of performance at global, domain-
specific, or test-specific levels (see Miller & Rohling, 2001 for the specific steps to using 
RIM). 
This method of statistical evaluation and calculations of indices of 
neuropsychological performance minimizes common problems associated with cognitive 
assessment using flexible batteries, such as issues related to co-variation of instruments 
and weighting decision (Miller & Rohling, 2001). Additionally, the RIM within the MNS 
harnesses the statistical power associated with evaluating cognitive performance using 
multiple measures through calculated global (OTBM) and domain indices (Miller & 
Rohling, 2001), above and beyond that of any one measure used independently and 
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screening measures of cognitive functioning. These features, when used together, are 
thought to reduced Type II error and improve diagnostic accuracy. Thus, use of the 
modified RIM within the MNS may be particularly effective in detecting subtle deficits 
and strengths across and within cognitive domains. 
Data Cleaning Procedures
Once test data were scored, normed, and integrated into a modified RIM 
approach, data were extracted from the MNS, deidentified, and provided to the principal 
investigator along with the neuropsychological report, if available. Necessary 
information, including demographic variables, such as age, sex, race, level of education, 
and occupation; current medications; substance use; psychiatric diagnoses; neurological 
diagnoses; medical diagnoses; and number of performance validity test failures were 
entered into a password protected database. 
Each medication listed for study participants was assigned three classifications: 
(1) therapeutic use, (2) drug family, and (3) drug name (generic; See table B.2). While 
many medications can be used for various therapeutic uses, information that would aid in 
illuminating the intended therapeutic use of the prescription medication was not typically 
available. For example, medications were not associated with specific diagnoses. 
Additionally, information regarding dosage, duration of use, and frequency of use, as 
well as when the medication was last administered in relation to the neuropsychological 
testing session, which could impact their effects on cognition (Burchum & Rosenthal, 
2016; Katzung, 2018), were not available in the data. Thus, all prescription medications 
reported by study participants were evaluated and the subsequent classifications were 
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based on their pharmaceutical composition, ACT code (WHO, 2021), and consultation 
with a pharmacology expert. 
The levels of medication classification were hierarchical in nature, with 
therapeutic use being the largest classification. Each therapeutic use group generally 
contained several different drug classes. Each drug class generally contained several 
specific drug names. Drug names were the most specific identification of medications 
used in this study. Participants who denied use of any medications at the time of their 
neuropsychological evaluation were entered into a “no medication” group at each of the 
three classification levels and served as a control group for the analyses.
The number of medications reported at the time of the neuropsychological 
evaluation were used to categorize cases into three polypharmacy groups. Participants 
who reported using one to five medications at the time of their neuropsychological 
evaluation were assigned to the “no polypharmacy” group. Participants who reported 
using six or more medications at the time of their neuropsychological evaluation were 
assigned to the “polypharmacy” group. Participants who denied using any medications at 
the time of their neuropsychological evaluation were again assigned into the “no 
medication” group and served as a control group for the analyses. 
Raw and standardized scores (T-scores corrected for age, education, gender, 
handedness, and ethnicity, where appropriate, according to MNS normative data or the 
WAIS III/IV manual) for all tests and MNB calculated domains were also entered into 
the database when available. If not already present in the archival data, OTBM, domain 




Calculation of OTBM and Domain Means.
The OTBM and domain means were calculated for each participant with missing 
data based on the battery of tests administered to that patient and, if valid, standardized 
T-scores were available according to the modified RIM (see Miller & Rohling, 2001). 
Specifically, additional tests were assigned to the MNB domains described in Table B.4 
with guidance from Miller and Rohling (2001), Lezak et al. (2012), and Strauss et al. 
(2006). Domain means were calculated by summing T-scores for a participant’s cognitive 
performance across all scores within the domain and dividing by the number of data 
points available for that patient. The OTBM was calculated by summing T-scores for a 
participant’s cognitive performance across all scores within the neuropsychological 
battery and dividing by the number of data points available for that patient. 
Calculation of IIV.
If not already present in the archival data, IIV was calculated for each participant 
with valid, standardized data (T-scores) for performance measures of cognitive 
functioning according to the modified RIM (see Miller & Rohling, 2001). This was 
accomplished by taking the square root of the variance within one person’s standardized 
score (T-score) performance on all MNB measures of cognitive function. The resulting 
overall test battery SD (OTBM SD) for each participant around their own OTBM serves 
as an index of variability within each participant’s performance on measures across the 
test battery, IIV. 
Plan of Analysis 
To address Aim One, to evaluate the effects of medication use and polypharmacy 
on global cognitive functioning, as assessed by OTBM, a two-way ANCOVA was 
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planned. Similarly, a two-way ANCOVA was planned to address Aim Two and evaluate 
the effects of medication use and polypharmacy on global cognitive functioning, as 
assessed by IIV. To address Aim Three, two-way MANCOVAs were planned to evaluate 
the effects of medication use and polypharmacy on domain specific cognitive 
functioning. 
Given the wide variety of medications reported by study participants, with some 
medications used by only one or two study participants, a deductive approach was taken 
to evaluate the effects of medication and polypharmacy on cognition using the 
medication classifications described above. For example, the initial evaluation of each 
aim was conducted using medications classified by therapeutic use. When a significant 
interaction or main effect was identified and subsequent simple effects/post-hoc analyses 
indicated that the OTBM, IIV, or cognitive domain means of subjects using medications 
from a specific therapeutic group differed significantly from subjects who were not 
taking medications from the therapeutic group and/or subjects who were not taking any 
medications, subsequent analyses were performed with the drug families categorized 
within the significant therapeutic use group.
Only drug families classified within the hierarchy of the therapeutic use 
categories which produced significant results were included in subsequent analyses. For 
those drug families, the same procedure was employed. Only when a significant 
interaction or main effect, and subsequent simple effects/post-hoc analyses, indicated that 
the OTBM, IIV, or cognitive domain mean of subjects using medications within the drug 
family was significantly different from subjects who were not taking medications from 
the drug family and/or subjects who were not taking any medications, were the drug 
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names within the medication group evaluated. Use of specific medications (medication 
name) were only included in analyses if both of the superordinate classifications were 
significant.  
The rational for this deductive approach is twofold. First, use of this deductive 
approach aided in controlling family-wise error and the inflated risk of Type I error 
associated with completing multiple analyses. Second, by evaluating the superordinate 
medication category first (e.g., therapeutic use), we ensured that the analyses had the 
highest number of reported users, and therefore the highest possible power to find mean 
differences, before exploring the effects of medications with individual drug names. This 
later point was particularly important because there was significant variability across use 
of specific medications. For example, while many of the specific medications used by 
study participants fell into the same therapeutic use or drug family groups, many of the 
individual medications were only used by a few subjects each (e.g., < 5 subjects). Thus, if 
analyses were initially run with drug names, the extremely small sample sizes across drug 
names would not have had sufficient power to identify significant results. 
A Priori Power Analysis
Another way power was optimized in this study was by limiting analyses to 
groups with a sufficient number of medication users. To determine the optimal sample 
size for the primary analyses, an a priori power analysis was conducted using G*Power 
(Faul et al., 2008) anticipating a medium effect size and a Bonferroni alpha correcting for 
10 analyses. Results from this analysis indicated that a sample size of 476 was required to 
achieve a power of .80 given an effect size of .20 (medium effect size), a Bonferroni 
corrected alpha of .005, and a numerator df of 4, for 7 groups, with covariates. Therefore, 
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the sample size of 497 was determined to be sufficiently powered to carry out the primary 
analyses. However, considering this overall sample size across groups, medication use 
categories needed at least 68 subjects to adequately power the analysis. Therefore, 











Prior to conducting the primary analyses, all variables were assessed for coding 
errors, missing values, univariate and multivariate outliers, and assumptions of normality 
using SPSS, Version 28 (IBM Corp., 2021). Coding errors were corrected based on the 
available raw scores and T-scores. Coding errors that were unable to be corrected were 
coded as missing.  
With regard to missing data, for the 497 cases, the proportion of missing data was 
minimal across most study variables. Data were missing across these variables as 
follows: diagnosis (19.5%); medication (0%); polypharmacy (0%); premorbid estimate 
(2.4%); OTBM (0%); IIV (4.4%); Attention and Working Memory (0.6%); Processing 
Speed (0.8%); Verbal Reasoning (0.4%); Visual Reasoning (0.2%); Verbal Memory 
(1.4%), Visual Memory (3.2%); Executive Functioning (0%); Dominant Motor 
Functioning (6.8%); and Non-Dominant Motor Functioning (7.0%). Analyses of these 
variables indicated that 49 subjects (9.9%) were missing data on any one variable.  
A series of one-way ANOVAs indicated that cases with missing values were 
systematically related to the sequence of data entry (a randomly constructed variable), the 
neuropsychologist who evaluated the patient, total PVT failures, processing speed, and 
executive functioning. This pattern of missingness is consistent with data that is missing 
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at random (MAR). While it is possible that the pattern of missingness is systematically 
related to another variable not measured in the data set, indicating that the data is not 
missing at random (NMAR), there is no obvious theoretical reason to suspect this in the 
present data. 
Given that cases with missing data were minimal across most variables, in most 
instances constituting less than 5% of the total sample, and the data are likely MAR, 
participants with missing data were retained in the sample. Subsequent analyses were 
completed on the sample of 497 cases. Pairwise deletion was used to address the minimal 
amount of missing data in primary analyses (Schlomer et al., 2010).  
Univariate outliers, defined as observations having z-scores > |3|, were found for 
3 cases (0.6%) on premorbid estimate, 6 cases (1.2%) on IIV, 2 cases (0.4%) on 
processing speed, 7 cases (1.4%) on verbal reasoning, 1 case (0.2%) on visual reasoning, 
1 case on executive functioning (0.2%), 8 cases (1.6%) on dominant motor functioning, 
and 4 cases (0.8%) on non-dominant motor functioning. Of these, only one value, on non-
dominant motor functioning, was extreme in nature (e.g., z-score > 5.0) and was replaced 
with the next closest value. Mahalanobis distances greater than 32.91 was identified for 
10 cases (2%), suggesting they may be possible multivariate outliers. Given the relatively 
small percentage of possible univariate and multivariate outliers, the relatively large 
sample size, and the fact that only one univariate outlier was extreme in magnitude 
requiring replacement, no other cases were deleted or modified, as recommended by 
Meyers et al. (2017). 
With regard to the distributions of variables, IIV and dominant motor functioning 
exhibited slight deviations from normality as evidenced by skew and kurtosis values, and 
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visual inspection of Q-Q plots and histograms. Specifically, IIV was slightly positively 
skewed (1.09) and dominant motor functioning was slightly negatively skewed (-1.37). 
Distributions for both IIV and dominant motor functioning were leptokurtic (kurtosis = 
1.62 and 3.53, respectively). However, according to Kim (2013), these values do not 
represent substantial deviations from normality given the large sample size. Distributions 
of all other variables were within normal limits with regard to skewness, kurtosis, and 
visual examination of QQ-plots and histograms. Therefore, no data transformations were 
deemed necessary. Linearity assumptions were deemed satisfactory by visual inspection 
of bivariate scatterplots and significant bivariate correlations (see Tables B.5 through 
B.11 for correlations between study variables).
Given that only two variables showed slight deviations from normality and 
simulation analyses indicate that ANOVA modes are robust to deviations from non-
normality, particularly in larger samples (Khan & Rayner, 2003), the data were judged to 
be appropriate for further analyses of variance. However, due to sample size limitations 
only medications within the following therapeutic use categories were able to be 
evaluated in the primary analyses: anticholinergics, antidepressants, anxiolytics, 
analgesics, antiepileptics, cardiovascular, anti-inflammatory, and hormones using the 
deductive approach described above. Given the reduction in analyses performed, the 
Bonferroni corrected alpha value was adjusted accordingly. 
Additionally, given the significant relationships identified across the outcome 
variables, medication’s therapeutic use categories, diagnoses, and additional cognitive 
and demographic related variables (e.g., estimated premorbid functioning, age, location 
of evaluation), as can be seen in tables B.5 through B.11, these variables were evaluated 
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for potential use as covariates in the primary analyses. Estimated premorbid functioning, 
subject age, location of evaluation; use of antidepressants, anxiolytics, antipsychotics, 
analgesics, AEDs, cardiovascular medications, anti-inflammatory medications, and 
hormones; and diagnoses of internalizing disorders, substance abuse, severe mental 
illness (SMI), learning disorders, neurodevelopmental disorders, seizure disorders, 
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory 
disorders, and pain conformed to the assumptions of linearity of regression and 
homogeneity of regression at both the univariate and the multivariate levels. Therefore, 
these variables were used as covariates in all primary analyses, except for when the 
corresponding or subordinate medication variable was used as an independent variable. 
 
Primary Analyses Aims One and Two 
To examine the effects of medication use and polypharmacy on global cognitive 
functioning, as assessed by OTBM and IIV, (use of medication) X 3 (polypharmacy) 
between subjects ANCOVAs were used to determine if there was an interaction between 
medication use and polypharmacy level on OTBM or IIV, if there were differential 
effects of medication use on the OTBM or IIV, and if there were differential effects of 
levels of polypharmacy on OTBM or IIV. See tables C.1-C.20 in Appendices for detailed 
results for Aims One and Two, as analyzed by two-way ANCOVA on global cognition as 
measured by the OTBM and IIV, respectively. 
Anticholinergic Medications
To address Aim One, a 3 (use of anticholinergic medication) X 3 (polypharmacy) 
between subjects ANCOVA evaluated the interaction and main effects of the use of 
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anticholinergic medication and polypharmacy on the OTBM. Levene’s test was not 
statistically significant, F(4, 383) = 2.40 p = .05. Therefore, the data did not violate the 
assumption of homogeneity of variance, and it was deemed appropriate for further 
analysis. 
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1, 364) = 27.10, p < .001], estimated premorbid functioning [F(1, 364) = 167.38 p < 
.001], neurocognitive disorder [F(1, 364) = 15.94, p < .001], moderate to severe TBI 
[F(1, 364) = 13.18, p < .001], and cardiovascular diagnoses [F(1, 364) = 21.622, p < 
.001] were statistically significant. However, there was not a statistically significant 
interaction between the effects of using anticholinergic medication and polypharmacy, 
F(1, 364) = 3.65, p = .05, nor were there significant main effects of use of anticholinergic 
medications, F(1, 364) = 0.45, p = .50, or polypharmacy, F(1, 364) = .25, p = .61, on 
OTBM. Therefore, despite adjusting for relevant variables, such as the neuropsychologist 
conducting the evaluation, estimated premorbid functioning, age, use of other 
medications, and diagnoses, there was no interaction between the use of anticholinergic 
medication and polypharmacy on overall cognitive functioning as assessed by the 
OTBM. There also were not independent effects of use of anticholinergic medications or 
polypharmacy on overall cognitive functioning as assessed by the OTBM.
To address Aim Two, a 3 (use of anticholinergic medication) X 3 (polypharmacy) 
between subjects ANCOVA evaluated the interaction and main effects of the use of 
anticholinergic medication and polypharmacy on IIV. Levene’s test was not statistically 
significant, F(4, 373) = 1.62, p = .17. Therefore, the data did not violate the assumption 
of homogeneity of variance, and it was deemed appropriate for further analysis. 
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In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1, 354) = 45.03, p < .001], moderate to severe TBI [F(1, 354) = 8.85, p = .003], and 
cardiovascular diagnoses [F(1, 354) = 15.33, p < .001] were statistically significant. 
There was not a statistically significant interaction between the effects of using 
anticholinergic medication and polypharmacy, F(1, 354) = 3.82, p = .05. There were also 
no significant main effects of use of anticholinergic medications, F(1, 354) = 0.65, p = 
.42 or polypharmacy on IIV, F(1, 354) = 0.88, p = .35. Overall, despite adjusting for 
relevant variables, such as the neuropsychologist conducting the evaluation, estimated 
premorbid functioning, age, use of other medications, and diagnoses, there was no 
interaction between use of anticholinergic medications and polypharmacy on overall 
cognitive functioning as assessed by IIV. There also were not independent effects of use 
of anticholinergic medications or polypharmacy on overall cognitive functioning as 
assessed by IIV.
Antidepressant Medications 
To address Aim One, a 3 (use of antidepressant) X 3 (polypharmacy) between 
subjects ANCOVA evaluated the interaction and main effects of the use of antidepressant 
medication and polypharmacy on the OTBM. Levene’s test was not statistically 
significant, F(4, 383) = 1.69, p = .15, indicating that the data did not violate the 
assumption of homogeneity of variance. Therefore, the data was deemed appropriate for 
further analyses of variance. 
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1, 363) = 23.93, p < .001], estimated premorbid functioning [F(1, 363) = 160.82, p < 
.001], neurocognitive disorder diagnosis [F(1, 363) = 16.89, p < .001], moderate to 
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severe TBI [F(1, 363) = 14.94, p < .001], and cardiovascular diagnoses [F(1, 363) = 
22.07, p < .001] were statistically significant. There was not a statistically significant 
interaction between the effects of using antidepressant medication and polypharmacy, 
F(1, 363) = 0.09, p = .77, nor were there significant main effects for the use of 
antidepressant medications, F(1, 363) = 0.80, p = .37 on OTBM, or polypharmacy on 
OTBM, F(1, 363) = .04, p = .85. Therefore, despite adjusting for relevant variables, such 
as the neuropsychologist conducting the evaluation, estimated premorbid functioning, 
age, use of other medications, and diagnoses, there was no interaction between use of 
antidepressant medications and polypharmacy on overall cognitive functioning as 
assessed by the OTBM. There also were not independent effects of use of antidepressant 
medications or polypharmacy on overall cognitive functioning as assessed by the OTBM.
To address Aim Two, a 3 (use of antidepressant) X 3 (polypharmacy) between 
subjects ANCOVA evaluated the interaction and main effects of the use of antidepressant 
medication and polypharmacy on IIV. Levene’s test was not statistically significant, F(4, 
373) = 1.10, p = .36, indicating that the data did not violate the assumption of 
homogeneity of variance. Therefore, the data was deemed appropriate for further 
analyses of variance. 
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1,353) = 24.37, p < .001), use of analgesics [F(1,353) = 8.50, p = .004], moderate to 
severe TBI [F(1,353) = 11.83, p < .001], and cardiovascular diagnoses [F(1,353) = 16.53, 
p < .001] were statistically significant. There was not a statistically significant interaction 
between the effects of using antidepressant medication and polypharmacy, F(1, 353) = 
0.01, p = .93, nor was there significant main effect of use of antidepressant medications, 
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F(1, 353) = 0.18, p = .68 on IIV. There was a significant main effect of polypharmacy on 
IIV at the .05 alpha level, F(1, 353) = 5.29, p = .02. However, when the more stringent 
alpha level of .006 (.05/8) was employed to reduce the risk of Type I error, this main 
effect was no longer considered significant. Overall, despite adjusting for relevant 
variables, such as the neuropsychologist conducting the evaluation, estimated premorbid 
functioning, age, use of other medications, and diagnoses, there was no significant 
interaction between the use of antidepressant medication and polypharmacy on overall 
cognitive functioning, as assessed by IIV. There also were not significant independent 
effects of use of antidepressant medications or polypharmacy on overall cognitive 
functioning as assessed by IIV at the alpha level of .006. 
Anxiolytic Medications
To address Aim One, a 3 (use of anxiolytics) X 3 (polypharmacy) between 
subjects ANCOVA evaluated the interaction and main effects of the use of anxiolytic 
medication and polypharmacy on the OTBM. Levene’s test was statistically significant, 
F(4, 383) = 3.29, p = .01, indicating that the data violated the assumption of homogeneity 
of variance. Therefore, a more stringent alpha value was used when determining whether 
the univariate tests were statistically significant. Given that a Bonferroni corrected alpha 
of .006 was employed due to the large number of statistical analyses being conducted, an 
alpha value of .001 was used for this analysis to further reduce the risk of Type I error.  
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1, 362) = 25.66, p < .001], estimated premorbid functioning [F(1, 362) = 162.02, p < 
.001], use of anti-inflammatory medications [F(1, 362) = 4.34, p = 0.04], neurocognitive 
disorder diagnosis [F(1, 362) = 17.02, p < .001], moderate to severe TBI [F(1, 362) = 
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13.90, p < .001], cardiovascular diagnoses [F(1, 362) = 25.41, p < .001], and respiratory 
diagnoses [F(1, 362) = 4.17, p = .04] were statistically significant. There was a 
statistically significant interaction between the effects of using anxiolytic medications 
and polypharmacy, F(1, 362) = 6.48, p = .01. However, when the more stringent 
corrected alpha of .001 is used, this interaction is not considered statistically significant. 
Neither the main effects for the use of anxiolytic medications, F(1, 362) = 2.00, p = .16, 
nor polypharmacy, F(1, 362) = .03, p = .88, on OTBM were statistically significant. 
Therefore, despite adjusting for relevant variables, such as the neuropsychologist 
conducting the evaluation, estimated premorbid functioning, age, use of other 
medications, and diagnoses, there was no significant interaction between use of 
anxiolytic medications and polypharmacy on overall cognitive functioning as assessed by 
the OTBM at the Bonferroni corrected alpha value of .001. There also were not 
significant independent effects of use of anxiolytic medications or polypharmacy on 
overall cognitive functioning as assessed by the OTBM at the Bonferroni corrected alpha 
value of .001. 
To address Aim Two, a 3 (use of anxiolytics) X 3 (polypharmacy) between 
subjects ANCOVAs evaluated the interaction and main effects of the use of anxiolytic 
medication and polypharmacy on IIV. Levene’s test was not statistically significant, F(4, 
373) = 1.21, p = .31, indicating that the data did not violate the assumption of 
homogeneity of variance. Therefore, the data was deemed appropriate for further 
analyses of variance. 
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1,352) = 44.49, p < .001], use of analgesics [F(1,352) = 7.09, p = .008], diagnosis of a 
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neurodevelopmental disorder [F(1, 352) = 4.08, p = .04], moderate to severe TBI [F(1, 
352) = 9.85, p = .002], and cardiovascular diagnoses [F(1, 352) = 18.80, p < .001] were 
statistically significant. There was a statistically significant interaction between the 
effects of using anxiolytic medication and polypharmacy, F(1, 352) = 4.76, p = .03. 
However, when a more stringent corrected alpha of .006 is used, this interaction is not 
considered statistically significant. Similarly, there was a significant main effect of 
polypharmacy on IIV, F(1, 352) = 4.47, p = .04, but when compared to the more stringent 
alpha of .006, this main effect was no longer significant. No main effect of use of 
anxiolytic medication was identified, F(1, 352) = 1.79, p = .18. Overall, despite adjusting 
for relevant variables, such as the neuropsychologist conducting the evaluation, estimated 
premorbid functioning, age, use of other medications, and diagnoses, there was no 
interaction between anxiolytic medication use and polypharmacy on overall cognitive 
functioning as assessed by IIV at p < .006. There also were not independent effects of use 
of anxiolytic medications or polypharmacy on overall cognitive functioning as assessed 
by IIV at the alpha level of .006. 
Analgesic Medications
To address Aim One, a 3 (use of analgesics) X 3 (polypharmacy) between 
subjects ANCOVA evaluated the interaction and main effects of the use of analgesic 
medication and polypharmacy on the OTBM. Levene’s test was statistically significant, 
F(4, 383) = 2.59, p = .04, indicating that the data violated the assumption of homogeneity 
of variance. Therefore, a more stringent alpha value was used when determining whether 
the univariate tests were statistically significant. Given that a Bonferroni corrected alpha 
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of .006 was employed due to the large number of statistical analyses conducted, an alpha 
value of .001 was used for this analysis to further reduce the risk of Type I error.  
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1, 362) = 25.13, p < .001], estimated premorbid functioning [F(1, 362) = 157.84, p < 
.001], neurocognitive disorder diagnosis [F(1, 362) = 15.00, p < .001], moderate to 
severe TBI [F(1, 362) = 14.35, p < .001], and cardiovascular diagnoses [F(1, 362) = 
22.70, p < .001] were statistically significant. The interaction between the effects of using 
analgesic medications and polypharmacy was not significant, F(1, 362) = 2.00, p = .16. 
The main effect of polypharmacy on the OTBM also was not significant, F(1, 362) = 
0.01, p = .93. The main effect for the use of analgesic medications was significant at the 
.05 alpha level, F(1, 362) = 3.97, p < .05. However, when the main effect of use of 
analgesic medications was compared to the more stringent alpha of .001, the effect was 
no longer significant. Therefore, despite adjusting for relevant variables, such as the 
neuropsychologist conducting the evaluation, estimated premorbid functioning, age, use 
of other medications, and diagnoses, there was no interaction between analgesic 
medication use and polypharmacy on overall cognitive functioning as assessed by the 
OTBM at the alpha value of .001. There also were not independent effects of analgesic 
medication use or polypharmacy on overall cognitive functioning as assessed by the 
OTBM at the alpha value of .001.
To address Aim Two, a 3 (use of analgesics) X 3 (polypharmacy) between 
subjects ANCOVA evaluated the interaction and main effects of the use of analgesic 
medication and polypharmacy on IIV. Levene’s test was not statistically significant, F(4, 
373) = 1.59, p = .18, indicating that the data did not violate the assumption of 
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homogeneity of variance. Therefore, the data was deemed appropriate for further 
analyses of variance.  
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1,352) = 45.89, p < .001], moderate to severe TBI [F(1, 352) = 10.25, p = .001], and 
cardiovascular diagnoses [F(1, 352) = 16.58, p < .001] were statistically significant. The 
interaction between the effects of using analgesic medication and polypharmacy was not 
significant, F(1, 352) = 2.89, p = .09. However, both the main effect of analgesic 
medication use and the main effect of polypharmacy on IIV were significant, F(1, 352) = 
11.29, p = < .001, η2 = .02, and F(1, 352) = 4.65, p = .03, respectively. Only the main 
effect of analgesic medication on IIV remained significant when applying the more 
stringent Bonferroni corrected alpha of .006. This result indicates that subjects taking 
analgesic medications showed more cognitive variability (M = 10.51, SD = 2.72) than 
those not taking analgesic medication (M = 9.99, SD = 2.37) and those not taking any 
prescription medications (M = 9.43, SD = 2.73). 
Analgesic Drug Families.
Triptans. Given this finding, and to further evaluate Aim Two with regard to analgesic 
medication families, four subsequent 3 (Analgesic group) X 3 (polypharmacy) between 
subjects ANCOVAs were used to evaluate the interaction and main effects of the use of 
medication in analgesic families and polypharmacy on IIV. The first two-way ANCOVA 
evaluated the interaction and main effects of the use of triptans and polypharmacy on IIV. 
Levene’s test was not statistically significant, F(4, 373) = 1.72, p = .15, indicating that 
the data did not violate the assumption of homogeneity of variance. Therefore, the data 
was deemed appropriate for further analyses of variance.  
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In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1, 352) = 44.03, p < .001], neurocognitive disorders [F(1, 352) = 3.98, p = .05], 
moderate to severe TBI [F(1, 352) = 9.78, p = .002], and cardiovascular diagnoses [F(1, 
352) = 17.47, p < .001] were statistically significant. The interaction between the effects 
of using triptans and polypharmacy was not significant, F(1, 352) = 0.44, p = .51. 
Additionally, the main effect of polypharmacy on IIV was not significant, F(1, 352) = 
2.79, p = .10. However, the main effect of triptan use on IIV was significant, F(1, 352) = 
12.91, p = < .001, η2 = .03. This result indicates that subjects using triptan medications 
showed more cognitive variability (M = 13.08, SD = 3.96) than those not taking analgesic 
medication (M = 9.24, SD = 2.40) and those not taking any prescription medications (M = 
9.26, SD = 2.73). 
This significant difference between subjects using triptan medications and 
subjects who do not use triptan medications suggests that further exploration with regard 
to specific drug names is warranted. However, these analyses were unable to be 
conducted due to the significantly low frequencies of almotriptan, eletriptan, rizatriptan, 
and sumatriptan use in the sample. Specifically, only one participant each reported using 
almotriptan and eletriptan, and two participants each reported using rizatriptan and 
sumatriptan. 
Opioids. The next two-way ANCOVA evaluated the interaction and main effects of the 
use of opioids and polypharmacy on IIV. Levene’s test was not statistically significant, 
F(4, 373) = 2.32, p = .06, indicating that the data did not violate the assumption of 
homogeneity of variance. Therefore, the data was deemed appropriate for further 
analyses of variance.  
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In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1, 352) = 44.03, p < .001], neurocognitive disorders [F(1, 352) = 4.42, p = .04], 
moderate to severe TBI [F(1, 352) = 8.85, p = .003], and cardiovascular diagnoses [F(1, 
352) = 15.70, p < .001] were statistically significant. There was not a statistically 
significant interaction between the effects of using opioid medication and polypharmacy, 
F(1, 352) = 0.07, p = .80, nor were there significant main effects of the use of opioids, 
F(1, 352) = 0.10, p = .75, or polypharmacy on IIV, F(1, 352) = 0.10, p = .75. Overall, 
despite adjusting for relevant variables, such as the neuropsychologist conducting the 
evaluation, estimated premorbid functioning, age, use of other medications, and 
diagnoses, there was no interaction between opioid medication use and polypharmacy on 
overall cognitive functioning as assessed by IIV at the Bonferroni corrected alpha value 
of .006. There also were not independent effects of the use of opioid medications or 
polypharmacy on overall cognitive functioning as assessed by IIV at the Bonferroni 
corrected alpha value of .006.
Opioid Combinations. The next two-way ANCOVA evaluated the interaction and main 
effects of the use of opioid combination medications and polypharmacy on IIV. Levene’s 
test was not statistically significant, F(4, 373) = 1.65, p = .16, indicating that the data did 
not violate the assumption of homogeneity of variance. Therefore, the data was deemed 
appropriate for further analyses of variance.  
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1, 352) = 42.94, p < .001], neurocognitive disorders [F(1, 352) = 4.42, p = .04], 
moderate to severe TBI [F(1, 352) = 9.20, p = .003], and cardiovascular diagnoses [F(1, 
352) = 15.49, p < .001] were statistically significant. There was not a statistically 
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significant interaction between the effects of using opioid combination medications and 
polypharmacy, F(1, 352) < 0.01, p = .98, nor were there significant main effects of opioid 
combination use, F(1, 352) = 2.13, p = .15, or polypharmacy on IIV, F(1, 352) = 1.70, p 
= .19. Overall, despite adjusting for relevant variables, such as the neuropsychologist 
conducting the evaluation, estimated premorbid functioning, age, use of other 
medications, and diagnoses, there was no effect of opioid combination medication use, 
polypharmacy, or the interaction between the two, on overall cognitive functioning as 
assessed by IIV at the Bonferroni corrected alpha value of .006.
Non-Opioid Analgesics. The final two-way ANCOVA within the analgesic family 
analyses evaluated the interaction and main effects of the use of non-opioid analgesics 
and polypharmacy on IIV. Levene’s test was statistically significant, F(4, 373) = 3.57, p 
= .007, indicating that the data violated the assumption of homogeneity of variance. 
Therefore, a more stringent alpha value was used when determining whether the 
univariate tests were statistically significant. Given that a Bonferroni corrected alpha of 
.006 was employed due to the large number of statistical analyses conducted, an alpha 
value of .001 was used for this analysis to further reduce the risk of Type I error.  
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1, 352) = 45.07, p < .001], moderate to severe TBI [F(1, 352 = 9.17, p = .003], and 
cardiovascular diagnoses [F(1, 352) = 14.73, p < .001] were statistically significant. 
There was not a statistically significant interaction between the effects of using non-
opioid analgesics and polypharmacy, F(1, 352) < 0.01, p = .98, nor were there significant 
main effects of non-opioid analgesic use, F(1, 352) = 0.20, p = .65, nor polypharmacy on 
IIV, F(1, 352) = 0.01, p = .93. Overall, despite adjusting for relevant variables, such as 
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the neuropsychologist conducting the evaluation, estimated premorbid functioning, age, 
use of other medications, and diagnoses, there was no interaction between use of opioid 
combination medications and polypharmacy on overall cognitive functioning as assessed 
by IIV at the corrected alpha value of .001. There also were not independent effects of 
opioid combination medication use or polypharmacy on overall cognitive functioning as 
assessed by IIV at the corrected alpha value of .001. 
Antiepileptic Medications
To address Aim One, a 3 (use of antiepileptics) X 3 (polypharmacy) between 
subjects ANCOVA evaluated the interaction and main effects of the use of antiepileptic 
medication and polypharmacy on the OTBM. Levene’s test was not statistically 
significant, F(4, 383) = 1.55, p = .19, indicating that the data did not violate the 
assumption of homogeneity of variance. Therefore, the data was deemed appropriate for 
further analyses of variance.  
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1, 362) = 24.90, p < .001], estimated premorbid functioning [F(1, 362) = 155.96, p < 
.001], use of anti-inflammatory medications [F(1, 362) = 5.09, p = 0.03], neurocognitive 
disorder diagnosis [F(1, 362) = 14.75, p < .001], moderate to severe TBI [F(1, 362) = 
12.613, p < .001], and cardiovascular diagnoses [F(1, 362) = 21.84, p < .001] were 
statistically significant. There was a statistically significant interaction between the 
effects of using antiepileptic medications and polypharmacy, F(1, 362) = 4.51, p = .03. 
However, when the more stringent corrected alpha of .006 is used, this interaction is not 
considered statistically significant. Neither the main effects for the use of antiepileptic 
medications, F(1, 362) = 3.41, p = .07, nor polypharmacy, F(1, 362) = 0.88, p = .35, on 
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OTBM were statistically significant. Therefore, despite adjusting for relevant variables, 
such as the neuropsychologist conducting the evaluation, estimated premorbid 
functioning, age, use of other medications, and diagnoses, there was no interaction 
between use of antiepileptic medication and polypharmacy on overall cognitive 
functioning as assessed by the OTBM at the Bonferroni corrected alpha value of .006. 
There also were not independent effects of the use of antiepileptic medications or 
polypharmacy on overall cognitive functioning as assessed by the OTBM.
To address Aim Two, a 3 (use of antiepileptics) X 3 (polypharmacy) between 
subjects ANCOVA evaluated the interaction and main effects of the use of antiepileptic 
medications and polypharmacy on IIV. Levene’s test was not statistically significant, F(4, 
373) = 0.99, p = .42, indicating that the data did not violate the assumption of 
homogeneity of variance. Therefore, the data was deemed appropriate for further 
analyses of variance.  
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1,352) = 44.51, p < .001], use of analgesics [F(1,352) = 9.27, p = .003], moderate to 
severe TBI [F(1, 352) = 8.83, p = .003], and cardiovascular diagnoses [F(1, 352) = 16.46, 
p < .001] were statistically significant. There was a statistically significant interaction 
between the effects of using antiepileptic medication and polypharmacy, F(1, 352) = 
4.79, p = .03. However, when a more stringent corrected alpha of .006 was used, this 
interaction was no longer considered statistically significant. Similarly, there was a 
significant main effect of polypharmacy on IIV, F(1, 352) = 9.56, p = .002, η2  = .20. 
Although, this significant main effect remained, even when compared to a more 
conservative alpha of .006. No main effect of use of antiepileptic medication on IIV was 
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identified, F(1, 352) = 1.87, p = .17. These results indicate that subjects without 
polypharmacy showed more cognitive variability (M = 10.45, SD = 2.42) than those 
taking more than 5 medications (e.g., polypharmacy; M = 8.89, SD = 2.52) and those not 
taking any prescription medications (M = 7.78, SD = 2.73). 
Cardiovascular Medications
To address Aim One, a 3 (cardiovascular medications) X 3 (polypharmacy) 
between subjects ANCOVA evaluated the interaction and main effects of the use of 
cardiovascular medications and polypharmacy on OTBM. Levene’s test was not 
statistically significant, F(4, 383) = 1.57, p = .18, indicating that the data did not violate 
the assumption of homogeneity of variance. Therefore, the data was deemed appropriate 
for further analyses of variance.  
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1, 362) = 23.28, p < .001], estimated premorbid functioning [F(1, 362) = 158.11, p < 
.001], use of anti-inflammatory medications [F(1, 362) = 3.97, p < 0.05], neurocognitive 
disorder diagnosis [F(1, 362) = 16.81, p < .001], moderate to severe TBI [F(1, 362) = 
14.14, p < .001], and cardiovascular diagnoses [F(1, 362) = 22.14, p < .001] were 
statistically significant. The interaction between the effects of using cardiovascular 
medications and polypharmacy was not significant, F(1, 362) = 0.53, p = .47. 
Additionally, neither the main effects of cardiovascular medication use, F(1, 362) = 2.48, 
p = .12, nor polypharmacy, F(1, 362) = 0.13, p = .72, on OTBM were statistically 
significant. Therefore, despite adjusting for relevant variables, such as the 
neuropsychologist conducting the evaluation, estimated premorbid functioning, age, use 
of other medications, and diagnoses, there was no interaction between use of 
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cardiovascular medication and polypharmacy on overall cognitive functioning as 
assessed by the OTBM at the Bonferroni corrected alpha value of .006. There also were 
not independent effects of cardiovascular medication use or polypharmacy on overall 
cognitive functioning as assessed by the OTBM at the Bonferroni corrected alpha value 
of .006. 
To address Aim Two, a 3 (use of antiepileptics) X 3 (polypharmacy) between 
subjects ANCOVA evaluated the interaction and main effects of the use of cardiovascular 
medications and polypharmacy on IIV. Levene’s test was not statistically significant, F(4, 
373) = 2.08, p = .08, indicating that the data did not violate the assumption of 
homogeneity of variance. Therefore, the data was deemed appropriate for further 
analyses of variance. 
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1,352) = 43.88, p < .001], use of analgesics [F(1,352) = 8.44, p = .004], moderate to 
severe TBI [F(1, 352) = 9.95, p = .002], and cardiovascular diagnoses [F(1, 352) = 16.13, 
p < .001] were statistically significant. The interaction between the effects of using 
cardiovascular medication and polypharmacy was not significant, F(1, 352) = 0.23, p = 
.63. No main effect of use of cardiovascular medication on IIV was identified, F(1, 352) 
= 0.01, p = .91. There was a significant main effect of polypharmacy on IIV, F(1, 352) = 
6.76, p = .01. However, when the more stringent corrected alpha of .006 was used, this 
interaction was no longer considered statistically significant. Overall, despite adjusting 
for relevant variables, such as the neuropsychologist conducting the evaluation, estimated 
premorbid functioning, age, use of other medications, and diagnoses, there was no 
interaction between use of cardiovascular medication and polypharmacy on overall 
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cognitive functioning as assessed by IIV at the Bonferroni corrected alpha value of .006. 
There also were not independent effects of cardiovascular medication use or 
polypharmacy on overall cognitive functioning as assessed by IIV at the Bonferroni 
corrected alpha value of .006.
Anti-Inflammatory Medications 
To address Aim One, a 3 (anti-inflammatory medication use) X 3 (polypharmacy) 
between subjects ANCOVA evaluated the interaction and main effects of the use of anti-
inflammatory medications and polypharmacy on the OTBM. Levene’s test was not 
statistically significant, F(4, 383) = 1.83, p = .18, indicating that the data did not violate 
the assumption of homogeneity of variance. Therefore, the data was deemed appropriate 
for further analyses of variance.  
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1, 362) = 24.03, p < .001], estimated premorbid functioning [F(1, 362) = 157.59, p < 
.001], neurocognitive disorder diagnosis [F(1, 362) = 16.76, p < .001], moderate to 
severe TBI [F(1, 362) = 14.08, p < .001], and cardiovascular diagnoses [F(1, 362) = 
21.99, p < .001] were statistically significant. The interaction between the effects of using 
anti-inflammatory medications and polypharmacy was not significant, F(1, 362) = 0.03, p 
= .87. Additionally, neither the main effects for the use of anti-inflammatory medications, 
F(1, 362) = 3.19, p = .08, nor polypharmacy, F(1, 362) = 0.18, p = .68, on OTBM were 
statistically significant. Therefore, despite adjusting for relevant variables, such as the 
neuropsychologist conducting the evaluation, estimated premorbid functioning, age, use 
of other medications, and diagnoses, there was no interaction between anti-inflammatory 
medication use and polypharmacy on overall cognitive functioning as assessed by the 
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OTBM. There also were not independent effects of anti-inflammatory medication use or 
polypharmacy on overall cognitive functioning as assessed by the OTBM. 
To address Aim Two, a 3 (use of anti-inflammatory) X 3 (polypharmacy) between 
subjects ANCOVA evaluated the interaction and main effects of the use of anti-
inflammatory medications and polypharmacy on IIV. Levene’s test was not statistically 
significant, F(4, 373) = 1.38, p = .24, indicating that the data did not violate the 
assumption of homogeneity of variance. Therefore, the data was deemed appropriate for 
further analyses of variance. 
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1,352) = 43.68, p < .001], use of analgesics [F(1,352) = 8.75, p = .003], moderate to 
severe TBI [F(1, 352) = 9.78, p = .002], and cardiovascular diagnoses [F(1, 352) = 16.05, 
p < .001] were statistically significant. The interaction between the effects of using anti-
inflammatory medication and polypharmacy was not significant, F(1, 352) = 0.29, p = 
.59. No main effect of use of anti-inflammatory medication on IIV was identified, F(1, 
352) = 0.34, p = .56. There was a significant main effect of polypharmacy on IIV, F(1, 
352) = 5.77, p = .02. However, when the more stringent corrected alpha of .006 was used, 
this interaction was no longer considered statistically significant. Overall, despite 
adjusting for relevant variables, such as the neuropsychologist conducting the evaluation, 
estimated premorbid functioning, age, use of other medications, and diagnoses, there was 
no interaction between anti-inflammatory medication use and polypharmacy on overall 
cognitive functioning as assessed by IIV. There also were not independent effects of anti-
inflammatory medication use or polypharmacy on overall cognitive functioning as 
assessed by IIV at the Bonferroni corrected alpha value of .006.
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Hormone Medications
To address Aim One, a 3 (hormone medication use) X 3 (polypharmacy) between 
subjects ANCOVA evaluated the interaction and main effects of the use of hormone 
medications and polypharmacy on the OTBM. Levene’s test was not statistically 
significant, F(4, 383) = 1.68, p = .15, indicating that the data did not violate the 
assumption of homogeneity of variance. Therefore, the data was deemed appropriate for 
further analyses of variance.  
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1, 362) = 24.20, p < .001], estimated premorbid functioning [F(1, 362) = 157.55, p < 
.001], neurocognitive disorder diagnosis [F(1, 362) = 16.75, p < .001], moderate to 
severe TBI [F(1, 362) = 14.20, p < .001], and cardiovascular diagnoses [F(1, 362) = 
22.12, p < .001] were statistically significant. The interaction between the effects of using 
hormone medications and polypharmacy was not significant, F(1, 362) = 0.23, p = .63. 
Additionally, neither the main effects for the use of hormone medications, F(1, 362) = 
0.09, p = .77, nor polypharmacy, F(1, 362) = 0.26, p = .61, on OTBM were statistically 
significant. Therefore, despite adjusting for relevant variables, such as the 
neuropsychologist conducting the evaluation, estimated premorbid functioning, age, use 
of other medications, and diagnoses, there was no interaction between use of hormone 
medications and polypharmacy on overall cognitive functioning as assessed by the 
OTBM. There also were not independent effects of hormone medication use and 
polypharmacy on overall cognitive functioning as assessed by the OTBM. 
To address Aim Two, a 3 (use of hormones) X 3 (polypharmacy) between 
subjects ANCOVA evaluated the interaction and main effects of the use of hormone 
 
102 
medications and polypharmacy on IIV. Levene’s test was not statistically significant, F(4, 
373) = 1.00, p = .41, indicating that the data did not violate the assumption of 
homogeneity of variance. Therefore, the data was deemed appropriate for further 
analyses of variance. 
In the omnibus analysis, the covariate effects of the location of the evaluation 
[F(1,352) = 43.90, p < .001], use of analgesics [F(1,352) = 8.27, p = .004], moderate to 
severe TBI [F(1, 352) = 10.12, p = .002], and cardiovascular diagnoses [F(1, 352) = 
16.37, p < .001] were statistically significant. The interaction between the effects of using 
hormone medications and polypharmacy was not significant, F(1, 352) = 0.18, p = .67. 
No main effect of use of hormones on IIV was identified, F(1, 352) = 1.13, p = .29. There 
was a significant main effect of polypharmacy on IIV, F(1, 352) = 6.76, p = .01. 
However, when the more stringent corrected alpha of .006 was used, this interaction was 
no longer considered statistically significant. Overall, despite adjusting for relevant 
variables, such as the neuropsychologist conducting the evaluation, estimated premorbid 
functioning, age, use of other medications, and diagnoses, there was no interaction 
between use of hormone medications and polypharmacy on overall cognitive functioning 
as assessed by IIV. There also were not independent effects of hormone medication use 
and polypharmacy on overall cognitive functioning as assessed by IIV at the Bonferroni 
corrected alpha value of .006. 
 
Primary Analyses Aim Three 
To examine the effects of medication use and polypharmacy on domain-specific 
cognitive functioning, two-way MANCOVAs were used to evaluate the interactions and 
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main effects of medication use and polypharmacy on the following cognitive domain 
means: attention/working memory, processing speed, verbal reasoning, visual reasoning, 
verbal memory, visual memory, EF, dominant motor and sensory functioning, and non-
dominant motor and sensory functioning.  
As can be seen in Tables B.5, B.9, B.10, and B.11, linear relationships were 
observed across relevant study variables. Specifically, cognitive domains correlated with 
each other between .17 and .60. The covariates (estimated premorbid functioning; subject 
age; location of evaluation; use of antidepressants, anxiolytics, antipsychotics, analgesics, 
AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and 
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, 
neurodevelopmental disorders, seizure disorders, neurocognitive disorders, moderate to 
severe TBI, cardiovascular diagnoses, respiratory disorders, and pain) were also linearly 
related to cognitive domain performance, meeting the assumption of linearity of 
regression. As noted above, the data also conformed to the assumption of homogeneity of 
regression both at the multivariate and univariate levels. 
Anticholinergic Medications
With regard to anticholinergic medications, a 3 (anticholinergic medication use) 
X 3 (polypharmacy) between subjects MANCOVA evaluated the interactions and main 
effects of medication use and polypharmacy across cognitive domains. Bartlett’s test of 
sphericity was statistically significant (approximate chi square = 1145.41, df = 44, p < 
.001), indicating that the correlation of the dependent variables was sufficient to support 
the MANCOVA. Box’s test of the equality of the variance-covariance matrices was also 
statistically significant [Box’s M = 258.32, F(180, 16076.90) = 1.26, p = .01], suggesting 
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that the matrices were not homogenous. Therefore, Pillai’s Trace was used to evaluate the 
multivariate effects because it is more robust to violations of this assumption compared to 
the other multivariate tests of significance.
The multivariate interaction of anticholinergic medication use X polypharmacy, 
when controlling for effects of the covariates, was examined prior to the multivariate 
main effects. The multivariate interaction effect on cognitive domain scores was not 
statistically significant [Pillai’s Trace = .03, F(9, 327) = 1.23, p = .27, 1 – Wilks’ lambda 
= .03]. The multivariate main effect of the following covariates were significant: location 
of the evaluation [Pillai’s Trace = .19, F(9, 327) = 8.37, p < .001, 1-Wilks’ lambda = 
.19], estimated premorbid functioning [Pillai’s Trace = .50, F(9, 327) = 35.57, p < .001, 
1-Wilks’ lambda = .50], moderate to severe TBI [Pillai’s Trace = .08, F(9, 327) = 3.13, p 
= .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, F(9, 327) 
= 3.20, p = .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s Trace = .06, 
F(9, 327) = 2.27, p = .02, 1-Wilks’ lambda = .06]. The multivariate main effects of the 
independent variables of anticholinergic medication use and polypharmacy, were not 
statistically significant [Pillai’s Trace = .01, F(9, 327) = 0.45, p = .91, 1-Wilks’ lambda = 
.01; Pillai’s Trace = .02, F(9, 327) = 0.76, p = .65, 1-Wilks’ lambda = .02, respectively]. 
Overall, despite adjusting for relevant variables, such as the neuropsychologist 
conducting the evaluation, estimated premorbid functioning, age, use of other 
medications, and diagnoses, there was no significant multivariate interaction between 
anticholinergic medication use and polypharmacy on cognitive functioning across 
domains. There also were not multivariate main effects of anticholinergic medication use 




With regard to antidepressant medications, a 3 (antidepressant medication use) X 
3 (polypharmacy) between subjects MANCOVA evaluated the interactions and main 
effects of medication use and polypharmacy across cognitive domains. Bartlett’s test of 
sphericity was statistically significant (approximate chi square = 1134.32, df = 44, p < 
.001), indicating that the correlation of the dependent variables was sufficient to support 
the MANCOVA. Box’s test of the equality of the variance-covariance matrices was also 
statistically significant [Box’s M = 226.21, F(135, 51260.58) = 1.57, p < .001], 
suggesting that the matrices were not homogenous. Therefore, Pillai’s Trace was used to 
evaluate the multivariate effects because it is more robust to violations of this assumption 
compared to the other multivariate tests of significance. 
The multivariate interaction of antidepressant medication use X polypharmacy, 
when controlling for effects of the covariates, was examined prior to the multivariate 
main effects. The multivariate interaction effect on cognitive domain scores was not 
statistically significant [Pillai’s Trace = .04, F(9, 325) = 1.51, p = .14, 1 – Wilks’ lambda 
= .04]. The multivariate main effect of the following covariates were significant: location 
of the evaluation [Pillai’s Trace = .18, F(9, 325) = 7.83, p < .001, 1-Wilks’ lambda = 
.18], estimated premorbid functioning [Pillai’s Trace = .48, F(9, 325) = 33.80, p < .001, 
1-Wilks’ lambda = .48], moderate to severe TBI [Pillai’s Trace = .08, F(9, 325) = 3.17, p 
= .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, F(9, 325) 
= 3.20, p = .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s Trace = .06, 
F(9, 325) = 2.26, p = .02, 1-Wilks’ lambda = .06]. The multivariate main effects of the 
independent variables of antidepressant medication use and polypharmacy, were not 
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statistically significant [Pillai’s Trace = .02, F(9, 325) = 0.85, p = .57, 1-Wilks’ lambda = 
.02; Pillai’s Trace = .02, F(9, 325) = 0.73, p = .68, 1-Wilks’ lambda = .02, respectively]. 
Overall, despite adjusting for relevant variables, such as the neuropsychologist 
conducting the evaluation, estimated premorbid functioning, age, use of other 
medications, and diagnoses, there was no significant multivariate interaction between 
antidepressant medication use and polypharmacy on cognitive functioning across 
domains. There also were not multivariate main effects of antidepressant medication use 
or polypharmacy on cognitive functioning across domains. 
Anxiolytic Medications 
With regard to anxiolytic medications, a 3 (anxiolytic medication use) X 3 
(polypharmacy) between subjects MANCOVA evaluated the interaction and main effects 
of medication use and polypharmacy across cognitive domains. Bartlett’s test of 
sphericity was statistically significant (approximate chi square = 1130.66, df = 44, p < 
.001), indicating that the correlation of the dependent variables was sufficient to support 
the MANCOVA. Box’s test of the equality of the variance-covariance matrices was also 
statistically significant [Box’s M = 280.78, F(180, 17583.63) = 1.35, p = .001], 
suggesting that the matrices were not homogenous. Therefore, Pillai’s Trace was used to 
evaluate the multivariate effects because it is more robust to violations of this assumption 
compared to the other multivariate tests of significance.
The multivariate interaction of anxiolytic medication use X polypharmacy, when 
controlling for effects of the covariates, was examined prior to the multivariate main 
effects. The multivariate interaction effect on cognitive domain scores was not 
statistically significant [Pillai’s Trace = .05, F(9, 325) = 1.70, p = .09, 1 – Wilks’ lambda 
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= .05]. The multivariate main effect of the following covariates were significant: location 
of the evaluation [Pillai’s Trace = .19, F(9, 325) = 8.37, p < .001, 1-Wilks’ lambda = 
.19], estimated premorbid functioning [Pillai’s Trace = .48, F(9, 325) = 33.61, p < .001, 
1-Wilks’ lambda = .48], moderate to severe TBI [Pillai’s Trace = .08, F(9, 325) = 3.17, p 
= .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, F(9, 325) 
= 3.30, p < .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s Trace = .06, 
F(9, 325) = 2.27, p = .02, 1-Wilks’ lambda = .06]. The multivariate main effects of the 
independent variables of anxiolytic medication use and polypharmacy, were not 
statistically significant [Pillai’s Trace = .02, F(9, 325) = 0.75, p = .66, 1-Wilks’ lambda = 
.02; Pillai’s Trace = .03, F(9, 325) = 0.98, p = .46, 1-Wilks’ lambda = .03, respectively]. 
Overall, despite adjusting for relevant variables, such as the neuropsychologist 
conducting the evaluation, estimated premorbid functioning, age, use of other 
medications, and diagnoses, there was no significant multivariate interaction between 
anxiolytic medication use and polypharmacy on cognitive functioning across domains. 
There also were not multivariate main effects of anxiolytic medication use or 
polypharmacy on cognitive functioning across domains.
Analgesic Medications 
With regard to anxiolytic medications, a 3 (analgesic medication use) X 3 
(polypharmacy) between subjects MANCOVA evaluated the interaction and main effects 
of medication use and polypharmacy across cognitive domains. Bartlett’s test of 
sphericity was statistically significant (approximate chi square = 1126.75, df = 44, p < 
.001), indicating that the correlation of the dependent variables was sufficient to support 
the MANCOVA. Box’s test of the equality of the variance-covariance matrices was also 
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statistically significant [Box’s M = 270.52, F(180, 17470.74) = 1.30, p = .004], 
suggesting that the matrices were not homogenous. Therefore, Pillai’s Trace was used to 
evaluate the multivariate effects because it is more robust to violations of this assumption 
compared to the other multivariate tests of significance.
The multivariate interaction of analgesic medication use X polypharmacy, when 
controlling for effects of the covariates, was examined prior to the multivariate main 
effects. The multivariate interaction effect on cognitive domain scores was not 
statistically significant [Pillai’s Trace = .04, F(9, 325) = 1.37, p = .20, 1 – Wilks’ lambda 
= .04]. The multivariate main effect of the following covariates were significant: location 
of the evaluation [Pillai’s Trace = .19, F(9, 325) = 8.25, p < .001, 1-Wilks’ lambda = 
.19], estimated premorbid functioning [Pillai’s Trace = .49, F(9, 325) = 34.24, p < .001, 
1-Wilks’ lambda = .49], moderate to severe TBI [Pillai’s Trace = .08, F(9, 325) = 3.27, p 
< .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, F(9, 325) 
= 3.21, p < .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s Trace = .06, 
F(9, 325) = 2.27, p = .02, 1-Wilks’ lambda = .06]. The multivariate main effects of the 
independent variables of analgesic medication use and polypharmacy, were not 
statistically significant [Pillai’s Trace = .04, F(9, 325) = 1.66, p = .10, 1-Wilks’ lambda = 
.04; Pillai’s Trace = .02, F(9, 325) = 0.81, p = .61, 1-Wilks’ lambda = .02, respectively]. 
Overall, despite adjusting for relevant variables, such as the neuropsychologist 
conducting the evaluation, estimated premorbid functioning, age, use of other 
medications, and diagnoses, there was no significant multivariate interaction between 
analgesic medication use and polypharmacy on cognitive functioning across domains. 
There also were not multivariate main effects of analgesic medication use or 
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polypharmacy on cognitive functioning across domains. 
Antiepileptic Medications 
With regard to antiepileptic medications, a 3 (antiepileptic medication use) X 3 
(polypharmacy) between subjects MANCOVA evaluated the interaction and main effects 
of medication use and polypharmacy across cognitive domains. Bartlett’s test of 
sphericity was statistically significant (approximate chi square = 1127.40, df = 44, p < 
.001), indicating that the correlation of the dependent variables was sufficient to support 
the MANCOVA. Box’s test of the equality of the variance-covariance matrices was also 
statistically significant [Box’s M = 283.06, F(180, 11870.59) = 1.36, p = .001], 
suggesting that the matrices were not homogenous. Therefore, Pillai’s Trace was used to 
evaluate the multivariate effects because it is more robust to violations of this assumption 
compared to the other multivariate tests of significance.
The multivariate interaction of antiepileptic medication use X polypharmacy, 
when controlling for effects of the covariates, was examined prior to the multivariate 
main effects. The multivariate interaction effect on cognitive domain scores was not 
statistically significant [Pillai’s Trace = .02, F(9, 325) = 0.76, p = .65, 1 – Wilks’ lambda 
= .02]. The multivariate main effect of the following covariates were significant: location 
of the evaluation [Pillai’s Trace = .18, F(9, 325) = 8.16, p < .001, 1-Wilks’ lambda = 
.18], estimated premorbid functioning [Pillai’s Trace = .48, F(9, 325) = 33.60, p < .001, 
1-Wilks’ lambda = .48], moderate to severe TBI [Pillai’s Trace = .08, F(9, 325) = 3.19, p 
= .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, F(9, 325) 
= 3.19, p = .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s Trace = .06, 
F(9, 325) = 2.31, p = .02, 1-Wilks’ lambda = .06]. The multivariate main effects of the 
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independent variables of antiepileptic medication use and polypharmacy, were not 
statistically significant [Pillai’s Trace = .04, F(9, 325) = 1.61, p = .11, 1-Wilks’ lambda = 
.04; Pillai’s Trace = .02, F(9, 325) = 0.69, p = .72, 1-Wilks’ lambda = .02, respectively]. 
Overall, despite adjusting for relevant variables, such as the neuropsychologist 
conducting the evaluation, estimated premorbid functioning, age, use of other 
medications, and diagnoses, there was no significant multivariate interaction between 
antiepileptic medication use and polypharmacy on cognitive functioning across domains. 
There also were not multivariate main effects of antiepileptic medication use or 
polypharmacy on cognitive functioning across domains.
Cardiovascular Medications 
With regard to cardiovascular medications, a 3 (cardiovascular medication use) X 
3 (polypharmacy) between subjects MANCOVA evaluated the interaction and main 
effects of medication use and polypharmacy across cognitive domains. Bartlett’s test of 
sphericity was statistically significant (approximate chi square = 1126.04, df = 44, p < 
.001), indicating that the correlation of the dependent variables was sufficient to support 
the MANCOVA. Box’s test of the equality of the variance-covariance matrices was also 
statistically significant [Box’s M = 262.89, F(180, 17816.35) = 1.28, p = .008], 
suggesting that the matrices were not homogenous. Therefore, Pillai’s Trace was used to 
evaluate the multivariate effects because it is more robust to violations of this assumption 
compared to the other multivariate tests of significance.
The multivariate interaction of cardiovascular medication use X polypharmacy, 
when controlling for effects of the covariates, was examined prior to the multivariate 
main effects. The multivariate interaction effect on cognitive domain scores was not 
 
111 
statistically significant [Pillai’s Trace = .04, F(9, 325) = 1.47, p = .16, 1 – Wilks’ lambda 
= .04]. The multivariate main effect of the following covariates were significant: location 
of the evaluation [Pillai’s Trace = .19, F(9, 325) = 8.33, p < .001, 1-Wilks’ lambda = 
.19], estimated premorbid functioning [Pillai’s Trace = .49, F(9, 325) = 33.98, p < .001, 
1-Wilks’ lambda = .49], moderate to severe TBI [Pillai’s Trace = .08, F(9, 325) = 3.25, p 
< .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, F(9, 325) 
= 3.18, p = .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s Trace = .06, 
F(9, 325) = 2.27, p = .02, 1-Wilks’ lambda = .06]. The multivariate main effects of the 
independent variables of cardiovascular medication use and polypharmacy, were not 
statistically significant [Pillai’s Trace = .04, F(9, 325) = 1.37, p = .20, 1-Wilks’ lambda = 
.04; Pillai’s Trace = .02, F(9, 325) = 0.86, p = .57, 1-Wilks’ lambda = .02, respectively]. 
Overall, despite adjusting for relevant variables, such as the neuropsychologist 
conducting the evaluation, estimated premorbid functioning, age, use of other 
medications, and diagnoses, there was no significant multivariate interaction between 
cardiovascular medication use and polypharmacy on cognitive functioning across 
domains. There also were not multivariate main effects of cardiovascular medication use 
or polypharmacy on cognitive functioning across domains.
Anti-Inflammatory Medications 
With regard to anti-inflammatory medications, a 3 (anti-inflammatory medication 
use) X 3 (polypharmacy) between subjects MANCOVA evaluated the interaction and 
main effects of medication use and polypharmacy across cognitive domains. Bartlett’s 
test of sphericity was statistically significant (approximate chi square = 1131.57, df = 44, 
p < .001), indicating that the correlation of the dependent variables was sufficient to 
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support the MANCOVA. Box’s test of the equality of the variance-covariance matrices 
was also statistically significant [Box’s M = 295.76, F(180, 15030.91) = 1.36, p = .001], 
suggesting that the matrices were not homogenous. Therefore, Pillai’s Trace was used to 
evaluate the multivariate effects because it is more robust to violations of this assumption 
compared to the other multivariate tests of significance.
The multivariate interaction of anti-inflammatory medication use X 
polypharmacy, when controlling for effects of the covariates, was examined prior to the 
multivariate main effects. The multivariate interaction effect on cognitive domain scores 
was not statistically significant [Pillai’s Trace = .01, F(9, 325) = 0.44, p = .91, 1 – Wilks’ 
lambda = .01]. The multivariate main effect of the following covariates were significant: 
location of the evaluation [Pillai’s Trace = .18, F(9, 325) = 8.11, p < .001, 1-Wilks’ 
lambda = .18], estimated premorbid functioning [Pillai’s Trace = .48, F(9, 325) = 33.78, 
p < .001, 1-Wilks’ lambda = .48], moderate to severe TBI [Pillai’s Trace = .08, F(9, 325) 
= 3.17, p = .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, 
F(9, 325) = 3.15, p = .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s 
Trace = .06, F(9, 325) = 2.32, p = .02, 1-Wilks’ lambda = .06]. The multivariate main 
effects of the independent variables of anti-inflammatory medication use and 
polypharmacy, were not statistically significant [Pillai’s Trace = .01, F(9, 325) = 0.43, p 
= .92, 1-Wilks’ lambda = .01; Pillai’s Trace = .03, F(9, 325) = 0.94, p = .49, 1-Wilks’ 
lambda = .03, respectively]. Overall, despite adjusting for relevant variables, such as the 
neuropsychologist conducting the evaluation, estimated premorbid functioning, age, use 
of other medications, and diagnoses, there was no significant multivariate interaction 
between anti-inflammatory medication use and polypharmacy on cognitive functioning 
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across domains. There also were not multivariate main effects of anti-inflammatory 
medication use or polypharmacy on cognitive functioning across domains. 
Hormone Medications
With regard to hormone medications, a 3 (hormone medication use) X 3 
(polypharmacy) between subjects MANCOVA evaluated the interaction and main effects 
of medication use and polypharmacy across cognitive domains. Bartlett’s test of 
sphericity was statistically significant (approximate chi square = 1131.05, df = 44, p < 
.001), indicating that the correlation of the dependent variables was sufficient to support 
the MANCOVA. Box’s test of the equality of the variance-covariance matrices was also 
statistically significant [Box’s M = 287.01, F(180, 13592.02) = 1.38, p < .001], 
suggesting that the matrices were not homogenous. Therefore, Pillai’s Trace was used to 
evaluate the multivariate effects because it is more robust to violations of this assumption 
compared to the other multivariate tests of significance. 
The multivariate interaction of hormone medication use X polypharmacy, when 
controlling for effects of the covariates, was examined prior to the multivariate main 
effects. The multivariate interaction effect on cognitive domain scores was not 
statistically significant [Pillai’s Trace = .03, F(9, 325) = 1.18, p = .31, 1 – Wilks’ lambda 
= .03]. The multivariate main effect of the following covariates were significant: location 
of the evaluation [Pillai’s Trace = .18, F(9, 325) = 8.06, p < .001, 1-Wilks’ lambda = 
.18], estimated premorbid functioning [Pillai’s Trace = .49, F(9, 325) = 34.01, p < .001, 
1-Wilks’ lambda = .49], moderate to severe TBI [Pillai’s Trace = .08, F(9, 325) = 3.26, p 
< .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, F(9, 325) 
= 3.16, p = .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s Trace = .06, 
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F(9, 325) = 2.28, p = .02, 1-Wilks’ lambda = .06]. The multivariate main effects of the 
independent variables of hormone medication use and polypharmacy, were not 
statistically significant [Pillai’s Trace = .02, F(9, 325) = 0.78, p = .64, 1-Wilks’ lambda = 
.02; Pillai’s Trace = .03, F(9, 325) = 0.97, p = .47, 1-Wilks’ lambda = .03, respectively]. 
Overall, despite adjusting for relevant variables, such as the neuropsychologist 
conducting the evaluation, estimated premorbid functioning, age, use of other 
medications, and diagnoses, there was no significant multivariate interaction between use 
of hormone medications and polypharmacy on cognitive functioning across domains. 
There also were not multivariate main effects of use of hormone medications or 









This study sought to add to and extend the literature regarding effects of 
medications and polypharmacy on cognition in a broad clinical sample (e.g., TBI, 
vascular/cerebrovascular accident [CVA], encephalitis, mental health diagnoses, etc.) 
using a comprehensive battery of neuropsychological tests. Collaborative and 
independent effects of medications and polypharmacy on cognitive functioning were 
thoroughly evaluated through three broad aims: 1) examining the effects of medication 
use and polypharmacy on global cognitive functioning, as assessed by OTBM; 2) 
examining the effects of medication use and polypharmacy on global cognitive 
functioning, as assessed by IIV; and 3) examining the effects of medication use and 
polypharmacy on domain-specific cognitive functioning. Additionally, the use of 
covariates in the analyses allowed for the relationships between cognitive performance 
and other variables in the sample (e.g., premorbid functioning, effects of underlying 
pathology related to diagnosis, effects of other prescribed medications) to be statistically 
controlled for, leaving a “purer” evaluation of the medication effects, addressing some of 
the limitations of previous studies (e.g., del Ser et al., 2019; Obermann et al., 2013).   
To control for increased Type 1 error, and at times heterogeneity of variance, 
alpha values were variously corrected to .006 (Bonferroni corrected alpha) or .001 as 
appropriate. Regarding Aim One, results of the two-way ANCOVAs evaluating the 
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interaction and main effects of medication use and polypharmacy on the OTBM did not 
reveal a significant interaction or main effect of medication use or polypharmacy, as 
hypothesized. With regard to Aim Two, results of the two-way ANCOVAs evaluating the 
interaction and main effects of medication use and polypharmacy on IIV found no 
significant interactions between medication use and polypharmacy. However, three 
significant main effects were identified. There was a significant main effect for use of 
analgesics on IIV and a significant main effect of triptan on IIV, such that those who used 
these medications demonstrated higher cognitive variability (IIV) with regard to their 
performance across neuropsychological tests. There was also a significant main effect of 
polypharmacy on IIV, such that subjects without polypharmacy showed more cognitive 
variability than those taking more than 5 medications and those who were not taking any 
medications. Aim Three, which evaluated the interaction and main effects of medications 
and polypharmacy on domain-specific cognitive functioning using multivariate analyses, 
did not produce any significant interactions or main effects for medication use or 
polypharmacy.
 Overall, the significant effects are interesting in that they suggest that the use of 
broad analgesics, and the use of triptans specifically, increase cognitive variability across 
a neuropsychological assessment, while polypharmacy reduces cognitive variability. 
While these findings may seem at odds with one another, they highlight a unique quality 
of cognitive variation: it can both positively and negatively impact cognition. 
Specifically, while many studies have identified associations between increased IIV and 
cognitive dysfunction (e.g., Ballard et al., 2001; Hill et al., 2013; Morgan et al., 2011; 
Murtha et al., 2002), some degree of cognitive variability is normal. For example, in their 
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evaluation of a sample of community dwelling adults, Schretlen et al. (2003) found that 
all subjects had a discrepancy of at least 1.6 SD between their highest and lowest scores 
on a comprehensive neuropsychological assessment. Additionally, two-thirds of these 
subjects had a discrepancy of more than three standard deviations between their highest 
and lowest scores.  
Similarly, across various normative samples of healthy individuals, Binder et al. 
(2009) found that the median number of abnormal scores, defined as a score more than 1 
SD away from the mean, was between 10 and 15% of the number of scores derived from 
the test battery. Therefore, on a neuropsychological assessment with at least 20 tests, such 
as that administered to participants in the current study, an individual will likely have at 
least two abnormal scores. However, the probability of obtaining low scores has also 
been associated with demographic characteristics, such as age and diverse ethnic and 
cultural backgrounds, and inversely related to intelligence and education (Iverson et al., 
2008; Schretlen et al., 2003). Thus, those with higher intelligence are more likely to have 
some low scores and likely would have higher IIVs. On the other hand, those with greater 
probabilities of low scores due to various demographic characteristics will likely have an 
IIV that is constricted and lower than the IIV of the general population.  
This is also true when considering the relationship between low scores and 
neurocognitive dysfunction. For those with severe, global cognitive impairment (e.g., 
later stages of dementia), there will likely be less variability with regard to 
neuropsychological test performance. This suggests that there is a curvilinear relationship 
between IIV and cognitive dysfunction. Although, additional research is needed to fully 
define this relationship.
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Regardless, with the exception of a significant effect of broad analgesics, triptans, 
and polypharmacy on IIV, these findings suggest that use of anticholinergics, 
antidepressants, anxiolytics, analgesics, antiepileptics, cardiovascular, anti-inflammatory, 
and hormone medications, and the combination of both medication use and 
polypharmacy, do not significantly impact cognition on global or domain specific levels 
above and beyond effects of estimated premorbid functioning, age, other medication 
effects, and disease pathology. These findings are somewhat consistent with the current 
literature regarding effects of medication use on cognition. 
Specifically, while fairly consistent cognitive deficits have been identified 
following use of some medications (e.g., anticholinergics and analgesics), similar to the 
relationship between analgesics and IIV illuminated here, many other therapeutic use 
groups (e.g., antidepressants, anxiolytics, and cardiovascular) have inconsistent findings 
regarding the relationship between medication use and cognition (see del Ser et al., 2019; 
Marpillat et al., 2013; Nevado-Holgado et al., 2016; Picton et al., 2018; Prado et al., 
2018). Based on the literature, one factor that may lead to this variability in identifying 
cognitive effects across current literature, as well as the null results in the present study, 
is the demographics of the participants in the sample.  
Sample Demographics 
As noted above, the average age of sample subjects in the present study was 
approximately 40 years old (SD = 14.6). While some studies containing younger adults 
have identified cognitive deficits secondary to the use of medications (Nevado-Holgado 
et al., 2016), it appears that strong or consistent cognitive findings secondary to 
medication effects are most often identified in older adult populations (> 65; e.g., 
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Campbell et al., 2009; Nader & Gowing, 2020; Obermann et al., 2013; Picton et al., 
2018). This may be due to a number of reasons, including pharmacokinetic and 
pharmacodynamic factors or premorbid cognitive fragility causing older adults to be at 
higher risk of cognitive effects of medication use (Fulton & Allen, 2005; Kinirons & 
O'Mahony, 2004). 
However, the clinical nature of the sample suggests that these participants may be 
more cognitively vulnerable than a sample of healthy adults. Nearly 20% of this sample 
was composed of individuals with a history of traumatic brain injury, nearly 10 % of this 
sample had a history of cardiovascular disorders, and approximately 6% of this sample 
were diagnosed with SMI. Individuals with these diagnoses are at heightened risk of 
cognitive dysfunction (Almeida et al., 2019; Huang et al., 2018; Kuller et al., 2005), like 
older adults. Additionally, over 6% of the sample were diagnosed with various 
neurocognitive disorders, suggesting that while the overall sample was composed of 
younger adults, a majority of the sample consisted of those who may not have had 
significant cognitive reserve to compensate for medication effects, if they were present. 
Despite this, no significant effects of medications were identified for OTBM or domain 
means and the only significant medication effects identified, above and beyond that of 
disease processes, were for the use of analgesic medications, the use of triptans, and 
polypharmacy, on cognitive variability.
Polypharmacy. 
Older adults also have higher rates of medication use and polypharmacy (Barnett 
et al., 2012; Kantor et al., 2015), which has been suggested as adding to the risk of 
cognitive dysfunction in older adults (Jyrkkä et al., 2011; Maher et al., 2014; Moore & 
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O’Keefe, 1999; Sordahl et al., 2019). While an effect of polypharmacy on IIV was 
identified, this relationship was only significant in one analysis and no significant effects 
of polypharmacy were found on overall cognition as measured by the OTBM or at the 
domain level, as has been suggested in the previous literature. These mostly null findings 
may have been due to the relatively low rate of polypharmacy in the current sample 
(11%). However, it is also possible that the previous findings of significant effects of 
polypharmacy on cognition were due to more than simply the number of medications 
used. 
For example, studies by Lam (2017) and Risacher et al. (2016) indicate that the 
effects of polypharmacy on cognition are particularly salient when resulting from the use 
of multiple anticholinergic drugs. Specifically, the use of one anticholinergic drug in the 
context of other medications may not lead to cognitive impairment. Rather, it is the 
overall anticholinergic burden which leads to cognitive impairment. While evaluating for 
the overall burden of specific medications was beyond the scope of this study, it is 
possible that low burden could have contributed to some of the null findings. 
Medication. 
In addition to the potential of medication burden effects, which were not able to 
be evaluated in the present study, there are several other variables that may have 
contributed to the present findings, despite generally findings of cognitive effects of 
anticholinergics, benzodiazepine anxiolytics, opioid analgesics, and AEDs in the previous 
literature. Specifically, medication dosage, duration of use, frequency of use, and when 
the medication was taken in relation to the date and time of the neuropsychological 
assessment would each affect a drug’s response, and subsequently the effect of the drug 
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on cognition. Unfortunately, these variables were not available for study participants 
given the archival nature of the data. Further, information regarding the reason for the 
prescription medication use or what specific diagnosis it was prescribed to treat were also 
not available in the current sample. Therefore, while classifications of medications were 
based on chemical compositions, the true therapeutic use of many medications was 
unknown given that many medications can be used for various purposes depending on 
does and frequency of use. This further complicates the medication use classifications 
and analyses of the current sample. While some of these variables were considered in 
previous literature, such as long-term use of benzodiazepines (Nader & Gowing, 2020), 
opioids (Allegri et al., 2019) and AEDs (Park & Kwon, 2008; Stein & Strickland,1998), 
further consideration should be given to evaluation of each of these variables in the 
context of effects on cognitive functioning in future studies.
Diagnoses and Estimated Premorbid Functioning. 
Results of this study also underlined the importance of controlling for 
neurological, psychological, and general health diagnoses, as well as estimated premorbid 
functioning when evaluating the cognitive effects of medication. Specifically, significant 
effects of moderate to severe TBI and the presence of a cardiovascular diagnosis on 
overall cognition, as measured by OTBM and IIV, and domain-specific cognition were 
identified for all univariate and multivariate analyses. Significant effects of estimated 
premorbid functioning were also identified for all analyses of OTBM and domain means. 
Further, many analyses also showed significant effects of neurocognitive disorders and 
respiratory disorders on cognition.  
Despite the clear influence of premorbid functioning and these various disease 
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processes on cognitive functioning, no known studies to date have controlled for both 
premorbid functioning and physical, psychiatric, and medical diagnoses when evaluating 
the relationship between medication use and cognitive functioning. Therefore, in the 
context of significant main effects of analgesics, triptans, and polypharmacy on IIV only, 
questions remain regarding the validity of many of the previously identified relationships 
between medication use and cognition. Additional studies of these effects while 
controlling for these factors are necessary to fully understand the extent of the 
contributions from premorbid functioning and underlying disease processes on previously 
identified medication effects.
Neuropsychological Test Battery 
Another factor that may have led to the variability in cognitive effects across 
current literature compared to the largely null results in the present study, is the use of a 
comprehensive battery of neuropsychological tests to evaluate cognitive functioning. As 
previously discussed, most of the previous studies examining the cognitive effects of 
medication used screening tests, such as the MMSE (Folstein et al., 1975), to evaluate 
global cognitive status. While this type of measure has benefits in briefly assessing 
cognition within the research setting, there are significant limitations to using such tests. 
Specifically, while screening measures are ideally sensitive and specific to cognitive 
dysfunction, this is not always the case. For example, in a heart failure population one 
study found that at a cut value of < 24, the MMSE only correctly identified 28% of 
individuals as having cognitive impairment, while nearly 10% of cognitively normal 
individuals were incorrected identified as having cognitive impairment (Hawkins et al., 
2014). Using a more conservative cut-off (<29/30), Hoops et al. (2009) found that the 
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MMSE correctly identified 92% of individuals with mild cognitive impairment in the 
context of Parkinson’s disease. However, 58% of cognitively normal individuals were 
also identified as having mild cognitive impairment. Given that many of the previous 
studies evaluating the cognitive effects of medication showed small to medium effect 
sizes and were plagued by small sample sizes, the use of screening measures to identify 
cognitive impairment, such as the MMSE, may further explain the discrepancies.
Even when specific neuropsychological tests are utilized to examine cognitive 
impairment, such as Trail Making Test (e.g., Allegri et al., 2019; Baldacchino et al., 
2012), there is significantly more risk of erroneously concluding impairment or a lack of 
impairment when researchers do not use a comprehensive battery of neuropsychological 
tests. This is because, as previously discussed, some degree of cognitive variability is 
normal (Binder et al., 2009; Schretlen et al., 2003). When combining scores across 
multiple tests from the same domain within a comprehensive test battery, such as with the 
MNS used in this study, the risk of Type I error is reduced. Additionally, given the 
number of analyses conducted, and at times heterogeneity of variance, corrected 
significance values were used in the present study to further reduce risk of false positive 
findings. 
Trends 
Using these criteria, the only significant effects were found for use of broad 
analgesic medications, triptans, and polypharmacy on IIV at .001 and .006 alpha levels. 
However, there were other effects that were trending towards significance at this higher 
level. Specifically, significant interactions between use of anxiolytics and polypharmacy 
on OTBM (p=.01) and on IIV (p=.03) were identified, as were significant interactions 
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between AEDs and polypharmacy on OTBM (p=.03) and on IIV (p=.03). A main effect 
of analgesics on OTBM, as well as main effects of polypharmacy on IIV when run with 
anticholinergic drugs, antidepressants, analgesics, cardiovascular medications, anti-
inflammatory medications, and hormone medications were also identified at p < .05. 
Overall, the pattern of these results continues to fit with the previous literature and 
suggest that most medications do not have significant effects on cognitive functioning 
when accounting for estimated premorbid functioning, the neuropsychologist who 
supervised the evaluation, use of other medications and various diagnoses. Small 
differential effects of anxiolytics and AEDs on the OTBM and IIV were identified. 
Although, these differences appear to be only in the context of polypharmacy. Consistent 
with the previously discussed results, a main effect of analgesic use on global cognitive 
functioning appears to be present when assessed by OTBM, as well as when assessed by 
IIV. This pattern also provides added support for the effects of polypharmacy on IIV 
across other medication use groups. 
Interestingly, when evaluating global cognitive effects, significant effects on the 
OTBM were rarely identified. Rather, more often, significant interaction and main effects 
for both medication use and polypharmacy were either significant for differences in both 
OTBM and IIV, or IIV independently. Additionally, no significant multivariate analyses 
assessing medication use and polypharmacy across cognitive domains were significant at 
conservative or typical alpha values. This pattern suggests that IIV may be particularly 
sensitive to the effects of medication use and polypharmacy on cognition and provide 
additional support for the use of this valuable metric of cognitive functioning in the 
context of neuropsychological assessment in a clinical sample of younger adults.  
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Implications 
 While this study was exploratory in nature, the findings have clinical relevance 
for physicians, neurologists, and neuropsychologists given that these physicians are often 
asked to identify and differentiate cognitive “signal” from “noise” through cognitive 
assessment following complaints of subjective cognitive change (Schoenberg & Scott, 
2011). The current results provide evidence for small effects of analgesics, triptans, and 
polypharmacy on cognitive IIV in this younger adult, clinical sample. These findings are 
above and beyond the effects of premorbid functioning; neurological, psychiatric, and 
general medical diagnoses; and use of other medications. However, while these effects 
were statistically significant, differences in IIV only equated to negligible differences in 
terms of clinical relevance across all significant results. For example, differences in IIV 
for analgesics triptans, and polypharmacy were within 1-3 points of the other groups.  
Given that recommendations to interpret significant discrepancies on 
neuropsychological tests ranges from 1 to 2 SD (Lezak et al., 2012), the differences 
identified in this study do not constitute clinically significant discrepancies in cognitive 
functioning from a neuropsychological perspective. In conjunction with the otherwise 
null results, this study provides support for younger adults’ relative resistance to 
significant cognitive effects of the medications evaluated in the present study. Therefore, 
it would be highly unlikely for most of the medications evaluated in this study to produce 
any more than a mild changes to variability on neurocognitive performance for younger 






Despite this, it is important to recognize some important limitations to the present 
study. First, while the overall sample size was large and it surpassed the minimal sample 
size identified by the a priori power analysis, due to the wide variety of medications 
reported by study subjects, not all medication groups had sufficient data to support an 
analysis. Due to this issue, a deductive approach to data analysis was employed. 
However, it is possible that because analyses were first run with the therapeutic use group 
category, specific effects of a drug class or specific medication were outweighed by the 
effects, or lack thereof, of the other drug classes. 
Additionally, given the high number of different medications reported, further 
caution had to be used when running analyses with sufficiently populated groups. 
Specifically, given that familywise error rate increases with the number of analyses, a 
Bonferroni corrected alpha was used to reduce the chance of Type I error. The alpha was 
further reduced in the event of violations of homogeneity of variance, which was not 
uncommon, particularly given the distribution of medications across the sample. While 
this helped reduce the risk of false positive errors, it is possible that legitimate 
interactions and main effects of medications and polypharmacy on global and domain 
specific cognitive functioning were not interpreted. 
Finally, given the circumstances regarding neuropsychological evaluations and 
the archival nature of the data, some data that would have aided in more accurate 
classifications and evaluations of medication use was missing. Specifically, all 
information regarding medication use and diagnoses was provided by the patient, and not 
a comprehensive medical record system. Thus, it is possible that some of the reported 
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medication and diagnosis information is inaccurate or incomplete. Additionally, 
information regarding why a medication had been prescribed, the dosage of medications, 
frequency of medication use, when the subject last took a dose of medication in relation 
to the date and time of the neuropsychological assessment, and how long the patient had 
been taking their medications was not available. These missing factors limit our 
understanding of the study results. 
Future Directions 
Further evaluation of the cognitive effects of medication use with a larger sample 
size and more comprehensive medication information (e.g., dose, frequency of 
administration, duration of use, reason for use, etc.) is warranted. While the present study 
provides a comprehensive baseline of the effects of medications and polypharmacy on 
cognition in a relatively young clinical sample, future studies should explore the effects 
of medication in older clinical and non-clinical samples using this comprehensive 
methodology to provide a more complete picture of the potential effects of these 
medications on comprehensive neuropsychological tests. Additionally, while this study 
focused exclusively on the use of prescription medications and their effects on cognition, 
future studies should also explore the use and effects of over-the-counter medications and 
dietary supplements on cognition. Much like the use of prescription medications, the use 
of dietary supplements has increased over time (Qato et al., 2016). Given that dietary 
supplements do not require FDA approval, the potential for unknown cognitive side 
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Frequency of Diagnoses for Study Participants 
Diagnosis n (Valid %) 
Internalizing Disorders 230 (46.3%) 
     Depression 173 (43.3%) 
     Anxiety 106 (26.5%) 
     PTSD 8 (2.0%) 
     Panic Disorder 7 (1.8%) 
     OCD 3 (0.8%) 
     Somatic Symptom Disorder 23 (5.8%) 
     Conversion Disorder 14 (3.5%) 
Impulse Control Disorder 1 (0.3%) 
Substance Use Disorder 66 (13.3%) 
Severe Mental Illness 23 (5.8%) 
     Schizophrenia 5 (1.3%) 
     Bipolar Disorder 16 (4.0%) 
     Other Psychotic Disorders 2 (0.5%) 
Learning Disorders 85 (21.3%) 
     Learning Disability 59 (14.8%) 
     ADHD 39 (9.8%) 
Neurodevelopmental Disorders 20 (5.0%) 
     ASD 6 (1.5%) 
     Developmental Motor Disorders 3 (0.8%) 
     Borderline Intellectual Functioning 9 (2.3%) 
     Intellectual Disability 2 (0.5%) 
Seizure Disorder 18 (4.5%) 
Neurocognitive Disorders 25 (6.3%) 
     Alzheimer’s Disease 6 (1.5%) 
     Cerebrovascular Disease 8 (2.0%) 
     FTLD 1 (0.3%) 
     Parkinson’s Disease 1 (0.3%) 
     Dementia 16 (4.0%) 
     Multiple Sclerosis 9 (2.3%) 




Table B.1 Cont.  
Diagnosis n (Valid %) 
Chiari Malformation 3 (0.8%) 
Brain Tumor 7 (1.8%) 
Traumatic Brain Injury 71 (17.8%) 
     Post Concussive Syndrome 7 (1.8%) 
     Mild TBI 48 (12.0%) 
     Moderate to Severe TBI 21 (5.3%) 
Cardiovascular Disorders 37 (9.3%) 
     Cardiac Disease 5 (1.3%) 
     Stroke 19 (4.8%) 
     Transient Ischemic Attack 3 (0.8%) 
     Aneurysm 4 (1.0%) 
Hyperlipidemia 7 (1.8%) 
Autoimmune Disorders 10 (2.5%) 
     Thyroid Dysfunction 5 (1.3%) 
     Lupus 2 (0.5%) 
     Diabetes 4 (1.0%) 
Hyperchloremia 1 (0.3%) 
Respiratory Dysfunction 17 (4.3%) 
     Sleep Apnea 12 (3.0%) 
     Asthma 4 (1.0%) 
     Chronic Obstructive Pulmonary Disease 1 (0.3%) 
Gastrointestinal 6 (1.5%) 
     Inflammatory Bowel Diseases 5 (1.3%) 
     Gastroesophageal Reflux Disease 2 (0.5%) 
Pain 74 (18.5%) 
Migraine 19 (4.8%) 
Tinnitus 1 (0.3%) 
Eating Disorders 2 (0.4%) 
Sleep Disorders 8 (2.0%) 
     Sleep Disturbance 7 (1.8%) 
     Narcolepsy 1 (0.3%) 
Note. n = 497. PTSD = Post-traumatic Stress Disorder. OCD = Obsessive Compulsive 
Disorder. ADHD = Attention-Deficit/Hyperactivity Disorder. ASD = Autism 














Frequency of Medication Use by Study Participants 
Therapeutic Use Drug Family Drug Name (Generic) n (Valid %) 
Anticholinergics   100 
(20.1%) 
Antidepressants   232 
(46.7%) 
 Atypical Antidepressants  67(13.5%) 
  Bupropion 37 (7.4%) 
  Mirtazapine 8 (1.6%) 
  Nefazodone 9 (1.8%) 
  Trazodone 19 (3.8%) 
 SNRI  33 (6.6%) 
  Desvenlafaxine 2 (0.4%) 
  Duloxetine 5 (1.0%) 
  Levomilnacipran 1 (0.2%) 
  Venlafaxine 25 (5.0%) 
 SSRI  138 (27.8%) 
  Citalopram 17 (3.4%) 
  Escitalopram 15 (3.0%) 
  Fluoxetine 26 (5.2%) 
  Fluvoxamine 2 (0.4%) 
  Paroxetine 30 (6.0%) 
  Sertraline 46 (9.3%) 
  Vortioxetine 2 (0.4%) 
 Tricyclics  43 (8.7%) 
  Amitriptyline 29 (5.8%) 
  Doxepin 1 (0.2%) 
  Imipramine 4 (0.8%) 
  Nortriptyline 4 (0.8%) 
  Cyclobenzaprine 5 (1.0%) 
Anxiolytics   68 (13.7%) 
 Benzodiazepines  51 (10.3%) 
  Alprazolam 20 (4.0%) 
  Chlordiazepoxide 1 (0.2%) 
  Clonazepam 13 (2.6%) 
  Diazepam 3 (0.6%) 
  Eszopiclone 1 (0.2%) 
  Lorazepam 12 (2.4%) 
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Therapeutic Use Drug Family Drug Name (Generic) n (Valid %) 
  Triazolam 1 (0.2%) 
 Benzodiazepine-Like  8 (1.6%) 
  Zolpidem 8 (1.6%) 
 Other Anxiolytics  13 (2.6%) 
  Buspirone 13 (2.6%) 
Antipsychotics   37(7.4%) 
 Atypical Antipsychotics  35 (7.0%) 
  Aripiprazole 3 (0.6%) 
  Brexpiprazole 2 (0.4%) 
  Olanzapine 10 (2.0%) 
  Risperidone 7 (1.4%) 
  Quetiapine 15 (3.0%) 
 Phenothiazines  1 (0.2%) 
  Prochlorperazine 1 (0.2%) 
 Butyrophenones  1 (0.2%) 
  Haloperidol 1 (0.2%) 
Mood Stabilizers   4 (0.8%) 
 Antimanic Agents  4 (0.8%) 
  Lithium 4 (0.8%) 
Analgesics   67 (13.5%) 
 Triptans  6 (1.2%) 
  Almotriptan 1 (0.2%) 
  Eletriptan 1 (0.2%) 
  Rizatriptan 2 (0.4%) 
  Sumatriptan 2 (0.4%) 
 Opioids  38 (7.6%) 
  Buprenorphine 1 (0.2%) 
  Dextropropoxyphene 9 (1.8%) 
  Fentanyl 2 (0.4%) 
  Hydrocodone 7 (1.4%) 
  Oxycodone 2 (0.4%) 
  Tramadol 19 (3.8%) 
 Opioid Combinations  20 (4.0%) 
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Therapeutic Use Drug Family Drug Name (Generic) n (Valid %) 
  Oxycodone-Acetaminophen 2 (0.4%) 
  Propoxyphene-Acetaminophen 2 (0.4%) 
 Non-Opioid  11 (2.2%) 
  Acetaminophen 11 (2.2%) 
Addiction   5 (1.0%) 
 Alcohol Antagonist  1 (0.2%) 
  Disulfiram 1 (0.2%) 
 Opioid Agonist  4 (0.8%) 
  Buprenorphine-Naloxone 1 (0.2%) 
  Methadone 3 (0.6%) 
Antiepileptics   96 (19.3%) 
 Traditional AEDs  47 (9.5%) 
  Carbamazepine 10 (2.0%) 
  Phenytoin 13 (2.6%) 
  Primidone 1 (0.2%) 
  Divalproex Sodium 24 (4.8%) 
 Newer AEDs  56 (11.3%) 
  Oxcarbazepine 3 (0.6%) 
  Gabapentin 33 (6.6%) 
  Lamotrigine 15 (3.0%) 
  Levetiracetam 5 (1.0%) 
  Topiramate 2 (0.4%) 
Stimulants   21 (4.2%) 
 
Amphetamine 
Combinations  13 (2.6%) 
  Dextroamphetamine-Amphetamine 11 (2.2%) 
 
Centrally Acting 
Sympathomimetics  12 (2.4%) 
  Lisdexamfetamine 2 (0.4%) 
  Methylphenidate 6 (1.2%) 
  Modafinil 3 (0.6%) 
  Pemoline 1 (0.2%) 
Antidementia   6 (1.2%) 
 
Cholinesterase 
Inhibitors  5 (1.0%) 
  Donepezil 5 (1.0%) 
 NMDA Antagonists  1 (0.2%) 
  Memantine 1 (0.2%) 
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Therapeutic Use Drug Family Drug Name (Generic) n (Valid %) 
 ACE Inhibitors  29 (5.8%) 
  Benazepril 3 (0.6%) 
  Fosinopril 3 (0.6%) 
  Lisinopril 9 (1.8%) 
  Moexipril 1 (0.2%) 
  Quinapril 11 (2.2%) 
  Ramipril 2 (0.4%) 
 
Alpha-Adrenergic 
Blockers  5 (1.0%) 
  Doxazosin 3 (0.6%) 
  Prazosin 2 (0.4%) 
 
Angiotensin II 
Receptor Blockers  8 (1.6%) 
  Candesartan 1 (0.2%) 
  Losartan 5 (1.0%) 
  Olmesartan 1 (0.2%) 
  Valsartan 1 (0.2%) 
 Beta Blockers  25 (5.0%) 
  Atenolol 4 (0.8%) 
  Betaxolol 1 (0.2%) 
  Labetalol 3 (0.6%) 
  Metoprolol 12 (2.4%) 
  Nebivolol 1 (0.2%) 
  Propranolol 4 (0.8%) 
 
Calcium Channel 
Blockers  18 (3.6%) 
  Amlodipine 9 (1.8%) 
  Diltiazem 6 (1.2%) 
  Nifedipine 3 (0.6%) 
  Verapamil 1 (0.2%) 
 Cardiac Glycosides  4 (0.8%) 
  Digoxin 4 (0.8%) 
 
Centrally Acting 
Alpha2 Agonist  5 (1.0%) 
  Clonidine 5 (1.0%) 
 Diuretics  23 (4.6%) 
  Hydrochlorothiazide 17 (3.4%) 
  Furosemide 4 (0.8%) 
  Spironolactone 3 (0.6%) 
 Nitrates  3 (0.6%) 
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Therapeutic Use Drug Family Drug Name (Generic) n (Valid %) 
 
Sodium Channel 
Blockers  1 (0.2%) 
  Lidocaine 1 (0.2%) 
Lipid Modifying 
Agents 
  41 (8.2%) 
 Fibrates  4 (0.8%) 
  Fenofibrate 3 (0.6%) 
  Gemfibrozil 1 (0.2%) 
 
HMG-CoA 
Reductase Inhibitors  38 (7.6%) 
  Atorvastatin 25 (5.0%) 
  Pravastatin 3 (0.6%) 
  Rosuvastatin 3 (0.6%) 
  Simvastatin 7 (1.4%) 
Antithrombotic 
Agents 
  15 (3.0%) 
 Anticoagulants  10 (2.0%) 
  Enoxaparin 1 (0.2%) 
  Warfarin 9 (1.8%) 
 Antiplatelet  6 (1.2%) 
  Clopidogrel 6 (1.2%) 
Anti-Inflammatory   79 (15.9%) 
 Corticosteroids  5 (1.0%) 
  Dexamethasone 1 (0.2%) 
  Prednisone 4 (0.8%) 
 
Second-Generation 
NSAID  25 (5.0%) 
  Celecoxib 13 (2.6%) 
  Rofecoxib 12 (2.4%) 
 
First-Generation 
NSAID  57 (11.5%) 
  Aspirin 27 (5.4%) 
  Diclofenac 1 (0.2%) 
  Diflunisal 1 (0.2%) 
  Ibuprofen 21 (4.2%) 
  Naproxen 1 (0.2%) 
  Relafen 1 (0.2%) 
  Ketorolac 1 (0.2%) 
  Sulindac 1 (0.2%) 
  Indomethacin 2 (0.4%) 
  Meloxicam 2 (0.4%) 
Hormones   79 (15.9%) 
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Therapeutic Use Drug Family Drug Name (Generic) n (Valid %) 
  Medroxyprogesterone Acetate 3 (0.6%) 
  Progesterone 2 (0.4%) 
 Non-contraceptives  69(13.9%) 
  Estrogens 26 (5.2%) 
  Levothyroxine 45 (9.1%) 
  Raloxifene 3 (0.6%) 
Respiratory   27 (5.4%) 
 Bronchodilators  20 (4.0%) 
  Albuterol 15 (3.0%) 
  Alupent 1 (0.2%) 
  Salmeterol 5 (1.0%) 
  Theophylline 1 (0.2%) 
  Tiotropium bromide 1 (0.2%) 
 Corticosteroids  9 (1.8%) 
  Flunisolide 2 (0.4%) 
  Fluticasone 7 (1.4%) 
 
Nonopioid 
Antitussives  1 (0.2%) 
  Benzonatate 1 (0.2%) 
 
Leukotriene 
Modifiers  6 (1.2%) 
  Montelukast 6 (1.2%) 
Antidiabetics   25 (5.0%) 
 Biguanides  10 (2.0%) 
  Metformin 10 (2.0%) 
 Incretin Mimetics  1 (0.2%) 
  Liraglutide 1 (0.2%) 
 Insulin Preparations  10 (2.0%) 
  Insulin 10 (2.0%) 
 Meglitinides  1 (0.2%) 
  Repaglinide 1 (0.2%) 
 SGLT-2 Inhibitor  1 (0.2%) 
  Dapagliflozin 1 (0.2%) 
 Sulfonylureas  3 (0.6%) 
  Glyburide (Glibenclamide) 1 (0.2%) 
  Glipizide 2 (0.4%) 
 Thiazolidinediones  3 (0.6%) 
  Pioglitazone 3 (0.6%) 
Antihistamines   24 (4.8%) 
 
First-Generation H1 
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  Diphenhydramine 1 (0.2%) 
  Hydroxyzine 5 (1.0%) 
  Meclizine 1 (0.2%) 
  Promethazine 1 (0.2%) 
 
Second-Generation 
H1 Antagonist  15 (3.0%) 
  Cetirizine 5 (1.0%) 
  Desloratadine 1 (0.2%) 
  Fexofenadine 5 (1.0%) 
  Loratadine 3 (0.6%) 
  Azelastine 1 (0.2%) 
Urological   15 (3.0%) 
 
Alpha-adrenergic 
Antagonists  2 (0.4%) 
  Terazosin 1 (0.2%) 
  Tamsulosin 1 (0.2%) 
 Anticholinergic  12 (2.4%) 
  Oxybutynin 7 (1.4%) 
  Solifenacin 3 (0.6%) 
  Tolterodine 2 (0.4%) 
 
Phosphodiesterase 
Type 5 Inhibitor  1 (0.2%) 
  Sildenafil 1 (0.2%) 
 
5-Alpha-Reductase 
Inhibitors  1 (0.2%) 
  Finasteride 1 (0.2%) 
Gastrointestinal   65 (13.1%) 
 Antispasmodic  3 (0.6%) 
  Dicycloverine 3 (0.6%) 
 
Gallstone Dilution 
Agents  1 (0.2%) 
  Ursodiol 1 (0.2%) 
 
H2-Receptor 
Antagonists  8 (1.6%) 
  Cimetidine 1 (0.2%) 
  Ranitidine 7 (1.4%) 
 Prokinetic  3 (0.6%) 
  Metoclopramide 3 (0.6%) 
 
Proton Pump 
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  Esomeprazole 9 (1.8%) 
  Lansoprazole 12 (2.4%) 
  Omeprazole 21 (4.2%) 
  Pantoprazole 5 (1.0%) 
  Rabeprazole 1 (0.2%) 
 Stool Softener  7 (1.4%) 
  Docusate Sodium 7 (1.4%) 
Muscle Relaxants   14 (2.8%) 
 Centrally Acting  13 (2.6%) 
  Baclofen 2 (0.4%) 
  Metaxalone 6 (1.2%) 
  Methocarbamol 2 (0.4%) 
  Tizanidine 3 (0.6%) 
 Peripherally Acting  1 (0.2%) 
  Orphenadrine 1 (0.2%) 
Calcium and Bone 
Mineralization 
  5 (1.0%) 
 Bisphosphonates  5 (1.0%) 
  Alendronic Acid 2 (0.4%) 
  Risedronic Acid 3 (0.6%) 
Immunomodulators   6 (1.2%) 
 Immunostimulants  4 (0.8%) 
  Glatiramer Acetate 2 (0.4%) 
  Interferon Beta-1a 2 (0.4%) 
 Immunosuppressants  2 (0.4%) 
  Etanercept 1 (0.2%) 
  Methotrexate 2 (0.4%) 
Movement Disorder   5 (1.0%) 
 
Dopamine-Releasing 
Agent  1 (0.2%) 
  Amantadine 1 (0.2%) 
 
Dopamine 
Replacement  2 (0.4%) 
  Levodopa-Carbidopa 2 (0.4%) 
 Dopamine Agonist  2 (0.4%) 
  Ropinirole 2 (0.4%) 
Antiglaucoma   3 (0.6%) 
 CAI  2 (0.4%) 
  Acetazolamide 2 (0.4%) 
 
Prostaglandin 
Analogs  1 (0.2%) 
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Other 
Antiglaucomas  1 (0.2%) 
  Dipivefrine 1 (0.2%) 
Dermatological   3 (0.6%) 
 Anti-infectives  1 (0.2%) 
  Fluconazole 1 (0.2%) 
 Corticosteroids  2 (0.4%) 
  Clobetasol 2 (0.4%) 
Antimalarial   2 (0.4%) 
 Aminoquinolines  2 (0.4%) 
  Hydroxychloroquine 2 (0.4%) 
Cytotoxic Drugs   2 (0.4%) 
 Alkylating Agents  2 (0.4%) 
  Temozolomide 2 (0.4%) 
Weight Loss Drugs   2 (0.4%) 
 Lipase Inhibitor  1 (0.2%) 
  Orlistat 1 (0.2%) 
 
Sympathomimetic 
Amines  1 (0.2%) 
  Phentermine 1 (0.2%) 
Antigout Agents   1 (0.2%) 
 Uric Acid Inhibitors  1 (0.2%) 
  Allopurinol 1 (0.2%) 
Note. N = 497. SNRI = Serotonin-Norepinephrine Reuptake Inhibitor. SSRI = 
Selective Serotonin Reuptake Inhibitor. AED = Antiepileptic Drug. NMDA = N-
Methyl-D-aspartate receptor. ACE = Angiotensin-Converting Enzyme. HMG-CoA 
= 3-hydroxy-3-methyl-glutaryl-coenzyme A. NSAID = Non-Steroidal Anti-
Inflammatory Drug. SGLT-2 = Sodium-Glucose Co-Transporter 2. CAI = Carbonic 
Anhydrase Inhibitor. Due to some participants having prescriptions for multiple 
medications within the same drug family and/or therapeutic use group, frequency 
of the larger groups are not always equivalent to the frequency of use identified at 













Medications with Strongly Anticholinergic used by Study Participants 
 Therapeutic Use Drug Family Drug Name (Generic) 
Antidepressants   
 Atypical Antidepressants  
 Tricyclics Paroxetine  
  Amitriptyline 
  Doxepin 
  Imipramine 
  Nortriptyline 
  Cyclobenzaprine 
Analgesics   
 Opioid Combinations  
  Hydrocodone-Chlorpheniramine 
Antipsychotics   
 Atypical Antipsychotics  
  Olanzapine 
 Phenothiazines  
  Prochlorperazine 
Antihistamines   
 First-Generation H1 Antagonist  
  Methscopolamine-Phenylephrine 
  Diphenhydramine 
  Hydroxyzine 
  Meclizine 
  Promethazine 
Urological   
 Anticholinergic  
  Oxybutynin  
Gastrointestinal   
 Antispasmodic  




 Peripherally Acting  





Meyers Neuropsychological Battery and Supplemental Tests by Domain 
# Test Name Cognitive Function 
Hypothesized 
Localization(s) Reference 
00 Performance Validitya 
 1) Word Memory Test (Green, 2003) 
Validity and verbal 






Lezak et al., 2004 (p. 850-
851); Strauss et al., 2006 
 2) Test of Memory Malingering 
(Tombaugh, 1996) 






Lezak et al., 2004 (p. 849-
850); Strauss et al., 2006 
0 Premorbid Functioninga 
 1) North American Adult Reading 









Lezak et al., 2004 (p. 
560); Strauss et al., 2006 
 2) Word Reading (WRAT-4; 









Lezak et al., 2004 (p. 
560); Strauss et al., 2006 
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1) Arithmetic (WAIS III/IV) 
(Wechsler, 1997; Wechsler, 2008) 
Mental Calculations and 
working memory 
Left parietal lobe 
Hom & Reitan, 1984; 
Lezak et al., 2004 (p. 
605); McFie, 1975; 
Newcombe, 1969; Sivak 
et al., 1981  
 
2) Digit Span (WAIS III/IV) 
(Wechsler, 1997; Wechsler, 2008) 
Verbal recall and auditory 
attention 
Left hemisphere 
Black, 1986; Hom & 
Reitan, 1984; Newcombe, 
1969 
 
3) Animal Naming (Spreen & 
Strauss, 1998) 




lobes; Broca’s area; 
left medial occipital 
lobe 
Damasio et al., 1996; 
Martin et al., 1996; Rosen, 
1980  
 
4) Auditory Verbal Learning Test 
(AVLT) – Trial 1 (Rey, 1964) 
Auditory working 






Geffen et al., 1990; Lezak 
et al., 2004; Powell et al., 
1991 
 
5) Sentence Repetition (Spreen & 
Strauss, 1991) 
Auditory comprehension, 








Goodglass & Kaplan, 
1983; Lezak et al., 2004;  
 6) Forced Choice (Brandt et al., 
1985) 
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7) Arithmetic (WRAT-4; Wilkinson 





Lezak et al., 2004 (p. 662) 
 8) Paced Auditory Serial Addition 
Test (Gronwall, 1977; Gronwall & 
Sampson, 1974) 
Attention, working 
memory, and information 
processing 
Frontal and parietal 
lobes 
Lazeron et al., 2003; 
Lezak et al., 2004  (p. 
412); Strauss et al., 2006 
 9) Minute Estimation (Meyers, 2019) Attention Frontal lobes Meyers, 2019 
 10) Dementia Rating Scale – 2 - 
Attention Index (Mattis, 2001) 
Attention and working 
memory 
Left hemisphere 
Lezak et al., 2004 (p. 
412); Strauss et al., 2006 
 11) IVA-2 CPT – Auditory and Visual 
attention and sustained attention 
(Sandford & Turner, 1995) 
Vigilance and sustained 
attention 
Frontal lobes 
Lezak et al., 2004 (p. 415-
416); Tinius, 2003 
II Processing Speed  
 
1) Digit Symbol/Coding (WAIS 
III/IV) (Wechsler, 1997; Wechsler, 
2008) 
Psychomotor speed and 
attention 
b Lezak et al., 2004 (p. 369) 
 
2) Trail Making Test – Part A 
(Reitan, 1958) 




Reitan, 1958; Segalowitz 
et al., 1992 
 
3) Brake Pedal Test (Brake Reaction 
Test) 
Psychomotor speed and 
attention 
b Hasegawa et al., 2020; 
Zhang et al., 2007 
III Verbal Reasoning/Verbal Comprehension 
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1) Similarities (WAIS III/IV) 
(Wechsler, 1997; Wechsler, 2008) 
Verbal abstraction 
Left temporal and 
frontal lobes 
Lezak et al., 2004 (p. 
572); McFie, 1975; 
Newcombe, 1969; 
Warrington et al., 1986 
 
2) Information (WAIS III/IV) 




Larrabee et al., 1985; 
Russell, 1987; Schoenberg 
et al., 2002; Sklar, 1963; 
Storandt et al., 1986 
 
 
3) Controlled Oral Word Association 
Test (Spreen & Strauss, 1998) 
Mental flexibility and 
abstract reason 
Left and right 
frontal 
Ferret, 1974; Miceli et al., 
1981; Rothi et al., 1991 
 
4) Boston Naming Test (Kaplan et 
al., 1983 





Kaplan et al., 1983; Lezak 
et al., 2004; Margolin et 
al., 1990; Spreen & 
Strauss, 1998 
 
5) Token Test (Boller & Vignolo, 
1966) 
Receptive language, 
ability to follow directions 
and concentration 
Left temporal and 
parietal 
Boller & Vignolo, 1966; 
Strauss et al., 2006 
 
6) Dichotic Listening Test – Left 







Lezak et al., 2004; Meyers 
et al., 2002; Roberts et al., 
1994 
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7) Dichotic Listening Test – Right 






system than right 
Lezak et al., 2004; Meyers 
et al., 2002; Roberts et al., 
1994 
 
8) Spelling (WRAT-4; Wilkinson & 
Robertson, 2006) 




Lezak et al., 2004 (p. 
564-565) 
 
9) Dementia Rating Scale – 2 – 
Conceptualization Index (Mattis, 
2001) 
Verbal abstraction and 
reasoning 
Left temporal and 
frontal lobes 
Lezak et al., 2004 (p. 
412); Strauss et al., 2006 
IV Visual Reasoning/Perceptual Organization 
 
1) Picture Completion (WAIS III/IV) 
(Wechsler, 1997; Wechsler, 2008) 
Visual spatial perceptual 
skills and discrimination 





Chase et al., 1984; Lezak 
et al., 2004 (p. 598) 
 
2) Block Design (WAIS III/IV) 
(Wechsler, 1997; Wechsler, 2008) 
Visual spatial organization 
Right posterior and 
left parietal lobes 
Black & Strub, 1976; 
Lezak et al., 2004 (p. 
560); McFie, 1975; 
Newcombe, 1969; 
Warrington et al., 1986 
 
3) Judgement of Line Orientation 
(Benton et al., 1983b) 
Ability to perceive visual 
information and judge 
lines and angles 
Right posterior 
parietal and anterior 
occipital lobes 
Benton et al., 1983b; 
Tranel et al., 2009 
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5) Dementia Rating Scale – 2 – 





Lezak et al., 2004 (p. 
412); Strauss et al., 2006 
V Verbal Memory/Auditory Memory and Learning 
 
1) Rey Auditory Verbal Learning 
Test – Total learning trials, 
immediate recall, delayed recall, 
and recognition (Rey, 1964) 
Learning, immediate and 
delayed free recall, and 
recognition of verbal 
information 
Left hemisphere 
Lezak et al., 2004; 
Geffen et al., 1990 
 
2) Dementia Rating Scale – 2 –
Memory Index (Mattis, 2001) 
Learning, immediate and 
delayed free recall, and 
recognition  
Hippocampus 
Lezak et al., 2004 (p. 
412); Strauss et al., 2006 
 
3) Wide Range Assessment of 
Memory and Learning – 2 
Immediate recall, delayed recall 
and recognition Story Memory 
(Sheslow & Adams, 2003) 
Immediate and delayed 




Lezak et al., 2004 (p. 
536); Strauss et al., 2006 
VI Visual Memory/Nonverbal Memory and Learning 
 
1) Rey Complex Figure Test – 
immediate recall, delayed recall, 
and recognition (Rey, 1964) 
Visual Organization, 
immediate and delayed 
recall of visual 
information 
Right hemisphere Meyers & Meyers, 1995 
VII Executive Functioning 
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1) Trail Making Test – Part B 
(Reitan, 1958) 




Greenlief et al., 1985; 
Reitan & Wolfson, 
1985; Ruffolo et al., 
2000; Segalowitz et al., 
1992 
 
2) Dichotic Listening Test– Both Left 








system than right 
Meyers et al., 2002; 
Lezak et al., 2004; 
Roberts et al., 1994  
 
3) Category Test (Spreen & Strauss, 
1991) 
Problem solving and 
reasoning abilities 
Right hemisphere 
Cullum & Bigler, 1986; 
Goldstein & Ruthven, 
1983; Halstead, 1947; 
King & Snow, 1981; 
Wang, 1987 
 
4) Wisconsin Card Sorting Test – 
percent errors, perseverative 
responses, and perseverative errors 
(Berg, 1948) 
Problem solving, set-





Lezak et al., 2004 (p. 
637-639) 
 
5) Dementia Rating Scale – 2 – 
Initiation/Perseveration Index 
(Mattis, 2001) 





Lezak et al., 2004 (p. 
412); Strauss et al., 2006 
 
6)  IVA-2 CPT – Auditory and 
Visual Response Control 





Lezak et al., 2004 (p. 
415-16); Tinius, 2003 
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1) Finger Tapping Test – Dominant 
(Reitan & Wolfson, 1985) 











Lezak et al., 2012; 
Prigatano et al., 2004; 
Strauss et al., 2006 
 
2) Finger Localization Test – 





Benton et al., 1983b; 
Gainotti, & Tiacci, 1973 
 
3) Grooved Pegboard Test – 
Dominant (Matthews & Klove, 
1964) 





Lezak et al., 2012; 
Strauss et al., 2006 
IX Non-Dominant Motor and Sensory 
 
1) Finger Tapping Test – Non-
Dominant (Reitan & Wolfson, 
1985) 











Lezak et al., 2012; 
Prigatano et al., 2004; 
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2) Finger Localization Test – Non-





Benton et al., 1983b; 
Gainotti, & Tiacci, 
1973 
 
3) Grooved Pegboard Test – Non-
Dominant (Matthews & Klove, 
1964) 





Lezak et al., 2012; 
Strauss et al., 2006 
Note. Adapted from Meyers and Rohling (2009). a = tests from this domain were not included in calculations of OTBM or IIV. b = 
very sensitive to brain damage and depressed regardless of location of the locus of a lesion. WRAT = Wide Range Achievement Test. 











Bivariate Correlations between Cognitive Variables 
  2 3 4 5 6 7 8 9 10 11 12 13 
1) OTBM -.45*** -.27*** .54*** .77*** .72*** .75*** .69*** .77*** .68*** .76*** .52*** .44*** 
2) IIV  -.20*** <-.01 -.35*** -.45*** -.21*** -.15*** -.31*** -.34*** -.26*** -.39*** -.30*** 
3) PVTs Failed   -.07 -.21*** -.13** -.11* -.14*** -.38*** -.20*** -.11* -.10* -.08 
4) Premorbid Est.    .41*** .23*** .66*** .54*** .36*** .31*** .50*** .12** .13** 
5) Attention/WM     .53*** .55*** .42*** .45*** .39*** .56*** .34*** .23*** 
6) Processing Speed      .46*** .36*** .29*** .39*** .55*** .45*** .33*** 
7) Verbal Reasoning       .48*** .43*** .34*** .64*** .24*** .17*** 
8) Visual Reasoning        .36*** .58*** .66*** .30*** .28*** 
9) Verbal Memory         .43*** .40*** .22*** .19*** 
10) Visual Memory          .49*** .30*** .31*** 
11) EF           .34*** .28*** 
12) Dom Motor            .59*** 
13) NonDom Motor             
Note. OTBM = Overall Test Battery Mean. IIV = Intra-Individual Variability. PVT = Performance Validity Test. Est. = Estimate. WM 
= Working Memory. EF = Executive Functioning. Dom Motor = Dominant Motor Functioning. NonDom Motor = Non-Dominant 
Motor Functioning. 
* < .05. **<.01. ***<.001. 












Bivariate Correlations between Sample Diagnoses and OTBM and IIV 
  OTBM IIV 
Internalizing .02 -.02 
Impulse Control .02 -.02 
Substance Abuse <-.01 .01 
Years of Substance Abuse -.02 -.05 
Severe Mental Illness .05 .01 
Learning .09 .04 
Neurodevelopmental .17*** -.06 
Seizure .03 -.08 
Neurocognitive .10* -.05 
Chiari Malformation -.02 .06 
Brain Tumor <.01 -.07 
All Types of Traumatic Brain Injury .03 .02 
Post Concussive Syndrome .09 -.02 
Mild TBI -.03 .12* 
Moderate to Severe TBI .14** -.14** 
Cardiovascular .16** -.21*** 
Hyperlipidemia -.06 .04 
Autoimmune .05 -.11* 
Hyperchloremia -.02 -.04 
Respiratory Dysfunction -.12** -.05 
Pain -.09 .12** 
Migraine -.03 -.03 
Tinnitus -.02 <.01 
Eating Disorders .01 -.04 
Sleep Dysfunction <-.01 .05 






















Bivariate Correlations between Therapeutic Use Categories and OTBM and IIV 
  OTBM IIV 
Polypharmacy .03 -.06 
Anticholinergic .06 -.02 
Antidepressant .01 -.04 
Anxiolytic .07 -.05 
Antipsychotic .10** -.05 
Mood Stabilizer .06 -.05 
Analgesic .07 -.07 
Addiction .06 -.05 
Antiepileptic .11** -.08 
Stimulant .05 -.05 
Antidementia .06 -.05 
Cardiovascular .07 -.06 
Lipid Modifying .04 -.04 
Antithrombotic .08 -.07 
Anti-inflammatory .01 <.01 
Hormone .03 -.01 
Respiratory .08 -.03 
Antidiabetic .10** -.05 
Antihistamine .07 -.06 
Urological .05 -.05 
Gastrointestinal .05 -.03 
Muscle Relaxants .06 -.06 
Calcium and Bone Mineralization .06 -.05 
Immunomodulator .06 -.06 
Movement Disorder .05 -.04 
Antiglaucoma .06 -.05 
Dermatological .06 -.06 
Antimalarial .06 -.04 
Cytotoxic .06 -.05 
Weight Loss .06 -.05 
Antigout .06 -.04 
















Bivariate Correlations between Demographic Variables and OTBM and IIV 
  OTBM IIV 
Age .15** -.05 
Gender .04 .01 
Ethnicity -.02 -.05 
Neuropsychologist -.03 .33*** 



























Internalizing -.05 .05 -.01 -.09 .07 -.02 .07 .01 .08 .01 
Impulse Control -.01 .02 <-.01 -.01 .01 .08 .01 <.01 .04 .01 
SA .07 <.01 -.03 .02 <-.01 .03 .04 -.01 -.07 -.02 
Years of SA -.05 <.01 .06 <-.01 -.06 -.02 -.05 -.02 .05 .01 
SMI .06 .04 <.01 .06 .07 .09 .06 .05 -.02 <.01 
Learning .18** .12* .02 .13** .08 <.01 .01 .09 -.09 -.10* 
Neurodevelopmental .29*** .12* .01 .21*** .20*** .09 .10* .17*** .10 .09 
Seizure -.01 .06 .04 .02 .01 -.01 <.01 -.01 -.01 .02 
Neurocognitive -.09 .03 .09 .01 .02 .11* .12* .06 .11* .14** 
Chiari Malformation -.03 .03 -.02 <.01 .01 -.03 <.01 -.02 <.01 .03 
Brain Tumor <-.01 -.04 .04 .03 -.02 <.01 -.01 -.02 -.02 .01 
All Types of TBI .03 -.01 .10* .11* -.04 .08 -.04 .02 -.04 -.04 
PCS .03 .07 .11* .09 -.01 .11* .09 .03 .02 .05 
Mild TBI .03 -.06 .02 .06 -.03 <-.01 -.07 .02 -.08 -.08 
Mod. to Severe TBI .03 .10* .16** .12* .01 .17*** .05 .04 .08 .08 
Cardiovascular -.04 .11* .16** .07 .09 .06 .10* .11* .22*** .19*** 
Hyperlipidemia -1.3* -.02 -.06 -.06 -.07 -.04 -.07 -.05 .11* .16** 
Autoimmune -1.2* .10 .03 -.08 -.04 -.03 .01 .06 .17** .11* 
Hyperchloremia -.09 .02 .02 -.04 -.02 -.09 -.04 .04 .12* <-.01 
Respiratory Disorder -.17*** -.07 -.12* -.14** -.15* -.07 -.04 -.01 <.01 -.03 
Pain .04 -.05 -.15** <.01 <-.01 -.06 -.06 -.05 -.09 -.03 


























Tinnitus -.09 -.02 -.01 -.05 .01 -.02 -.05 .06 -.04 -.05 
Eating Disorder -.06 -.07 .05 -.02 .02 -.03 .04 .03 .06 .06 
Sleep Disorder -.06 .02 .04 <-.01 .03 <.01 .03 -.01 -.05 -.09 
Note. N = 497. SA = Substance Abuse. SMI = Severe Mental Illness. TBI = Traumatic Brain Injury. PCS = Post Concussive 
Syndrome. Mod. = Moderate. Dis. = Disorder. Est. = Estimate. Attn/WM = Attention/Working Memory. PS = Processing Speed. EF 
= Executive Functioning. Dom Motor = Dominant Motor Functioning. Non-Dom Motor = Non-Dominant Motor Functioning. 























Bivariate Correlations between Therapeutic Use Categories and Cognitive Domains
 
Premorbid 














Polypharmacy .05 .01 .05 .07 -.02 .02 -.03 -.03 -.09 -.09 
Anticholinergics .05 .05 .07 .05 .03 .02 .04 -.02 -.02 .01 
Antidepressants <-.01 .02 .01 -.01 <.01 -.02 .01 -.08 -.02 <-.01 
Anxiolytics .06 .07 .06 .08 .03 .07 .02 <-.01 -.01 -.02 
Antipsychotics .11* .08 .09* .11* .06 .07 .07 .03 -.02 -.01 
Mood Stabilizers .06 .04 .08 .08 <.01 .04 .01 -.02 -.03 -.04 
Analgesics .05 .06 .06 .07 .03 .04 .03 -.01 -.01 .03 
Addiction .07 .04 .08 .08 .01 .04 .01 -.01 -.04 -.05 
Antiepileptics .10* .09* .16*** .13** .02 .06 .01 .04 .02 .01 
Stimulants .05 .02 .09* .07 .01 .01 <.01 -.02 -.03 -.05 
Antidementia .05 .05 .08 .08 <.01 .04 <.01 -.01 -.02 -.04 
Cardiovascular .04 .03 .08 .07 .01 .08 .02 <.01 <.01 .01 
Lipid Modifying .03 .02 .07 .06 .01 .02 .01 -.02 -.03 -.02 
Antithrombotic .07 .05 .10* .10* .02 .05 .02 <.01 <.01 -.03 
Anti-inflammatory .08 -.01 .03 .06 <-.01 <-.01 -.01 -.03 -.06 -.02 
Hormones .02 .05 .03 .04 -.01 .03 <-.01 -.02 -.02 -.05 
Respiratory .09 .06 .09 .09* .01 .04 .02 .02 -.02 -.03 
Antidiabetics .08 .08 .10* .11* .03 .06 .03 .05 -.01 -.02 
Antihistamines .05 .06 .09 .07 <.01 .04 .04 -.02 -.01 -.01 
Urological .06 .03 .07 .08 .01 .02 <.01 -.01 -.04 -.02 
Gastrointestinal .05 .04 .08 .07 .01 -.01 .02 -.01 -.02 .02 
























Calcium & Bone 
Mineralization 
.05 .03 .09* .08 .01 .03 .01 -.01 -.03 -.03 
Immunomodulators .06 .05 .09* .09 .01 .03 .01 -.01 -.02 -.03 
Movement Disorder .06 .04 .07 .08 <-.01 .04 <.01 -.02 -.03 -.04 
Antiglaucoma .06 .05 .08 .09 .01 .04 .01 -.01 -.03 -.04 
Dermatological .06 .04 .08 .09 .01 .03 .01 -.01 -.03 -.04 
Antimalarial .06 .04 .08 .09 .01 .04 .01 -.01 -.04 -.04 
Cytotoxic .06 .04 .08 .08 <-.01 .04 .01 -.02 -.03 -.04 
Weight Loss .06 .04 .08 .08 .01 .03 .01 -.01 -.03 -.04 
Antigout .06 .05 .08 .08 .01 .04 .01 -.01 -.03 -.04 
Note: N = 497. Est. = Estimate. Attn/WM = Attention/Working Memory. PS = Processing Speed. EF = Executive Functioning. Dom 
Motor = Dominant Motor Functioning. Non-Dom Motor = Non-Dominant Motor Functioning.  






































Age .14** .14** .18*** .15*** .09* .01 .08 .08 .02 -.09* 
Gender .03 .12** -.08 .03 .08 .02 .07 .05 -.03 -.04 
Ethnicity -.05 -.07 .01 -.02 -.02 -.01 -.02 <.01 .09 .07 
Neuropsychologist .34*** -.15*** -.19*** .24*** .11** .12** -.03 <-.01 -.16*** -.07 
Note: N = 497. Est. = Estimate. Attn/WM = Attention/Working Memory. PS = Processing Speed. EF = Executive Functioning. Dom 
Motor = Dominant Motor Functioning. NonDom Motor = Non-Dominant Motor Functioning.  








Appendix C – ANCOVA Tables 
 
Table C.1 
Interaction and Main Effects of 3x3 ANCOVA of Effects of Anticholinergic Medication Use and Polypharmacy on OTBM 
     Polypharmacy 
      
  Polypharmacy 
(n = 46) 
No Polypharmacy 
(n = 277) 
No Meds 
(n = 65) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 77) 
43.18 5.88 45.20 5.16 - - Anticholinergics 0.45 < .01 
OTBM 
No  
(n = 246) 
44.48 6.18 44.22 5.79 - - Polypharmacy 0.25 < .01 
 No Meds  
(n = 65) 
- - - - 43.86 4.66 Anticholinergic x Polypharm 3.65 < .01 
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of 
anxiolytics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and diagnoses of internalizing 
disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, neurocognitive disorders, 
moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as covariates.  













Interaction and Main Effects of 3x3 ANCOVA of Effects of Anticholinergic Medication Use and Polypharmacy on IIV 
     Polypharmacy 
      
  Polypharmacy 
(n = 44) 
No Polypharmacy 
(n = 271) 
No Meds 
(n = 63) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 75) 
10.04 2.96 9.38 2.39 - - Anticholinergics 0.65 < .01 
IIV 
No  
(n = 240) 
9.34 2.22 9.86 2.42 - - Polypharmacy 0.88 .01 
 No Meds  
(n = 63) 
- - - - 10.03 2.73 Anticholinergic x Polypharm 3.82 < .01 
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of anxiolytics, 
AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and diagnoses of internalizing disorders, 
substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, neurocognitive disorders, moderate to 
severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as covariates.  
















Interaction and Main Effects of 3x3 ANCOVA of Effects of Antidepressant Medication Use and Polypharmacy on OTBM 
     Polypharmacy 
      
  Polypharmacy 
(n = 46) 
No Polypharmacy 
(n = 277) 
No Meds 
(n = 65) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 180) 
44.21 5.64 45.02 5.64 - - Antidepressant 0.80 < .01 
OTBM 
No  
(n = 143) 
43.00 8.07 43.81 5.65 - - Polypharmacy 0.04 < .01 
 No Meds  
(n = 65) 
- - - - 43.86 4.66 Antidepressant x Polypharm 0.09 < .01 
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of 
anxiolytics, antipsychotics, analgesics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and 
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, 
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as 
covariates.  















Interaction and Main Effects of 3x3 ANCOVA of Effects of Antidepressant Medication Use and Polypharmacy on IIV 
     Polypharmacy 
      
  Polypharmacy 
(n = 44) 
No Polypharmacy 
(n = 271) 
No Meds 
(n = 63) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 175) 
9.62 2.69 9.70 2.39 - - Antidepressant 0.18 < .01 
IIV 
No  
(n = 140) 
9.56 1.68 9.82 2.46 - - Polypharmacy 5.29 0.01 
 No Meds  
(n = 63) 
- - - - 10.03 2.73 Antidepressant x Polypharm <0.01 < .01 
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of, anxiolytics, 
antipsychotics, analgesics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and diagnoses of 
internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, neurocognitive 
disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as covariates.  
















Interaction and Main Effects of 3x3 ANCOVA of Effects of Anxiolytic Medication Use and Polypharmacy on OTBM 
     Polypharmacy 
      
  Polypharmacy 
(n = 46) 
No Polypharmacy 
(n = 277) 
No Meds 
(n = 65) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 55) 
43.05 5.39 44.48 6.78 - - Anxiolytics 1.99 < .01 
OTBM 
No  
(n = 268) 
44.88 6.57 44.43 5.52 - - Polypharmacy 0.03 < .01 
 No Meds  
(n = 65) 
- - - - 43.86 4.66 Anxiolytics x Polypharm 6.48 < .01 
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, antipsychotics, analgesics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and 
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, 
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as 
covariates.  















Interaction and Main Effects of 3x3 ANCOVA of Effects of Anxiolytic Medication Use and Polypharmacy on IIV 
     Polypharmacy 
      
  Polypharmacy 
(n = 44) 
No Polypharmacy 
(n = 271) 
No Meds 
(n = 63) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 54) 
10.12 2.37 9.62 2.71 - - Anxiolytic 1.79 < .01 
IIV 
No  
(n = 261) 
9.10 2.62 9.78 2.38 - - Polypharmacy 4.47 < .01 
 No Meds  
(n = 63) 
- - - - 10.03 2.73 Anxiolytic x Polypharm 4.76  .01 
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, antipsychotics, analgesics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and 
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, 
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as 
covariates.  














Interaction and Main Effects of 3x3 ANCOVA of Effects of Analgesic Medication Use and Polypharmacy on OTBM 
     Polypharmacy 
      
  Polypharmacy 
(n = 46) 
No Polypharmacy 
(n = 277) 
No Meds 
(n = 65) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 53) 
42.41 6.65 44.97 7.61 - - Analgesic 3.97 < .01 
OTBM 
No  
(n = 270) 
45.46 5.14 44.37 5.39 - - Polypharmacy < 0.01 < .01 
 No Meds  
(n = 65) 
- - - - 43.86 4.66 Analgesic x Polypharm 2.00 < .01 
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, anxiolytics, antipsychotics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and 
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, 
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as 
covariates.  















Interaction and Main Effects of 3x3 ANCOVA of Effects of Analgesic Medication Use and Polypharmacy on IIV 
     Polypharmacy 
      
  Polypharmacy 
(n = 44) 
No Polypharmacy 
(n = 271) 
No Meds 
(n = 63) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 51) 
10.40 2.68 9.95 2.79 - - Analgesic 11.29  .02** 
IIV 
No  
(n = 264) 
8.89 2.19 9.73 2.38 - - Polypharmacy 4.65 .01 
 No Meds  
(n = 63) 
- - - - 10.03 2.73 Analgesic x Polypharm 2.89 < .01 
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, anxiolytics, antipsychotics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and 
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, 
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as 
covariates.  















Interaction and Main Effects of 3x3 ANCOVA of Effects of Using Triptans and Polypharmacy on IIV 
     Polypharmacy 
      
  Polypharmacy 
(n = 44) 
No Polypharmacy 
(n = 271) 
No Meds 
(n = 63) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 6) 
12.08 3.03 12.70 3.96 - - Triptans 12.91  .03** 
IIV 
No  
(n = 309) 
9.36 2.37 9.74 2.40 - - Polypharmacy 2.79 < .01 
 No Meds  
(n = 63) 
- - - - 10.03 2.73 Triptans x Polypharm 0.44 < .01 
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, anxiolytics, antipsychotics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and 
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, 
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as 
covariates.  















Interaction and Main Effects of 3x3 ANCOVA of Effects of Using Opioid Analgesics and Polypharmacy on IIV 
     Polypharmacy 
      
  Polypharmacy 
(n = 44) 
No Polypharmacy 
(n = 271) 
No Meds 
(n = 63) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 27) 
9.65 2.07 9.55 2.23 - - Opioids 0.10  < .01 
IIV 
No  
(n = 288) 
9.60 2.68 9.77 2.43 - - Polypharmacy 1.87 < .01 
 No Meds  
(n = 63) 
- - - - 10.03 2.73 Opioids x Polypharm 0.07 < .01 
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, anxiolytics, antipsychotics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and 
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, 
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as 
covariates.  














Interaction and Main Effects of 3x3 ANCOVA of Effects of Using Opioid-Combination Analgesics and Polypharmacy on IIV 
     Polypharmacy 
      
  Polypharmacy 
(n = 44) 
No Polypharmacy 
(n = 271) 
No Meds 
(n = 63) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 14) 
10.75 1.97 10.44 3.99 - - Opioid-Combinations 2.13  < .01 
IIV 
No  
(n = 301) 
9.43 2.57 9.74 2.36 - - Polypharmacy 1.70 < .01 
 No Meds  
(n = 63) 
- - - - 10.03 2.73 Opioid Combos x Polypharm <0.01 < .01 
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, anxiolytics, antipsychotics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and 
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, 
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as 
covariates.  
















Interaction and Main Effects of 3x3 ANCOVA of Effects of Using Non-Opioid Analgesics and Polypharmacy on IIV 
     Polypharmacy 
      
  Polypharmacy 
(n = 44) 
No Polypharmacy 
(n = 271) 
No Meds 
(n = 63) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 10) 
10.90 3.93 8.76 1.22 - - Non-Opioids 0.20  < .01 
IIV 
No  
(n = 305) 
9.44 2.31 9.78 2.43 - - Polypharmacy 0.01 < .01 
 No Meds  
(n = 63) 
- - - - 10.03 2.73 Non-Opioids x Polypharm 1.48 < .01 
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, anxiolytics, antipsychotics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and 
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, 
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as 
covariates.  















Interaction and Main Effects of 3x3 ANCOVA of Effects of Antiepileptic Medication Use and Polypharmacy on OTBM 
     Polypharmacy 
      
  Polypharmacy 
(n = 46) 
No Polypharmacy 
(n = 277) 
No Meds 
(n = 65) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 76) 
45.62 4.95 42.43 5.87 - - Antiepileptic 3.41 < .01 
OTBM 
No  
(n = 247) 
43.13 6.46 44.99 5.50 - - Polypharmacy 0.88 < .01 
 No Meds  
(n = 65) 
- - - - 43.86 4.66 Antiepileptic x Polypharm 4.51 < .01 
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, anxiolytics, antipsychotics, analgesics, cardiovascular medications, anti-inflammatory medications, and hormones; 
and diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, 
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as 
covariates.  














Interaction and Main Effects of 3x3 ANCOVA of Effects of Antiepileptic Medication Use and Polypharmacy on IIV 
     Polypharmacy 
      
  Polypharmacy 
(n = 44) 
No Polypharmacy 
(n = 271) 
No Meds 
(n = 63) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 74) 
9.13 1.96 10.47 2.41 - - Antiepileptic 1.83 < .01 
IIV 
No  
(n = 241) 
9.86 2.76 9.56 2.39 - - Polypharmacy 9.56 0.02* 
 No Meds  
(n = 63) 
- - - - 10.03 2.73 Antiepileptic x Polypharm 4.79  .01 
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, anxiolytics, antipsychotics, analgesics, cardiovascular medications, anti-inflammatory medications, and hormones; 
and diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, 
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as 
covariates.  
















Interaction and Main Effects of 3x3 ANCOVA of Effects of Cardiovascular Medication Use and Polypharmacy on OTBM 
     Polypharmacy 
      
  Polypharmacy 
(n = 46) 
No Polypharmacy 
(n = 277) 
No Meds 
(n = 65) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 72) 
43.08 6.43 43.69 5.61 - - Cardiovascular 2.48 < .01 
OTBM 
No  
(n = 251) 
45.00 5.56 44.59 5.68 - - Polypharmacy 0.13 < .01 
 No Meds  
(n = 65) 
- - - - 43.86 4.66 Cardiovascular x Polypharm 0.53 < .01 
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, anxiolytics, antipsychotics, analgesics, AEDs, anti-inflammatory medications, and hormones; and diagnoses of 
internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, neurocognitive 
disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as covariates.  
















Interaction and Main Effects of 3x3 ANCOVA of Effects of Cardiovascular Medication Use and Polypharmacy on IIV 
     Polypharmacy 
      
  Polypharmacy 
(n = 44) 
No Polypharmacy 
(n = 271) 
No Meds 
(n = 63) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 69) 
9.86 2.97 10.04 2.30 - - Cardiovascular 0.01 < .01 
IIV 
No  
(n = 246) 
9.34 1.95 9.70 2.44 - - Polypharmacy 6.76 0.01 
 No Meds  
(n = 63) 
- - - - 10.03 2.73 Cardiovascular x Polypharm 0.23 < .01 
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, anxiolytics, antipsychotics, analgesics, AEDs, anti-inflammatory medications, and hormones; and diagnoses of 
internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, neurocognitive 
disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as covariates.  
















Interaction and Main Effects of 3x3 ANCOVA of Effects of Anti-Inflammatory Medication Use and Polypharmacy on OTBM 
     Polypharmacy 
      
  Polypharmacy 
(n = 46) 
No Polypharmacy 
(n = 277) 
No Meds 
(n = 65) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 63) 
44.24 6.06 45.60 5.41 - - Anti-Inflammatory 3.19 < .01 
OTBM 
No  
(n = 260) 
43.80 6.14 44.23 5.70 - - Polypharmacy 0.18 < .01 
 No Meds  
(n = 65) 
- - - - 43.86 4.66 
Anti-Inflammatory x 
Polypharm 
0.03 < .01 
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, anxiolytics, antipsychotics, analgesics, AEDs, cardiovascular medications, and hormones; and diagnoses of 
internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, neurocognitive 
disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as covariates.  















Interaction and Main Effects of 3x3 ANCOVA of Effects of Anti-Inflammatory Medication Use and Polypharmacy on IIV 
     Polypharmacy 
      
  Polypharmacy 
(n = 44) 
No Polypharmacy 
(n = 271) 
No Meds 
(n = 63) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 61) 
9.43 2.48 9.15 2.23 - - Anti-Inflammatory 0.34 < .01 
IIV 
No  
(n = 254) 
9.75 2.59 9.87 2.44 - - Polypharmacy 5.77 0.01 
 No Meds  
(n = 63) 
- - - - 10.03 2.73 Anti-Inflammatory x Polypharm 0.29 < .01 
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, anxiolytics, antipsychotics, analgesics, AEDs, cardiovascular medications, and hormones; and diagnoses of 
internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, neurocognitive 
disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as covariates.  
















Interaction and Main Effects of 3x3 ANCOVA of Effects of Hormone Medication Use and Polypharmacy on OTBM 
     Polypharmacy 
      
  Polypharmacy 
(n = 46) 
No Polypharmacy 
(n = 277) 
No Meds 
(n = 65) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 61) 
44.88 5.12 45.09 5.53 - - Hormone 0.09 < .01 
OTBM 
No  
(n = 262) 
43.53 6.51 44.31 5.70 - - Polypharmacy 0.26 < .01 
 No Meds  
(n = 65) 
- - - - 43.86 4.66 Hormone x Polypharm 0.23 < .01 
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, anxiolytics, antipsychotics, analgesics, AEDs, cardiovascular medications, and anti-inflammatory medications; and 
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, 
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as 
covariates.  














Interaction and Main Effects of 3x3 ANCOVA of Effects of Anti-Inflammatory Medication Use and Polypharmacy on IIV 
     Polypharmacy 
      
  Polypharmacy 
(n = 44) 
No Polypharmacy 
(n = 271) 
No Meds 
(n = 63) 
   
  M SD M SD M SD Factors F η2 
 Yes  
(n = 60) 
9.60 3.15 9.22 2.86 - - Anti-Inflammatory 1.13 < .01 
IIV 
No  
(n = 255) 
9.61 2.15 9.86 2.43 - - Polypharmacy 6.76 0.01 
 No Meds  
(n = 63) 
- - - - 10.03 2.73 Anti-Inflammatory x Polypharm 0.18 < .01 
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of 
antidepressants, anxiolytics, antipsychotics, analgesics, AEDs, cardiovascular medications, and anti-inflammatory medications; and 
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, 
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as 
covariates.  
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